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2 Abstract	
	
Background	
There	are	>100000	new	HIV	infections	in	children	each	year,	nearly	90%	of	which	are	
in	Africa.	Untreated	HIV	results	in	activation	across	all	axes	of	the	immune	system	and	
this	immune	activation	is	linked	to	poor	outcome.		This	study	aimed	to	investigate	
microbial	translocation	(the	crossing	of	microbial	products	such	as	bacterial	DNA	and	
components	of	bacterial	cell	walls	from	the	gut	into	the	blood	stream)	as	a	potential	
driver	of	immune	activation	and	poor	outcome	in	African	children	with	HIV.	
Method	
The	study	included	HIV-infected	children	initiating	treatment	with	antiretroviral	
therapy	(ART)	in	the	clinical	trial	CHAPAS-3	in	Uganda	(ISRCTN69078957).	ART	naïve	
and	ART-experienced	children	from	urban	(Kampala)	and	rural	(Gulu)	settings	were	
included	with	age-matched	HIV	uninfected	controls	from	urban	communities.	Plasma	
was	collected	at	3	time	points	from	HIV	infected	children	and	a	one-off	plasma	
sample	from	HIV	uninfected	controls.	Cell	pellet	samples	from	HIV-infected	children	
in	the	urban	setting	and	baseline	were	also	available.	Microbial	translocation	was	
assessed	using	broad	range	16S	rDNA	polymerase	chain	reactions	(PCR)	with	next	
generation	sequencing	(NGS)	and	a	panel	of	specific	bacterial	PCRs.	Intestinal	barrier	
function	was	assessed	using	Intestinal	fatty	acid	binding	protein	(I-FABP).		
Results	
In	total,	305	children	were	included:	119	ART	naïve	(median	age	2.8	years,	
interquartile	range	(IQR)	1.7-4,	median	baseline	CD4%	20,	IQR	14-24);	22	ART	
experienced	children	(median	age	6.5	years	IQR	5.9-9.2,	median	baseline	CD4%	34,	
IQR	31-39)	(urban	site);	55	ART-naïve	children	(rural	site)(median	age	2	IQR	1.7-3.5,	
median	baseline	CD4%	30,	IQR	22-41)	and	109	age-matched	HIV-uninfected	controls.	
For	the	HIV-infected	groups,	immune	recovery	was	good.	Most	molecular	assays	
including	broad	range	PCR	were	negative	or	very	low	at	all	time	points	and	across	all	
groups.	No	relationship	was	seen	between	molecular	assay	results	and	clinical	events	
including	invasive	infections	in	the	HIV-infected	group.	I-FABP	was	significantly	higher	
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in	control	groups	than	HIV	infected	(urban)	groups	at	baseline,	and	the	rural	group	
was	also	higher.	I-FABP	increased	in	both	urban	HIV-infected	groups	over	time.		
Conclusion	
In	this	longitudinal	study,	there	was	no	convincing	relationship	between	markers	of	
microbial	translocation	and	clinical	progress	in	HIV	infected	children	from	Uganda	
after	ART	initiation.	Levels	of	translocation	were	low	and	similar	in	HIV-uninfected	
controls.	I-FABP	may	be	a	marker	of	a	healthy	gut	in	this	setting.	Microbial	
translocation	does	not	play	a	pivotal	role	in	driving	immune	activation	in	this	setting.	
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6 Abbreviations	
	
95%	CI	 95	per	cent	Confidence	Interval	
ABC	 abacavir	
AHR	 Adjusted	hazard	ratio	
AIDS	 Acquired	immunodeficiency	syndrome	
ART	 Antiretroviral	therapy	
AZT	 zidovudine	
BLASTN	 Nucleotide	basic	local	alignment	search	tool	
BMI	 Body	mass	index	
Bp	 Base	pair	
CFU	 Colony	forming	unit	
CI	 Confidence	Interval	
CMV	 Cytomegalovirus	
CT	 Cycle	threshold	
D4T	 stavudine	
DNA	 Deoxyribonucleic	acid	
EBV	 Epstein-Barr	virus	
EDTA	 Ethylenediaminetetraacetic	acid	
EFV	 Efavirenz	
EndoCab	 Anti-endotoxin	core	antibodies	
FASTA	 Fast-All	format	
FASTQ	 Fast-Quality	format	
FLASH	 Fast	length	adjustment	of	short	reads	
GALT	 Gut	associated	lymphoid	tissue		
GOSH	 Great	Ormond	Street	Hospital		
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HAART	 Highly	active	antiretroviral	therapy,	also	referred	to	as	ART.	
HAD	 HIV-associated	dementia		
HAZ	 height-for-age	Z-score		
HIV	 Human	immunodeficiency	virus	
hsCRP	 High	sensitivity	C-reactive	protein		
IDO	 Indoleamine	2,3-dioxygenase-1	
I-FABP	 Intestinal	fatty	acid	binding	protein	
IFN	 Interferon	
Ig	 Immunoglobulin		
IL	 Interleukin	
iNKT	 Invariant	natural	killer	T	cells		
JCRC	 Joint	Clinical	Research	Centre,	Kampala	
KT	 Kynurenine	to	tryptophan		
LBP	 Lipopolysaccharide-binding	protein		
LPS	 Lipopolysaccharide	
mDCs	 myeloid	dendritic	cells		
MRC	CTU	 Medical	Research	Council	Clinical	Trials	Unit	
MT	 Microbial	translocation	
NF-κB	 Nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells	
NGS	 Next	generation	sequencing	
NK	 Natural	Killer		
NHL	 Non-Hodgkins	lymphoma	
NNRTI	 Non-nuceloside	reverse	transcriptase	inhibitor	
NVP	 Nevirapine	
OTU	 Operational	taxonomic	unit	
PAMP	 Pathogen	associated	molecular	pattern	
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PMTCT	 Preventing	mother	to	child	transmisssion	
PCR	 Polymerase	chain	reaction	
PCoA	 Principal	Coordinates	Analysis	
QIIME	 Quantitative	insights	into	microbial	ecology	
qPCR	 Quantitative	polymerase	chain	reaction	
rDNA	 Ribosomal	deoxynucleic	acid	
RM	 Rhesus	macaques		
sCD14	 Soluble	CD14	
SD	 Standard	deviation	
SDG	 Sustainable	Development	Goal	
SIV	 Simian	immunodeficiency	virus		
SM	 Sooty	mangabey	
Th17	 T-helper	17	
TLR4	 Tol-like	receptor	4		
Tm	 Melting	temperature	
TNFα	 Tumour	necrosis	factor	alpha		
Tregs	 T	regulatory	cells		
WAZ	 Weight-for-age	z	score	
WHO	 World	Health	organisation	
WHZ	 weight-for-height	Z-score		
μL	 microlitre	
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8 Chapter	8	Background	
	
8.1 Human	Immunodeficiency	Virus	(HIV)	
The	human	immunodeficiency	virus	(HIV)	is	an	RNA	lentivirus	within	the	Retroviridae	
family	which	can	cause	acquired	immune	deficiency	syndrome	(AIDS)	in	humans1.	It	
consists	of	two	copies	of	positive	single	stranded	RNA	within	a	capsid	which	also	
contains	vital	enzymes	for	viral	replication:	integrases,	proteases	and	reverse	
transcriptases,	and	transcriptional	transactivator	(Tat)	proteins(Figure	1).		The	virus	
envelope	is	a	lipid	bilayer	formed	from	the	host	cell	membrane	expressing	the	HIV	
envelope	protein	Env,	consisting	of	the	gp120	and	gp41	glycoproteins2.		
	
	
Figure	1	Structure	of	HIV	reproduced	from	Splettstoesser	2014	3		
Schematic	of	HIV	viral	structure,	showing	envelope	proteins	gp120	and	gp41,	the	positions	of	integrase	and	protease	enzymes,	
the	viral	RNA	within	the	capsid	and	the	Tat	(transcriptional	transactivator)	proteins.	Reproduced	under	Creative	Commons	
Licence.	
	
The	virus	is	tropic	for	the	cluster	differentiation	4	(CD4)	antigen	found	on	T	helper	
cells,	dendritic	cells	and	macrophages.	The	viral	protein	gp120	binds	with	host	cell	
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CD4	molecules,	and	viral	adsorption	is	triggered	with	concomitant	viral	interaction	
with	host	CXCR4	and	CCR5	co-receptors	(Figure	2)4,5.	This	is	followed	by	fusion	of	viral	
and	host	cell	membranes,	releasing	the	viral	capsid	into	the	host	cell.	The	viral	
reverse	transcriptase	then	copies	viral	RNA	into	double	stranded	complementary	DNA	
(cDNA)	in	an	error-prone	process	which	is	one	of	the	main	drivers	of	viral	mutation6.	
The	viral	DNA	is	integrated	into	host	DNA	in	the	nucleus	using	the	viral	integrase	
enzyme.	At	this	point	the	virus	can	enter	a	latent	phase,	particularly	in	macrophages	
which	can	act	as	long	standing	reservoirs	for	HIV7.		Viral	replication	takes	place	in	the	
presence	of	host	transcriptional	factors	such	as	the	nuclear	factor	kappa-light-chain-
enhancer	of	activated	B	cells	(NF-κB)	which	is	upregulated	in	activated	T-cells1.	This	
triggers	transcription	of	the	integrated	proviral	DNA	into	RNA,	some	of	which	is	
translated	into	viral	proteins	such	as	Tat	which	further	upregulates	viral	production	
and	the	structural	proteins	Gag	and	Env8.	The	virion	is	assembled,	and	buds	out	of	the	
host	cell	with	the	protease	enzyme	mediating	a	crucial	cleavage	of	the	gag	
polyprotein	into	matrix,	capsid	and	nucleocapsid	proteins1.
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Figure	2	Schematic	of	HIV	lifecycle	reproduced	from	Splettstoesser	20143		
Schematic	of	HIV	life	cycle	showing	membrane	proteins	gp120	and	gp41	binding	with	CD4	and	CCR5	receptors	on	CD4	T	cell	prior	to	membrane	fusion,	reverse	transcription	and	integration	of	viral	DNA	
into	host	DNA.	This	is	followed	by	transcription	of	the	viral	RNA	and	translation	of	viral	proteins,	before	cleavage	of	viral	proteins	by	a	protease	and	assembly	of	the	virion.	The	final	stage	is	budding	of	the	
mature	virus	from	the	host	cell.	Reproduced	under	Creative	Commons	Licence.	
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The	virus	is	then	released	to	infect	further	CD4	T	cells,	resulting	over	time	in	a	
dramatic	depletion	of	CD4	T	cells	and	decline	in	cell-mediated	immunity	with	
concomitant	increase	in	viral	load	(Figure	3).	This	depletion	of	cell-mediated	
immunity	over	time	leaves	HIV-infected	people	vulnerable	to	opportunistic	infections	
that	were	the	hallmark	of	AIDS	in	the	pre-ART	era.	Since	the	advent	of	ART,	AIDS	is	no	
longer	an	inevitably	terminal	state	in	that	those	attending	hospital	with	severe	
opportunistic	infections	or	AIDS-related	malignancies	(previously	known	as	“AIDS-
defining”	conditions),	can	reconstitute	their	immune	system	on	initiation	of	therapy,	
although	mortality	remains	increased.	Disease	progression	has	been	defined	
according	both	to	the	level	of	CD4	T-cells	and	the	presence	of	specific	opportunistic	
infections	that	occur	with	diminishing	immunity9.	Thus	the	disease	is	classified	into	
four	clinical	stages	by	the	World	Health	Organization,	with	WHO	Stage	1	being	
asymptomatic	and	Stage	4	being	the	most	severe9.		
	
	
Figure	3	Schematic	of	HIV	disease	progression	over	time	adapted	from	Pantaleo	et	al.	199310	
Schematic	graph	of	relationship	between	CD4	T-cell	count	and	HIV	copies	(viral	load)	during	course	of	untreated	HIV	infection:	
individual	time	courses	may	vary.	Blue	line:	CD4	T	cell	count	(cells/μL).	Red	line:	HIV	RNA	copies	per	mL	plasma.	Reproduced	with	
permission	from	Pantaleo	et	al.	Copyright	Massachusetts	Medical	Society	10	
	
	
8.2 The	HIV	Pandemic	in	Children:	Current	and	Future	Challenges	
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In	2015	an	estimated	36.7	million	people	were	living	with	HIV	globally,	including	1.8	
million	children	<15	years	of	age11.		Significant	strides	have	been	made	towards	the	
United	Nations	Sustainable	Development	Goal	(SDG)	of	reducing	new	HIV	infection	to	
zero	by	2030,	but	there	is	still	much	work	to	be	done.	Although	the	rate	of	new	
infections	in	children	has	fallen	from	a	peak	of	490000	per	annum	in	2000	there	were	
still	110000	new	paediatric	infections	in	201512.		Nearly	90%	of	these	HIV-infected	
children	are	in	Africa	(Figure	4)13.		
	
	
Figure	4	Number	of	Children	Living	with	HIV	globally	(adapted	with	permission	from	UNAIDS/WHO	2015)13	
	
ART,	combined	therapy	usually	with	three	antiretroviral	agents,	has	revolutionised	
the	management	of	HIV.	It	has	dramatically	increased	the	life	expectancy	of	both	
adults	and	children	with	HIV,	as	well	as	reducing	both	horizontal	transmission	
between	serodiscordant	partners	and	vertical	transmission	in	prevention	of	mother-
to-child	transmission	(PMTCT)	programmes14,15.		Mortality	rates	in	HIV	infected	
children	in	African	settings	were	over	50%	by	age	2	prior	to	widespread	antiretroviral	
therapy	(ART)	roll	out16.		In	a	cohort	of	>3500	children	with	HIV	in	the	United	States,	
death	rates	fell	from	7.2	per	100	person	years	in	1994	to	0.8	from	2000-200617.	
Similarly	in	the	United	Kingdom,	the	combined	rate	of	AIDS	defining	events	and	
mortality	declined	from	13.3	cases	per	person	years	before	1997	to	2.5	in	the	years	
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from	2003-200618.	In	low/middle	income	settings,	mortality	rates	and	rates	of	disease	
progression	have	also	decreased	with	ART	roll	out:	in	a	large	clinical	trial	(the	ARROW	
Trial)	in	Uganda	and	Zimbabwe,	rates	of	death	or	WHO	Stage	4	events	combined	was	
1.7-2	per	100	child	years,	and	mortality	rates	were	1.1-1.3	per	100	child-years19.	
National	ART	programmes	have	also	seen	improved	survival	rates	to	adolescence	in	
Sub-Saharan	Africa20-22.		
	
Herculean	efforts	have	been	made	to	roll	out	ART	globally:	over	15.8	million	people	
are	now	estimated	to	now	be	receiving	treatment,	with	a	concomitant	(although	
slower)	increase	in	the	number	of	children	accessing	ART	to	just	under	900000	(Figure	
5)12,23.		On	the	basis	of	the	South	African	CHER	trial	which	demonstrated	that	early	
ART	reduced	mortality	fourfold	in	infants	compared	with	deferred	therapy,	together	
with	other	observational	data,	the	World	Health	Organization	(WHO)	guidelines	were	
altered	in	2008	to	advise	commencing	all	HIV-infected	children	under	2	on	ART24,25.	In	
2016,	based	on	data	from	the	adult	START	trial,	this	recommendation	was	extended	
to	all	people	living	with	HIV	in	20169.			
	
	
Figure	5	Number	of	children	receiving	ART	(adapted	with	permission	from	WHO	2016)23	
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PMTCT	programmes	play	a	crucial	role	in	the	reduction	of	paediatric	HIV.	These	
programmes	were	among	the	first	to	use	ART	for	prevention	of	ongoing	HIV	
transmission.		In	2012,	on	the	basis	of	trial	and	programmatic	data	the	WHO	
recommended	the	“Option	B+”	for	pregnant	women,	whereby	all	women	newly	
diagnosed	with	HIV	commence	ART	during	pregnancy	and	remain	on	it	for	life,	rather	
than	stopping	therapy	after	the	time	of	potential	exposure	for	the	infant26.	This	
simplification	of	regimens	had	been	shown	to	be	effective	in	reducing	numbers	of	
infected	infants	Malawi	in	field	settings27.		As	most	of	the	22	high	priority	countries	
have	now	adopted	“Option	B+”,	and	in	line	with	the	revised	recommendation	of	ART	
initiation	for	all,	the	WHO	has	further	simplified	guidelines	to	remove	other	options	
and	advocate	that	all	pregnant	women	should	start	and	continue	triple	therapy	with	
ART9.	In	terms	of	the	efficacy	of	PMTCT,	transmission	rates	of	as	low	as	1%	were	
achieved	in	a	trial	setting	in	Botswana,	and	rates	of	<1%	transmission	are	now	seen	
routinely	in	high	income	settings15,28.	
	
However,	despite	ART	scale	up,	less	than	half	of	children	living	with	HIV	were	
estimated	to	be	accessing	treatment	in	2015,	and	there	were	approximately	150000	
deaths	in	children	<15	years	due	to	HIV12.		Delays	in	early	infant	diagnosis	and	losses	
to	follow	up	meant	that	in	2014	only	50%	of	perinatally	infected	infants	were	tested	
in	the	first	two	months	of	life,	and	in	previous	years	only	30%	of	infants	completed	
the	cascade	from	diagnosis	to	ART	initiation29.		There	is	increasing	evidence	that	early	
ART	initiation	promotes	better	long	term	immune	reconstitution	in	children,	and	that	
even	without	evidence	of	immune	suppression,	there	may	be	other	pathways	leading	
to	increased	morbidity	and	mortality	(namely	that	of	inflammation)30,31.	Streamlining	
the	early	infant	diagnosis	cascade	by	effective	identification	of	high-risk	infants,	
minimising	delays	between	testing	and	mother-infant	pairs	receiving	test	results,	and	
starting	appropriate	treatment	is	a	crucial	priority	to	reduce	both	early	infant	deaths	
and	later	morbidity	in	children	on	ART.		
	
Even	once	initiated	on	ART,	the	long-term	health	implications	for	children	living	with	
HIV	are	substantial.	Mortality	in	the	first	year	of	ART	can	be	up	to	20%	with	
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sepsis/meningitis	and	pneumonia	being	common	causes	of	death32,33.		However,	in	
general,	mortality	is	low	if	ART	is	started	promptly,	with	many	children	surviving	to	
adolescence,	both	in	high	income	and	low/middle	income	countries,	and	living	with	
HIV	as	a	chronic	condition20,21,34.	This	changing	population	brings	its	own	challenges.	
During	the	turbulent	time	of	adolescence,	adherence	can	drop,	with	a	high	risk	of	loss	
to	follow	up35,36.	Triple-class	virological	failure	was	found	in	10%	of	a	northern	cohort	
of	1007	adolescents	with	perinatal	HIV	infection,	significantly	associated	with	delayed	
treatment	initiation	and	with	longer	time	on	ART37.	The	implications	of	virological	
failure	on	future	treatment	options	for	these	children	is	still	unclear	but	likely	to	
represent	significant	challenges	for	adult	services	caring	for	vertically-infected	young	
people	both	in	low	and	high	income	settings34,38.		
	
Long	term	chronic	morbidity	for	children	and	adolescents	living	with	HIV	is	a	growing	
concern.	For	children	with	HIV	who	have	survived	to	adolescence	without	ART,	these	
conditions	included	poor	growth,	recurrent	respiratory	infections,	diarrhoea	and	
chronic	lung	disease	as	well	as	more	classic	acute	opportunistic	infections38,39.		
Stunting,	with	poorer	catch	up	after	ART	commencement	compared	to	ponderal	
growth,	appears	to	affect	those	in	African	settings	more	than	European.	This	may	
reflect	higher	background	rates	of	malnutrition40.	Neurocognitive	dysfunction,	skin	
diseases,	renal	and	bone	disease	are	recognised	features	of	adolescent	HIV38.	There	is	
also	the	question	of	increased	future	risk	of	non-AIDS	related	conditions	such	as	
malignancy	and	cardiovascular	disease.	In	terms	of	cardiovascular	risk,	a	large	study	
of	HIV-infected	children	enrolled	in	the	CHAPAS	3	trial	in	Uganda	and	Zambia	with	
some	overlap	with	the	population	in	this	study	(see	section	9.1),	demonstrated	
significantly	poorer	markers	of	arterial	stiffness	and	carotid	intima	media	thickness	in	
HIV-infected	children	than	age-matched	controls	from	the	same	community41.	
Perinatally	infected	children	and	adolescents	with	HIV	in	the	United	States	had	high	
aggregate	cardiovascular	risk	scores	when	assessed	using	the	Pathobiological	
Determinants	of	Atherosclerosis	in	Youth	(PDAY)	scoring	system42.	Indeed,	in	both	
high	income	and	low/middle	income	settings,	cardiac	pathologies	such	as	ventricular	
hypertrophy	are	a	feature	of	perinatally	infected	adolescents43,44.	
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In	summary,	ART	roll	out	has	dramatically	increased	the	longevity	of	people	living	
with	HIV,	including	children.	However	there	are	still	significant	challenges	to	be	faced	
in	the	field	of	paediatric	HIV.	First,	further	reducing	the	numbers	of	infants	vertically	
infected;	second,	addressing	gaps	in	the	cascade	of	early	infant	diagnosis,	to	ensure	
all	HIV-infected	infants	access	treatment	promptly;	third,	ensuring	ART	regimens	and	
associated	therapy	minimise	development	of	acute	and	chronic	complications	of	HIV,	
including	ART	toxicity;	and	finally	ensuring	adequate	viral	suppression	to	preserve	
future	treatment	options	for	children	and	adolescents	needing	lifelong	ART.		This	
thesis	addresses	the	third	challenge:	investigating	microbial	translocation	and	
immune	activation	as	potential	drivers	of	chronic	complications	in	children	with	HIV.		
	
8.3 Immune	Activation	in	HIV	
	
Untreated	HIV	results	in	a	state	of	chronic	immune	activation	across	all	the	axes	of	
the	immune	system.		Both	CD4	and	CD8	T-cells	are	affected,	with	increased	
expression	of	CD38	and	HLA-DR	along	with	increased	expression	of	the	death	
receptor	Fas	(CD95)	on	CD8	cells45.	Indeed,	higher	levels	of	activated	
CD8+CD38+CD45RO+	cells	predicted	CD4	T	cell	decline	in	the	pre-ART	era	better	than	
viral	load,	as	did	increased	expression	of	CD38	on	CD4	T	cells	in	adults46,47.	This	
immune	activation	and	consequent	poorer	CD4	T	cell	count	recovery	are	linked	to	
increased	rates	of	non-AIDS	related	diseases	and	increased	all-cause	mortality	in	
patients	on	ART48-53	(Figure	6).	
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Figure	6	Schema	of	interaction	between	HIV	infection,	immune	activation	and	microbial	translocation	(adapted	with	permission	from	Klatt	et	al.)	
HIV	initiates	and	sustains	a	cycle	of	immune	activation.	Demonstrating	hypothesised	interaction	of	i)	direct	immune	activation	by	HIV	proteins	ii)	Reduced	inhibition	by	dysfunctional	immune	system	iii)	
other	chronic	and	acute	infections	such	as	cytomegalovirus	(CMV)	or	herpes	simplex	virus	(HSV)	iv)	microbial	translocation	as	mechanisms	of	immune	activation	leading	to	non-AIDS	pathogenesis.	Adapted	
with	permission	from	Klatt	et	al.54	
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Monocytes	and	dendritic	cells	are	also	activated.		An	early	study	found	an	expansion	
of	the	monocyte	CD14lowCD16high	subset	expressing	HLA-DR	in	untreated	HIV,	with	an	
associated	increase	in	expression	of	pro-inflammatory	cytokines	Interleukin-1	(IL-1),	
and	Tumour	necrosis	factor	alpha	(TNFα)55.	The	enzyme	indoleamine	2,3-
dioxygenase-1	(IDO)	is	expressed	in	activated	monocytes	and	dendritic	cells	and	
produces	kynurenine	and	downstream	toxic	metabolites	of	tryptophan.	In	Ugandan	
adults	with	HIV	initiating	therapy,	kynurenine	produced	by	these	activated	monocytes	
and	dendritic	cells	independently	predicted	poor	CD4	T	cell	recovery	and	increased	
mortality56.	Alongside	increased	production	of	IL-1,	TNFα	and	IL-6	there	is	polyclonal	
B	cell	activation	and	resultant	hypergammaglobulinaemia	57-59.	Indeed	B	cell	
activation	and	dysfunction	was	one	of	the	earliest	described	hallmarks	of	AIDS60.	
Consequences	of	immune	activation	may	be	divided	into	the	impact	on	the	immune	
system	itself	and	on	end	organs.		
	
8.3.1 Effects	on	the	Immune	System	
	
Effects	on	the	immune	system	include	the	immediate	consequence	both	of	
generating	a	larger	pool	of	activated	CD4	T	cells	expressing	CCR5	and	so	vulnerable	to	
HIV	infection,	and	the	upregulation	of	NF-κB	which	in	turn	activates	transcription	of	
HIV	itself	and	thus	increases	viral	replication61.	However,	the	proportion	of	CD4	T	cells	
infected	with	HIV	(0.01-1%)	during	chronic	infection	is	too	low	to	account	for	the	
decline	in	CD4	T	cell	count	seen	in	HIV	progression-	a	discrepancy	which	may	be	
accounted	for	by	a	further	consequence	of	immune	activation,	that	of	
immunosenescence62	(Figure	7).		Immunosenescence	refers	to	the	normal	process	of	
aging	of	the	immune	system	seen	in	older	adults.	It	involves	involution	of	the	thymus,	
a	decrease	in	haematopoietic	stem	cells,	reduced	naïve	T-cells	with	concomitant	
increase	in	well-differentiated	memory	T-cells	with	limited	capacity	to	proliferate,	
and	increased	levels	of	proinflammatory	cytokines63-65.		In	HIV,	it	appears	that	this	
process	is	accelerated.	Through	multiple	pathways	including	bystander	apoptosis,	
pyroptosis	mediated	by	caspase-1,	thymic	involution,	lymphatic	fibrosis	and	clonal	
exhaustion,	there	is	a	gradual	decline	in	the	ability	of	the	immune	system	to	renew	
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naïve	T	cell	pools,	produce	HIV-specific	T	cells	and	control	HIV	infection	(Figure	7)66-71.	
In	particular,	caspase-1-mediated	pyroptosis	of	CD4	T	cells	due	to	abortive	infection	
with	HIV	is	intensely	inflammatory	and	could	provide	a	key	link	between	immune	
activation	and	the	dramatic	CD4	T	cell	depletion	seen	in	HIV68.	
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Figure	7	Schema	of	immunosenescence	in	HIV	(reproduced	from	Deeks	2011,	no	permission	required)65	
HARRT:	Highly	active	retroviral	therapy	or	ART.	
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Children	with	HIV	may	be	more	resilient	to	this	process	of	immunosenescence,	with	
an	increased	thymic	output	acting	as	the	source	for	a	restored	CD4	T	cell	population	
after	commencing	ART,	dependent	on	the	initial	stage	of	CD4	T	cell	depletion72.		
However,	when	comparing	children	on	ART	who	achieve	viral	suppression	with	those	
who	do	not,	those	who	fail	to	achieve	suppression	had	persistently	higher	levels	of	
activated	CD8+CD38+	T	cells	versus	those	who	achieved	suppression,	alongside	
higher	lipopolysaccharide	(LPS:	a	component	of	Gram	negative	bacterial	cell	walls,	
see	section	8.4),	and	lower	numbers	of	central	memory,	effector/memory	and	CD38+	
T	cells73.		
	
Support	for	the	importance	of	immune	activation	in	the	pathogenesis	of	HIV	is	seen	in	
simian	models	of	SIV	infection.	Sooty	mangabeys	are	natural	hosts	of	SIV	and	
maintain	normal	CD4	T	cell	counts	and	remain	clinically	well	despite	high	viral	loads.	
They	do	not	demonstrate	immune	activation.	By	contrast,	rhesus	macaques	(RMs)	
which	are	not	natural	hosts	of	SIV,	have	aberrant	immune	activation	with	subsequent	
immune	exhaustion	and	experience	a	similar	progressive	immunodeficiency	
syndrome	to	humans	with	HIV74.	
	
8.3.2 End	Organ	Effects	of	Immune	Activation	
	
Markers	of	immune	activation	have	been	consistently	linked	to	increased	all-cause	
mortality	and	disease	progression	in	HIV	(Figure	6)46,53,75.		In	the	SMART	study,	high	
levels	of	IL-6,	high	sensitivity	C-reactive	protein	(hsCRP)	and	D-Dimer	were	all	found	
to	be	associated	independently	with	an	increased	risk	of	mortality	from	non-AIDS	
events,	particularly	cardiovascular	disease.	In	co-infection	of	HIV	with	either	hepatitis	
B	or	C,	increased	TNFα	was	associated	with	a	more	rapid	rate	of	liver	fibrosis,	
compared	with	patients	with	lower	levels	of	TNFα76.		Plasma	soluble	CD14,	a	marker	
of	monocyte	activation	was	found	to	be	associated	with	poorer	scores	in	cognitive	
function	tests	indicating	global	impairment	and	with	a	diagnosis	of	HIV-associated	
dementia	(HAD),	as	well	as	increased	cardiovascular	risk52,77,78.	Kynurenine	
production	from	IDO-expressing	activated	monocytes	has	also	been	linked	to	HAD79.		
		
33	
In	pathogenic	SIV,	immunohistochemical	staining	for	LPS	and	Escherichia	coli	in	the	
liver	was	associated	with	the	recruitment	of	hypercytotoxic	Natural	Killer	(NK)	cells	
and	subsequent	markers	of	liver	damage,	hepatitis	and	fibrosis	at	necropsy80.	
Increased	B	cell	activation	appears	to	be	implicated	in	the	development	of	AIDS-Non-
Hodgkins	lymphoma	(AIDS-NHL)	of	the	B	cell	lineage,	and	finally	raised	renal	
interstitial	and	glomerular	non-polymorphic	MHC	Class	II,	interferon	(IFN)-alpha	and	
IFN-gamma	receptor	protein	were	found	to	be	positively	associated	with	HIV	
associated	nephropathy51,81.		
	
8.3.3 Causes	of	Immune	Activation	
	
Immune	activation	in	HIV-infected	individuals	is	likely	to	be	multifactorial	with	4	main	
pathways	implicated:	i)	driven	directly	by	HIV	proteins	ii)	immune	response	to	HIV	
infection	including	loss	of	regulatory	T-cells	iii)	re-activation	or	primary	infection	with	
other	persistent	infections	such	as	cytomegalovirus	(CMV),	Epstein-Barr	virus	(EBV)	
and	tuberculosis;	and	iv)	driven	by	translocation	of	microbial	products	from	the	gut	
(Figure	6).		
i. HIV	proteins	such	as	gp120	and	Nef	can	cause	immune	activation	not	only	by	
causing	direct	infection	of	T	cells	but	also	indirectly.	For	example,	
gp120/chemokine	interactions	on	macrophages	lead	to	release	of	pro-
inflammatory	cytokines	such	as	TNFα	and	macrophage-inflammatory	protein	
1β82.	The	Nef	protein,	amongst	other	roles,	appears	to	be	responsible	for	the	
down-regulation	of	the	negative	T	cell	modulator	CTLA-4	so	leading	to	
uncontrolled	T	cell	activation.83	
ii. Increasingly,	the	process	of	maladaptive	immune	activation	appears	in	part	to	
be	due	to	reduced	inhibition	by	regulatory	mechanisms,	such	as	the	
interaction	between	Nef	and	CTLA-4	described	above.	In	a	study	of	untreated	
HIV	infected	individuals,	a	significant	negative	relationship	was	found	
between	declining	numbers	of	T	regulatory	cells	(Tregs)	and	CD8	activation	
(HLA-DR	and	CD38)	(R	=-0.33,	P	=	0.03)84.	This	study	supports	other	work	
which	suggest	that	Tregs	have	a	protective	role	in	limiting	immune	activation,	
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and	their	decline	is	associated	with	an	increase	in	immune	activation	both	in	
HIV	and	simian	immunodeficiency	virus	(SIV)	infection85-87.	In	a	virus-free	
mouse	model,	activated	CD4	T-cell	ablation	(to	mimic	the	destruction	of	these	
cells	by	HIV)	resulted	in	generalised	immune	activation	which	was	prevented	
by	reconstitution	of	regulatory	T	cells.88	
iii. Other	infections,	either	chronic	and	reactivating	or	as	acute	primary	infections	
may	also	have	a	role.	CMV	in	particular	appears	to	be	associated	with	poor	
outcomes	in	HIV	infection:	a	cohort	study	of	over	6000	Italian	HIV	infected	
individuals	found	that	those	with	a	positive	CMV-Immunoglobulin	(Ig)	G	at	
baseline	were	more	likely	to	suffer	severe	non-AIDS	events	or	death	(adjusted	
hazard	ratio	(AHR)	1.53,	95%	confidence	intervals	(CI):1.08-2.16)	with	a	non-
significant	trend	towards	increased	risk	of	cardiovascular	disease89.	This	
supports	previous	evidence	that	in	HIV	infected	individuals,	CMV	specific	T	cell	
responses	and	T	cell	activation	were	both	independently	associated	with	
increased	carotid	intima	media	thickness	(a	precursor	to	atherosclerosis)90.	A	
further	study	found	significantly	increased	levels	activated	T	cells	specific	for	
herpes	viruses	(persistent	infections)	when	compared	to	HIV	negative	controls	
and	also	to	the	non-persistent	antigen	tetanus	toxoid91.	In	Ugandan	HIV	
infected	adults,	co-infections	were	significantly	associated	with	CD4	T	cell	
activation92.	These	infections	included	tuberculosis	(40%),	candida	(30%),	
malaria	(13%),	and	herpes	zoster	(13%)92.	Visceral	leishmaniasis	has	also	been	
implicated93.	
iv. Microbial	translocation	as	a	cause	of	immune	activation	in	HIV	is	the	principal	
focus	of	this	thesis	and	is	discussed	at	greater	length	below.	
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8.4 Microbial	Translocation	in	HIV	
	
It	is	postulated	that	rapid	depletion	of	CD4	T	cells	within	gut-associated	lymphoid	
tissue	(GALT)	in	early	HIV	infection	allows	microbial	translocation	from	the	gut94-97.		
Bacterial	products	have	been	identified	at	higher	levels	in	the	bloodstream	of	patients	
with	HIV	as	compared	to	uninfected	controls98,99.	These	products	include	potential	
immunostimulants,	including	lipopolysaccharide	(LPS),	a	component	of	Gram-
negative	bacteria,	and	16S	ribosomal	DNA	(16S	rDNA),	common	to	all	bacterial	
species.		Increased	circulating	LPS	is	associated	with	higher	levels	of	immune	
activation	in	HIV-infected	patients52,99.		Higher	levels	of	16S	rDNA	detected	with	
broad-range	polymerase	chain	reactions	(PCR)	and	LPS	were	associated	with	poorer	
immune	restoration	in	patients	on	ART98.		Immune	activation	in	those	with	poor	CD4	
T	cell	responses	to	ART	has	been	associated	with	Enterobacteriaceae	detected	in	the	
blood	by	16S	rDNA	PCR	and	sequencing100.		
	
Microbial	translocation	as	a	mechanism	for	inducing	immune	activation	was	first	
proposed	by	Brenchley	et	al.	in	2006.99	Having	noted	the	dramatic	decline	of	CD4	T	
cells	in	the	gut	associated	lymphoid	tissue	(GALT)	early	in	HIV	infection	demonstrated	
by	Veazey	et	al.94	and	their	own	earlier	work97,	they	quantified	LPS	in	monkeys	with	
pathogenic	and	non-pathogenic	SIV,	finding	a	significant	difference	between	hosts	
and	over	the	course	of	disease	(see	Figure	8	and	section	8.4.1	for	description	of	HIV-
related	gut	damage).	In	the	pathogenic	model	they	found	evidence	of	the	LPS	being	
bio-active,	in	that	there	was	a	significant	increase	in	the	level	of	soluble	CD14	(sCD14:	
a	marker	of	monocyte	activation	produced	particularly	in	response	to	LPS)	with	
increasing	LPS.	In	vitro,	it	was	possible	to	induce	CD8	activation	in	HIV	negative	cells	
by	culturing	with	plasma	from	HIV	infected	individuals	containing	increased	levels	of	
LPS.	In	a	cross	sectional	substudy	comparing	HIV-infected	adults	with	slow	and	rapid	
disease	progress	(in	the	absence	of	ART)	alongside	HIV-uninfected	controls,	increased	
levels	of	LPS	were	found	in	adults	with	HIV99.		However,	the	slow	progressors	had	
lower	levels	of	sCD14	and	LBP,	and	higher	levels	of	EndoCAb	(anti-endotoxin	core	
antibodies,	which	are	involved	in	LPS	clearance)	than	the	rapid	progressors.	This	
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implies	that	in	those	individuals	who	maintain	a	low	level	of	viraemia	without	ART	
(sometimes	termed	‘elite	controllers’),	the	immunostimulatory	effect	of	LPS	may	be	
diminished99.	
		
Exogenous	administration	of	LPS	to	SIV-infected	African	green	monkeys	(which	have	a	
non-pathogenic	infection	phenotype),	led	to	an	increase	in	D-dimer	levels	(indicative	
of	a	procoagulant	state),	sCD14	and	a	small	but	significant	increase	in	viral	load101.	
LPS	may	also	impact	on	immune	dysfunction	by	triggering	memory	B	cell	death	via	
the	Fas/Fas	ligand	pathway102.		
	
There	have	been	multiple	further	investigations	into	microbial	translocation,	both	
mechanistically	at	the	gut	barrier	and	further	downstream	aiming	to	detect	bacterial	
products	in	the	blood	of	HIV	infected	individuals	and	any	putative	impact.		
	
8.4.1 Mechanisms	of	Microbial	Translocation	
	
Mechanistically,	there	appear	to	be	several	pathways	leading	to	impaired	intestinal	
barrier	function	(Figure	8).	In	adults	with	untreated	HIV,	there	appears	to	be	
decreased	epithelial	resistance	as	assessed	by	both	impedance	spectroscopy	and	
[3H]mannitol	fluxes	compared	with	HIV	infected	but	treated	adults	or	HIV-uninfected	
controls103.		This	was	associated	with	increased	evidence	of	apoptosis:	upregulation	
of	the	pore-forming	claudin-2,	and	mucosal	production	of	interleukin-2	(IL-2)	and	
tumour	necrosis	factor-α	(TNFα)103(Figure	8).		Massive	CD4	T	cell	depletion	in	the	
lamina	propria	is	mirrored	by	gut	epithelial	cell	apoptosis,	potentially	driven	directly	
by	the	virus	itself94,104.		The	mucosal	CD4	T	cell	population	in	the	gut	appears	to	be	
preserved	if	ART	is	initiated	during	acute	infection,	and	shows	better	recovery	if	ART	
initiation	occurs	at	a	threshold	of	>350	CD4	T	cells/mm3	compared	to	lower	CD4	
counts	105.	There	also	appears	to	be	a	reduction	of	tight-junction	proteins	in	intestinal	
epithelial	cells	among	those	infected	with	HIV	compared	with	controls,	more	marked	
in	the	distal	than	proximal	colon,	and	in	those	with	incomplete	CD4	T	cell	recovery	
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versus	those	with	better	immune	restoration106,107.		In	vitro,	Nazli	et	al.	demonstrated	
a	decline	in	transepithelial	resistance	in	epithelial	cells	in	response	to	exposure	to	HIV	
envelope	protein	gp120	with	associated	disruption	of	tight	junction	proteins	and	
upregulation	of	inflammatory	cytokines,	with	possible	further	disruption	to	barrier	
function95.		
	
Poor	response	to	ART	is	also	associated	with	decreased	epithelial	proliferation	
despite	neutrophil	infiltration	(representing	epithelial	breaches)	in	the	gut	of	adults	
with	HIV	in	the	USA108(Figure	8).	T-helper	17	(Th17)	cells,	a	CD4	T-cell	subset	
necessary	for	mucosal	defence	also	appear	to	be	preferentially	depleted	in	
pathogenic	SIV	infection	as	compared	to	non-pathogenic	SIV,	where	Th17	mucosal	
frequencies	are	unaffected109,110.	Th17	cell	numbers	and	function	both	appear	to	
decline	with	more	advanced	HIV	infection	and	concomitant	increasing	immune	
activation111.		
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Figure	8	The	intestinal	epithelium	in	health	and	during	HIV	infection,	reproduced	with	permission	from	Sandler	
et	al.,	2012112	
The	intestinal	epithelium	in	a	healthy	individual.	A	continuous	enterocyte	lining	with	intact	tight	junctions	prevents	translocation	
of	commensal	bacteria	from	the	intestinal	lumen	into	the	intestinal	wall.	Neutrophils	(recruited	by	T	helper	17	(Th17)	cells	in	the	
gut-associated	lymphoid	tissue	(GALT)),	defensins	(produced	by	Th17	cells)	and	secretory	immunoglobulin	A	(IgA)	maintain	
control	over	the	growth	of	commensal	bacteria,	further	impeding	microbial	translocation113	
The	intestinal	epithelium	in	an	HIV-infected	individual.	The	villus	height	in	the	intestine	of	an	HIV-infected	individual	decreases	
with	an	increase	in	crypt	depth114,115	in	association	with	CD8	T	cell	infiltration116.	The	decreased	villus	height/crypt	depth	ratio	
has	been	attributed	to	abnormal	enterocyte	differentiation117	and	enterocyte	apoptosis,	which	in	turn	may	be	caused	by	failure	
of	the	cells	to	maintain	ionic	balance	and	by	increased	production	of	interferon-γ	(IFNγ)	and	tumour	necrosis	factor	(TNF).	
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Increased	TNF	production	may	also	lead	to	the	destruction	of	the	tight	junctions118.	B	cell	dysfunction	may	contribute	to	
decreased	luminal	IgA	concentrations114,119,	and	HIV	infection	of	CD4	T	cells	is	likely	to	drive	the	loss	of	CD4	T	cells120-122,	
particularly	Th17	cells,	from	the	GALT.	Lower	IgA	levels	and	Th17	cell	loss	may	allow	bacterial	overgrowth,	which	may	also	
contribute	to	increased	microbial	translocation123.	The	continued	presence	of	the	high	endothelial	venules	(HEVs)	suggests	there	
is	not	an	anatomical	abnormality	preventing	T	cells	from	trafficking	into	the	GALT.			
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There	is	evidence	of	increased	density	of	macrophages	in	the	duodenal	mucosa	of	
adults	with	untreated	HIV	compared	with	uninfected	controls,	with	associated	
increased	levels	of	potentially	damaging	pro-inflammatory	molecules	such	as	IL-1β,	
CCL5,	CXCL9	and	CXCL10	and	reduced	phagocytic	activity124.	Impaired	ability	of	
intestinal	macrophages	to	phagocytose	microbial	products	has	been	demonstrated	in	
pathogenically	SIV-infected	primates,	and	in	humanised	mice	infected	with	HIV	
(Figure	8)118,125.	Gut	mucosal	macrophages	are	usually	anergic	in	response	to	
stimulation	by	pathogen	associated	molecular	patterns	(PAMPs);	although	they	are	
effective	phagocytes,	they	do	not	initiate	an	inflammatory	cascade,	enabling	them	to	
maintain	the	gastrointestinal	barrier	without	inducing	an	inflammatory	response	to	
the	host’s	intestinal	flora126,127.		Increased	macrophage	related	pro-inflammatory	
cytokines	could	have	downstream	results	of	inflammation	and	tissue	injury124.		In	
vitro,	incubation	of	IL-2,	IL-4,	TNFα	and	IL-13	all	reduced	the	transepithelial	resistance	
of	rat	jejunal	mucosa103.	
	
It	appears	the	gut	microbiota	itself	is	also	altered	by	HIV	infection.	Several	studies	
examining	stool,	rectal	biopsies	and	rectal	sponges	have	found	decreased	diversity	in	
the	microbiota	of	adults	with	HIV	(mostly	on	ART),	with	an	increased	proportion	of	
Enterobacteriaceae	and	Proteobacteria,	with	a	decrease	in	Clostridia	and	
Bacteroides128-132.		In	pathogenic	SIV,	ART	initiation	was	found	to	decrease	the	
abundance	of	Bacteroidetes	and	Firmicutes	with	an	increase	in	Proteobacteria	(and	a	
concomitant	increase	in	the	metabolic	activity	of	the	Proteobacteria	as	measured	by	
stool	RNA),	although	this	normalised	over	time133.	Lactobacillus	decreased	
dramatically	on	initial	infection,	but	recovered	after	one	month	of	ART.	One	study	
found	increased	diversity	in	stool	samples	from	untreated	adults	with	HIV	in	the	
United	States	(U.S.),	with	a	microbiotal	profile	more	closely	resembling	that	found	in	
agrarian	societies	than	that	usually	seen	in	samples	from	healthy	adults	in	the	U.S131.	
Most	other	studies	found	a	decrease	in	diversity,	more	pronounced	with	more	severe	
immunosuppression,	impacting	on	both	stool	and	mucosal	microbiotal	profiles134,135.		
One	large	study	of	Ugandan	adults	(82	HIV	infected,	40	HIV-uninfected)	also	
demonstrated	a	reduced	richness	in	the	gut	microbiome	to	be	associated	with	poorer	
immune	status,	alongside	an	increase	in	Enterobacteriaceae	and	a	decrease	in	
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Ruminococcus136.	This	study	also	found	an	expansion	of	Adenovirus	and	Anelloviridae	
within	the	virome	of	adults	with	advanced	HIV,	the	pathological	significance	of	which	
is	as	yet	unknown.	
	
Bringing	together	mucosal	dysfunction	and	dysbiosis	of	the	microbiota,	Dillon	et	al.	
described	an	increased	frequency	of	activated	colonic	myeloid	dendritic	cells	(mDCs)	
in	HIV,	with	an	associated	increased	abundance	of	Prevotella	species,	which	in	vitro	
had	the	capability	of	inducing	inflammatory	cytokine	production	from	those	mDCs.	
Increased	activity	of	IDO-1	with	resulting	Th17	depletion	was	seen	in	SIV-infected	
rhesus	macaques	was	associated	with	a	specific	depletion	of	gut	Lactobacillus137,	and	
in	adults	newly	infected	with	HIV,	an	increased	proportion	of	Lactobacillales	was	
associated	with	lower	markers	of	microbial	translocation,	higher	CD4	T	cell	
percentage	and	lower	viral	loads	both	prior	to	and	during	ART138.		There	was	some	
reduction	in	IDO-1	activity	on	supplementation	with	a	Lactobacillus-containing	
probiotic137.	There	also	appears	to	be	a	positive	relationship	between	Bacteroides	
species	and	the	frequency	and	ability	of	invariant	natural	killer	T	cells	(iNKT)	in	the	
GALT	to	produce	IL-4	and	IL-10,	which	in	turn	was	associated	with	less	immune	
activation139.		With	the	exception	of	the	Ugandan	study136,	numbers	have	been	small	
(maximum	cohort	size	40	patients	of	whom	half	were	receiving	ART135)	and	little	work	
has	been	done	investigating	the	gut	microbiome	of	children	with	HIV.	
	
Estes	et	al.	investigated	evidence	of	microbial	translocation	in	pathogenic	versus	non-
pathogenic	SIV	infection	in	rhesus	macaques	(RMs)	and	sooty	mangabeys	(SMs)	
respectively118.	Using	qualitative	image	analysis	to	examine	colonic	mucosa,	there	
was	evidence	of	increased	staining	with	a	monoclonal	antibody	to	lipopolysaccharide	
(LPS)	core	antigen	in	the	lamina	propria	of	RMs	with	chronic	SIV	infection	compared	
to	early	acute	infection	and	uninfected	controls.		LPS	staining	was	also	found	in	both	
locally	draining	and	remote	lymph	nodes	in	chronically	infected	RMs,	as	well	as	in	the	
liver.	Using	quantitative	image	analysis	techniques	involving	staining	large	sections	of	
colonic	mucosa,	a	positive	association	was	found	between	the	percentage	of	
intestinal	mucosa	staining	positive	for	LPS	and	that	found	in	local	and	remote	nodes.		
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LPS	staining	was	co-localised	with	staining	for	the	innate	pro-inflammatory	cytokine	
interferon-α	(IFNα)	and	Interleukin-18	(IL-18),	neither	of	which	were	found	in	close	
proximity	to	areas	of	viral	replication.	Staining	for	the	tight	junction	protein	claudin-3	
revealed	evidence	of	discontinuity	and	epithelial	loss	in	the	gut	mucosa	of	chronically	
infected	RMs,	but	not	those	uninfected	or	those	in	early	stage	infection	(Figure	8).	
Furthermore,	loss	of	claudin-3	was	significantly	associated	with	the	amount	of	LPS	
within	the	lamina	propria	(r=0.57,	p=0.032),	supporting	the	hypothesis	that	microbial	
translocation	and	intestinal	barrier	dysfunction	is	a	key	feature	of	SIV	pathogenesis.		
Neither	infiltration	of	LPS	nor	damage	to	the	intestinal	barrier	was	seen	in	SMs	
infected	with	SIV118.	Furthermore,	early	initiation	of	ART	may	preserve	gut	barrier	
function,	GALT	tissue	structure	and	Th17	cell	numbers	and	poly-functionality111,140.		
	
8.4.2 Evidence	of	Microbial	Translocation	in	the	Bloodstream	
	
The	downstream	evidence	for	and	effects	of	microbial	translocation	have	proved	
complex	to	investigate	due	to	controversy	about	the	best	methods	with	which	to	
measure	microbial	translocation,	assay	variability	and	lack	of	consistency	in	results	
seen	in	different	settings.	In	adults,	Jiang	et	al.	performed	a	cross-sectional	study	in	
173	HIV	infected	patients,	along	with	a	longitudinal	cohort	of	54	followed	up	for	48	
weeks	and	15	HIV	uninfected	controls98.	LPS	was	measured	using	a	limulus	
amebocyte	assay	and	bacterial	DNA	was	measured	using	a	quantitative	broad	range	
polymerase	chain	reaction	for	the	bacterial	ribosomal	subunit	16S	rDNA	(16S	rDNA	
PCR).	No	evidence	of	16S	rDNA	was	found	in	the	HIV	negative	controls.	16S	rDNA	was	
negatively	associated	with	CD4	T	cell	restoration	after	adjustment	for	viral	load	at	
week	48	in	HIV-infected	patients,	but	not	before.	Those	who	were	on	treatment	had	
lower	16S	rDNA	levels	detected	than	ART	naïve	patients.		
	
However	other	studies	have	given	less	clear-cut	results.	Merlini	et	al.	studied	groups	
of	patients	with	either	partial	or	no	immune	response	to	ART	and	found	divergent	
CD4	T	cell	count	recovery	despite	no	change	in	sCD14	or	LPS	between	the	groups141.	
An	analysis	of	adults	enrolled	in	the	SMART	trial	(investigating	continuous	versus	
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intermittent	ART)	measured	Intestinal	Fatty	Acid	Binding	protein	(I-FABP)	–	a	small	
protein	released	from	intestinal	epithelial	cells	after	damage	–	together	with	LPS,	
sCD14,	EndoCAb	and	16S	rDNA	to	elucidate	the	relationship	between	these	potential	
markers	of	microbial	translocation	and	immune	activation142.	sCD14	was	positively	
associated	with	IL-6,	CRP,	amyloid	A	and	D-dimer,	and	I-FABP	was	higher	in	HIV	
infected	individuals	than	in	controls.	However,	there	were	no	differences	in	16S	rDNA	
levels	between	subjects	and	healthy	volunteers.	Only	sCD14	was	associated	with	
mortality,	not	LPS	or	any	other	marker.		The	authors	raised	the	possibility	that	host	
bioreactivity	to	microbial	translocation	might	be	more	important	than	the	actual	level	
of	translocated	organisms.		This	was	mirrored	in	a	Danish	cohort	where	sCD14	was	
linked	to	an	increased	risk	of	cardiovascular	events,	but	microbial	translocation	
markers	were	not78.	Indeed	one	study	demonstrated	an	independent	association	of	
specific	CD14	and	Toll-like	receptor	4	(TLR4)	gene	polymorphisms	with	CD4	T	cell	
recovery,	although	no	genome-wide	significant	determinant	of	I-FABP	or	sCD14	were	
found	in	717	untreated	adults	in	a	Swiss	cohort143.		
	
In	a	large	prospective	cohort	of	ART-naïve	adults	in	Uganda,	markers	of	immune	
activation	were	raised	without	any	evidence	of	concomitant	microbial	
translocation144.	Both	sCD14	and	CRP	were	raised,	and	CRP	was	associated	with	
mortality	but	there	was	no	change	in	LPS	over	time	in	the	absence	of	ART145.	More	
recently,	an	Italian	cohort	of	HIV	infected	adults	found	that	CRP	was	the	only	
biomarker	pre-ART	to	predict	non-AIDS	events,	with	sCD14,	LPS	and	EndoCAb	all	
unrelated	to	disease	progression146.		A	French	study	of	early	HIV	infection	in	27	adults	
found	that	immune	activation	occurred	in	the	apparent	absence	of	microbial	
translocation	(as	measured	by	I-FABP	and	16S	rDNA	PCR)	in	the	first	6	months	of	
infection	which	suggests	that	microbial	translocation	is	not	the	primary	driver	of	
immune	activation	at	this	stage	of	infection147.	There	was	modest	association	of	LPS	
with	an	increased	ratio	of	kynurenine	to	tryptophan	(KT	ratio)	(rho=0.12,	p=0.02)	
linking	monocyte	activation	to	microbial	translocation	in	Ugandan	adults	initiating	
ART,	and	an	independent	association	of	a	high	KT	ratio	with	poor	CD4	T	cell	recovery	
at	1	year	and	increased	mortality56.		However,	another	adult	cohort	study	in	Uganda	
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found	that	only	viral	load,	not	T	cell	activation,	was	independently	associated	with	
morbidity	and	mortality148.	
8.4.3 Microbial	Translocation	in	Children	with	HIV	
In	children	the	available	evidence	is	more	conflicting.	Pillakka	Kanthikiel	et	al.	studied	
85	ART-experienced	children	in	India	over	48	weeks	who	were	treated	with	a	
protease	inhibitor	in	1997149.	Potential	markers	of	microbial	translocation	including	
16S	rDNA,	sCD14	and	LPS	were	compared	with	markers	of	immune	activation	and	
viral	load.	Interestingly	they	reported	an	increase	in	all	markers	of	microbial	
translocation	compared	with	HIV-uninfected	adults	with	no	change	over	time	despite	
48	weeks	of	ART.	There	was	an	association	between	levels	of	16S	rDNA,	CD4	T	cell	
count	and	immune	activation	but	counter-intuitively	no	association	with	LPS	or	viral	
load,	implying	that	microbial	translocation	was	persisting	despite	viral	control.		
Papasavvas	et	al.	compared	LPS,	sCD14,	LPS	binding	protein	(LBP)	and	T	cell	activation	
in	54	HIV	infected	infants	enrolled	in	the	South	African	CHER	trial	with	22	exposed,	
uninfected	children150.	LPS	was	higher	in	HIV-infected	children	compared	to	controls	
and	LPS,	sCD14,	LBP,	and	T	cell	activation	were	all	higher	in	those	infants	in	whom	
ART	was	deferred	as	compared	to	those	starting	immediate	therapy.	No	LPS	was	
detectable	in	any	child	between	the	ages	of	6	months	and	one	year.	However	there	
was	no	association	between	T	cell	activation	and	LPS	or	between	the	T	cell	activation	
rate	of	change	and	the	LPS	rate	of	change.		In	a	cross	sectional	Spanish	cohort	of	77	
children	with	HIV	infection,	HIV	viraemia	was	linked	to	T	cell	activation,	but	neither	
LPS	or	16S	rDNA	levels	(assessed	with	a	qPCR)	were	associated	with	markers	of	
immune	activation151.		The	same	group	compared	markers	of	immune	activation	and	
microbial	translocation	between	10	children	receiving	standard	ART	and	5	receiving	
ritonavir-boosted	protease	inhibitor	monotherapy	and	found	no	difference	between	
the	groups.		
In	contrast,	Wallet	et	al.,	evaluating	33	children	starting	ART	over	96	weeks	found	
that	10%	had	an	elevated	LPS,	but	with	no	associated	rise	in	sCD14152.	Although	
immune	recovery	was	seen	along	with	a	decrease	in	immune	activation,	there	was	no	
association	with	LPS	levels.	A	raised	LPS	level	was	associated	with	monocyte	
activation,	but	not	with	T	cell	activation,	CD4	T	cell	count,	thymic	output	or	EndoCAb.			
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8.4.4 Interventions	Targeting	Immune	Activation	and	Microbial	Translocation	
There	have	been	numerous	studies	investigating	therapies	targeting	immune	
activation	and	its	potential	drivers	in	animal	models	and	adults	with	HIV,	including	
statins,	pro/prebiotics,	chloroquine,	hydroxychloroquine,	cyclooxygenase	type	2	
inhibitors,	leflunomide,	intravenous	immunoglobulin,	minocycline,	bovine	colostrum,	
micronutrient	supplementation,	raltegravir	and	maraviroc	ART	intensification,	
valganciclovir	(targeting	CMV	coinfection),	rifaximin,	sevelamer,	mesalamine,	
lisinopril,	methotrexate	and	most	recently	fecal	microbiotal	transplantation153.	
Results	have	been	mixed,	with	no	single	therapy	having	sustained	clinical	and	
immunological	impact	across	settings154-156.	Sevelamer	for	example,	a	phosphate	
binding	drug	used	with	the	aim	of	binding	LPS	in	the	gut,	appeared	promising	in	
reducing	immune	activation	and	even	viral	replication	(albeit	slightly)	in	acutely	SIV	
infected	pigtailed	macaques,	but	in	ART	naïve	humans,	no	impact	was	found	on	
markers	of	immune	activation	or	microbial	translocation157,158.	A	combination	of	both	
probiotics	and	IL-21	to	promote	Th-17	cell	recovery	in	the	gut	was	reported	to	
contribute	to	a	reduction	morbidity	in	ART-treated,	SIV-infected	rhesus	macaques,	
although	no	significant	change	in	microbial	translocation	was	measured,	as	measured	
by	E.	coli	antigen	detection	in	gut	related	tissues159.	Trials	in	children	are	lacking.		In	
one	randomised	double	blind	controlled	trial	of	77	children	in	Brazil,	(55%	of	whom	
were	receiving	ART),	probiotics	(Bifidobacterium	bifidum	with	Streptococcus	
thermophiles,	2.5	x1010	CFU	(colony	forming	units))	led	to	greater	CD4	T	cell	rise	in	
the	intervention	group	compared	to	controls	after	2	months	of	therapy160.	
	
8.4.5 Challenges	in	Quantifying	Microbial	Translocation	
It	appears	the	evidence	for	microbial	translocation	causing	immune	activation	in	HIV	
is	limited	and	conflicting	particularly	in	children.	This	may	in	part	be	due	to	small	
study	sizes,	limited	prospective	data	and	limited	use	of	appropriate	age-matched	
controls.	However,	in	studies	in	both	adults	and	children,	there	is	also	a	lack	of	
consensus	about	the	optimal	methodology	to	test	for	microbial	translocation.	LPS	is	
limited	in	that	the	ranges	obtained	in	different	studies	vary	by	several	logs-	i.e.	
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reproducibility	is	poor142,144,149.	Plasma	inhibition	within	the	Limulus	Amoebocyte	
assay	used	for	quantifying	LPS	can	also	be	a	problem,	with	different	researchers	
recommending	sample	dilution	from	5	to	100-fold	to	prevent	inhibition,	with	
considerable	variation	in	plasma	inhibition	between	samples	within	the	same	study	
(and	even	from	the	same	individual)73,161.	Soluble	CD14	is	also	problematic	in	that	it	
appears	to	be	influenced	by	factors	other	than	microbial	translocation,	including	
differences	in	ethnicity162.		Soluble	CD14	is	a	marker	of	monocyte	activation	which	
can	be	caused	by	multiple	processes,	including	raised	levels	of	interferons	and	by	
exposure	to	HIV	itself	in	addition	to	microbial	translocation163,164.	It	has	even	been	
shown	to	be	independently	associated	with	smoking	in	adults	with	HIV165,166.	It	
therefore	appears	to	be	a	generic	marker	of	immune	activation	rather	than	of	
microbial	translocation	alone.			
	
8.4.6 Molecular	Methods	for	Investigating	Microbial	Translocation	in	Blood	
	
8.4.6.1 	Broad	Range	16S	rDNA	PCR	
	
One	previously	used	technique	for	investigating	microbial	translocation	in	blood	is	a	
quantitative	broad	range	polymerase	chain	reaction	for	the	gene	of	the	bacterial	16S	
ribosomal	subunit	(16S	rDNA	PCR)	(Figure	9).	This	involves	using	primers	that	target	
the	conserved	regions	of	the	16S	ribosomal	subunit,	aiming	to	amplify	any	bacterial	
DNA	present	in	the	sample.	The	amplicon	includes	variable	regions	which	can	be	used	
to	identify	the	bacterial	species	present	via	sequencing	techniques.		Positive	samples	
are	identified	via	gel	electrophoresis	(Figure	9)	or	by	a	quantitative	PCR	reaction	using	
a	dye	such	as	SYBR	Green™	(Life	Technologies)	to	stain	double	stranded	DNA.			
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Figure	9	Schema	of	Broad	range	16S	rDNA	PCR	
A:	Schematic	of	principle	of	polymerase	chain	reactions,	showing	sequential	denaturation	and	extension,	resulting	in	exponential	
amplification	of	DNA	strand	
B:	Schematic	of	16S	ribosomal	subunit	gene	showing	variable	and	conserved	regions	and	primer	sites	
C:	Example	image	of	gel	electrophoresis	post	library	amplification	demonstrating	and	strong	and	weak	positive	result	from	serial	
dilutions		 	
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It	is	important	to	emphasise	the	methodological	difficulties	that	measuring	16S	rDNA	
presents.	16S	rDNA	PCR	is	subject	to	artefact	from	endogenous	and	exogenous	
bacterial	products167-169	and	therefore	without	sequencing	the	PCR	product,	there	is	
concern	that	changes	in	the	quantity	of	bacterial	DNA	detected	by	PCR	may	not	
necessarily	be	due	to	gut-derived	organisms.			In	particular,	using	high	numbers	of	
cycles	such	as	reported	in	studies	undertaken	by	both	Jiang	et	al.	and	Pilakka-
Kanthikeel	et	al.	will	increase	the	likelihood	of	false	positive	results	due	to	
contamination98,149.	Without	sequencing,	It	is	possible	that	differences	in	results	from	
a	quantitative	PCR	alone	might	be	due	to	variable	copy	numbers	of	the	16S	rDNA	
gene	between	(and	within)	species170.		
	
Additionally,	differing	levels	of	host	DNA	in	the	blood	or	plasma	can	impact	on	
extraction	efficiency	of	bacterial	DNA	and	therefore	on	bacterial	load171.	Although	
two	studies	reported	higher	levels	of	16S	rDNA	in	HIV-infected	individuals	versus	
controls98,149,	another	found	no	difference169,	and	there	has	been	discrepancy	in	the	
associations	demonstrated	between	16S	rDNA	and	other	markers	of	immune	
activation	and	microbial	translocation.	Several	studies	have	found	no	relationship	
between	16S	rDNA	and	other	markers	such	as	sCD14,	LPS,	I-FABP,	LPS-binding	protein	
(LBP)	or	markers	of	T-cell	activation172-175.		
	
8.4.6.2 Next	Generation	Sequencing	
	
As	described	above,	most	previous	studies	investigating	microbial	translocation	in	
blood	using	molecular	techniques	have	used	broad-range	16S	rDNA	PCR	either	with	
or	without	conventional	Sanger	sequencing	techniques100,141	(See	Figure	10	for	Sanger	
sequencing	method).		The	limitation	of	this	technique	is	that	typically	a	single	
dominant	species	will	be	identified	with	minority	species	often	being	out-competed	
in	the	PCR,	or	generation	of	mixed	sequences141	(Figure	10).	Cloning	can	go	some	way	
to	resolve	mixed	sequences,	but	the	maximum	number	of	sequences	generated	
would	still	be	in	the	order	of	100,	and	the	process	would	be	extremely	labour	
intensive	and	expensive.	Attempts	to	identify	the	16S	rDNA	in	blood	using	both	
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restriction	enzyme	digestion	or	Sanger	sequencing	with	cloning	has	so	far	yielded	
results	compatible	with	environmental	contamination	rather	than	recognised	gut	
commensals100,141,176.
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Figure	10	Schematic	of	Sanger	sequencing	technique	(adapted	from	Wellcome	Trust	Sanger	Institute	animation	with	permission)	
Schematic	of	Sanger	sequencing	technique	demonstrating	stages	of	strand	extension,	chain	termination,	and	recording	fluorescence.	Also	showing	the	difficulty	presented	by	mixed	sequencing177	
1.  Polymerase	extension	of	DNA	strand		
incorpora8ng	nucleo8des	and	ﬂuorescently		
labeled	chain	terminators	
2.	Repe88on	generates	many	fragments		
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3.	Samples	transferred	to	glass	capillaries	
in	sequencer	where	an	electrical	charge	
moves	the	nega8vely	charged	DNA	
molecules	through	a	gel	matrix	
4.	The	longer	fragments	move	more	slowly	so	
Molecules	are	sorted	by	size,	and	a	laser	at	the	
end	of	the	capillary	excites	the	ﬂuorescent	base	
which	is	recorded	as	a	coloured	peak	
5.	Each	peak	represents	the	ﬁnal	base	in	the	strand	
ordered	by	size	so	the	sequence	of	the	DNA	can	be	
decoded.	
6.	Result	of	Sanger	sequencing	reac8on	with	single	
amplicon	clone	present	
7.	However,	if	mixed	sequences	are	
present	it	can	be	impossible	to	decode	
the	individual	sequences	
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High-throughput	sequencing	(next	generation	sequencing	or	NGS)	can	generate	107	
sequences	from	a	single	sample	and	give	a	much	more	comprehensive	description	of	
microbial	DNA	present	in	the	sample,	including	those	in	the	minority	(Figure	11)178,179.	
This	technique	involves	amplifying	a	PCR	library	with	barcoded	primers,	then	clean-up	
and	normalization	steps	followed	by	the	sequencing	process	on	a	machine	such	as	a	
MiSeq™	(Illumina).	The	massively	parallel	nature	of	the	process	enables	rapid	and	
relatively	inexpensive	sequence	generation	(as	compared	with	the	Sanger	method).	
Utilising	paired-end	reads	allows	longer	amplicons	to	be	sequenced	to	the	point	
where	operational	taxonomic	units	(OTUs)	can	be	identified	to	a	species	level,	and	
dual-indexing	the	barcodes	mean	fewer	individual	barcodes	need	to	be	used	even	
when	pooling	up	to	384	samples	(Figure	11)180,181.		
	
After	sequencing,	downstream	bioinformatics	processing	is	necessary	to	demultiplex	
samples	(allocate	barcoded	sequences	to	the	samples	they	derive	from),	cluster	
sequences	to	OTUs,	build	phylogenetic	trees,	quality-filter	and	rarefy	the	data	in	
preparation	for	analysis,	and	perform	that	analysis.	A	method	which	is	widely	used	is	
the	open	source	software	platform	Quantitative	Insights	into	Microbial	Ecology	
(QIIME)	which	‘wraps’	various	other	software	dependencies	(e.g.	the	OTU	clustering	
programme	uclust	and	the	GreenGenes	database	which	is	used	as	a	reference	for	
OTU	picking182)183	into	a	single	pipeline	for	analysis184.		Decisions	made	at	each	of	
these	steps	can	have	important	implications	on	the	results	generated:	for	example,	
QIIME	supports	three	methods	of	OTU	picking,	de	novo,	closed	reference	and	open	
reference.	De	novo	groups	sequences	based	on	sequence	identity	alone,	and	can	be	
extremely	time	consuming.	Closed	reference	compares	sequences	to	a	reference	
database	(e.g.	GreenGenes)	and	discards	those	which	do	not	match,	and	open	
reference	combines	the	two	other	methods,	initially	comparing	with	the	database,	
and	then	de	novo	clustering	remaining	samples184.	Therefore	these	methods	are	
heavily	dependent	on	the	quality	of	the	reference	database.		
	
To	date,	one	study	in	pathogenic	SIV	has	used	pyrosequencing	with	454	FLX	
technology	to	sequence	16S	rDNA	isolated	from	mesenteric	lymph	nodes	and	the	
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Figure	11	Schematic	of	Illumina	next	generation	sequencing	method	(adapted	from	Wellcome	Trust	Sanger	Institute	animation	with	permission)	
Method	utilized	by	MiSeq	™	sequencer	showing	steps	from	post-library	amplification185.
1.	Adaptors	added	to	
fragmented	DNA/amplicons	
post	library	PCR	
2.	Samples	bound	to	lawn	
	of	primers	on	slide	 3.	AmpliﬁcaBon:	the	DNA	bends	over	and		
ﬁnds	a	complementary	primer	on	the	lawn	
surface	
4.	From	the	primer	on	the	surface,	a	complementary	strand	
of	DNA	is	made.	The	strands	are	split	apart	and	the	
replicaBon	process	is	repeated	creaBng	more	copies	and		
forming	dense	clusters	of	DNA	
in	each	channel	
5.	One	type	of	strand	is	
discarded	to	make	sequencing	
more	eﬃcient		
6.	Sequencing	primers,	polymerase	and		
nucleoBdes	are	added	to	the	mix	
7.	As	bases	are	incorporated,	a	laser	is	used		
to	acBvate		ﬂuorescence	and	colour	is	read	
8.	The	computer	monitors	each	cluster	and	each		
colour	as	a	new	base	is	incorporated.	The	cluster	sequence	
is	therefore	recorded.	
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Figure	12	Schema	of	positioning	of	dual	index	bar	codes	and	sequencing	primers	for	Illumina	MiSeq™	sequencing	method	(reproduced	with	permission	from	Illumina	Indexed	
sequencing	overview	guide181.	
!
Red	&	Dark	Blue:	
Sequencing	primers	
Green:	barcodes	
Pale	blue	&	Orange:	
16S	primers	
Grey:	amplicon	
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liver133.	This	study	identified	Proteobacteria	as	preferentially	translocating	from	the	
gut	as	evidenced	by	higher	proportions	in	the	tissues	studied133.		
The	vast	majority	of	studies	utilizing	next	generation	sequencing	to	investigate	the	
human	microbiome	has	focused	on	bacterial	rich	samples	such	as	stool,	other	gut	
samples,	the	female	genital	tract,	the	nasal	cavity	or	the	skin186,187.	By	contrast,	
studies	using	NGS	to	investigate	microbial	DNA	in	blood	samples	are	much	scantier,	
and	the	bacterial	load	is	likely	to	be	several	orders	of	magnitude	lower	than	in	stool	
for	example188-191.		We	anticipated	that	a	method	designed	for	studying	high	bacterial	
load	samples	was	likely	to	need	modification	for	lower	load	samples	such	as	in	this	
study.	
	
8.4.6.3 	Real	Time/Quantitative	Polymerase	Chain	Reactions	
	
Specific	or	quantitative	polymerase	chain	reactions	(qPCRs)	are	a	well-established	
method	of	detecting	bacterial	DNA	(See	Figure	13	for	schematic	of	qPCR	
methodology).	They	have	particular	advantages	over	standard	PCRs	in	that	the	
product	(in	the	form	of	fluorescence)	is	detected	in	real	time	during	the	assay,	
reducing	the	time	to	result	and	quantifying	the	product.	The	point	at	which	a	qPCR	is	
deemed	positive	is	known	as	the	cycle	threshold	(CT)	and	can	be	used	to	quantify	the	
amount	of	DNA	present	in	a	sample	when	compared	with	controls	(Figure	14).		
They	are	also	less	vulnerable	to	contamination	than	broad	range	PCRs.	As	broad	
range	16S	rDNA	PCRs	will	amplify	any	bacterial	DNA	present	in	the	sample	or	reagent,	
they	risk	being	overwhelmed	by	contamination	at	a	high	number	of	cycles,	limiting	
the	sensitivity167.	qPCRs	target	specific	organisms	that	are	not	associated	with	
environmental	contamination	and	so	can	be	made	more	sensitive	by	increasing	the	
number	of	cycles.	However,	as	they	are	specific,	there	is	the	possibility	that	
unpredicted	bacteria	will	be	missed.	A	combination	of	both	a	panel	of	specific	and	
broad	range	PCRs	can	provide	both	sensitivity	and	specificity	in	the	detection	of	
bacteria	that	are	difficult	to	grow	in	culture,	such	as	much	of	the	gut	flora192.	
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Figure	13	Schematic	of	qPCR	methodology	illustrating	Taqman™	primer	probe	method	
	
Primer	
Probe	
Q	
F	
Quencher	
Fluorescein	
Taq	polymerase	
Q	
F	 Q	
Hybridises	
F	
F	 Q	
1.	Denatura+on		
2.	Primer	annealing/	
				Probe	hybridisa+on		
3.	Extension	
TaqMan™	primer	probe	method	for	Quan+ta+ve	(real	+me)	PCR	
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Figure	14	qPCR	results	showing	Cycle	Threshold.	
Serial	dilutions	of	qPCR	assay	demonstrating	position	of	cycle	threshold	for	samples	with	increasing	dilution	(higher	cycle	threshold	indicates	higher	dilution	and	less	initial	DNA	load)
Cycle 
Threshold 
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8.4.7 Methods	for	Assessment	of	Gastrointestinal	Tract	Injury		
	
I-FABP	is	a	plasma	marker	of	small	intestinal	damage	used	in	diverse	settings	
including	adult	HIV142,193-195.		In	a	cohort	of	27	adults	with	early	HIV	in	France,	I-FABP	
was	similar	at	baseline	to	healthy	controls,	but	increased	by	month	6	(both	in	ART	
naïve	and	ART	treated	patients)147.	In	treated	adult	HIV,	raised	I-FABP	was	found	to	
be	predictive	of	mortality	along	with	markers	of	innate	immune	activation	such	as	
sCD14	and	D-dimers194.	In	untreated	adult	HIV,	a	strong	association	exists	between	I-
FABP	and	sCD14	although	not	with	HIV	viral	load196.		
HIV-infected	children	in	Africa	might	be	more	vulnerable	to	gut	damage	than	either	
adults	or	children	with	HIV	in	developed	settings,	in	part	due	to	the	contribution	of	
environmental	enteropathy.	Environmental	enteropathy	is	characterized	by	intestinal	
inflammation,	villous	atrophy	(with	associated	malabsorption)	and	impaired	intestinal	
barrier	function,	potentially	leading	to	microbial	translocation	and	downstream	
effects	such	as	anaemia	and	stunting	that	is	prevalent	amongst	those	living	in	
unhygienic	conditions197.	This	could	manifest	in	more	pronounced	stunting	and	
wasting	in	HIV-infected	children,	even	than	uninfected	peers	from	the	same	
community.	Investigating	I-FABP,	microbial	translocation	markers	and	anthropometry	
could	help	to	tease	out	the	relative	contribution	of	HIV	and	microbial	translocation	to	
gut	damage,	stunting	and	wasting.		
	
8.5 Pilot	Study	
I	undertook	a	cross-sectional	pilot	study	using	broad	range	16S	rDNA	PCR	with	
standard	Sanger	sequencing	(See	section	8.4.6.1)	and	developed	new	assays	to	
identify	microbial	16S	rDNA	in	the	blood	of	HIV-infected	children	attending	Great	
Ormond	Street	Hospital	(GOSH),	London.(Appendix	E	Paper:	“Evidence	Microbial	
Translocation	Occurs	in	HIV-Infected	Children	in	the	United	Kingdom”;	AIDS	Research	
and	Human	Retroviruses;	October	2013)	Discard	whole	blood	EDTA	samples	were	
collected	from	children	attending	the	HIV	outpatient	clinic	at	GOSH.	Broad	range	16S	
rDNA	PCR	was	carried	out	using	two	primer	sets167.	16SFa/16SFb	
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(GCTCAGATTGAACGCTGG/	GCTCAGGAYGAACGCTGG)	and	16SR	
(TACTGCTGCCTCCCGTA)	amplified	the	V1	and	V2	region	of	the	16S	rDNA	gene	and	
785F	(GGATTAGATACCCBRGTAGTC)	and	1175R	(ACGTCRTCCCCDCCTTCCTC)	amplified	
the	V5	and	V6	region.	Amplicons	derived	from	positive	samples	were	sequenced	
using	the	Big-Dye	v.3.1	cycle	sequencing	kit	(Applied	Biosystems,	Warrington,	UK)	and	
analyzed	on	the	3130	genetic	analyzer	(Applied	Biosystems).	A	subset	of	samples	
found	to	be	positive	by	broad	range	16S	rDNA	PCR	was	analyzed	by	high-throughput	
sequencing.	Attached	to	the	16S	rDNA	primers	were	standard	454	Titanium	adapters	
and	an	individual	barcode	sequence	for	each	sample.	The	library	was	pyrosequenced	
on	a	454	FLX	Titanium	(Roche)	platform	according	to	the	manufacturer’s	
recommended	protocol.	Sequences	were	processed	and	analyzed	using	QIIME198.	
16SFa/16SFb/16SR	and	785F/1175R	reads	were	discarded	if	they	contained	
ambiguous	bases,	if	the	quality	score	was	<	25,	if	the	run	of	homopolymer	bases	was	
>	6,	if	there	was	a	mismatch	in	primer	sequence,	and	if	the	barcode	could	not	be	
corrected.	Operational	taxonomic	units	(OTUs)	were	clustered	at	97%	sequence	
similarity	and	chimeric	sequences	were	removed	using	USEARCH182.	Representative	
OTUs	were	assigned	taxonomy	using	the	RDP	classifier199	at	a	minimum	support	
threshold	of	80%	again	the	Greengenes	database183	
	
Samples	were	obtained	from	105	sequential	children	attending	the	outpatient	clinic,	
representing	85%	of	the	clinic	population.	9	samples	were	positive	using	broad	range	
16S	rDNA	PCR,	a	positivity	rate	of	8.6%.	Of	the	nine	patients	in	whom	microbial	DNA	
was	detected,	five	(55%)	had	an	undetectable	viral	load;	four	(45%)	had	a	CD4	
percentage	above	30%	and	two	(22%)	had	a	CD4	of	less	than	10%.	In	
immunocompetent	children	of	equivalent	age,	the	positivity	rate	was	less	than	1%.	
From	3	of	these	amplicons,	16S	rDNA	sequences	were	identified	using	Sanger	
sequencing	as	Streptococcus	species	(mitis	group);	Propionibacterium	acnes	and	
Coagulase	negative	Staphylococcus.	Direct	Sanger	sequencing	failed	in	6	samples,	
probably	due	to	a	mixture	of	16S	rDNA	sequences	from	different	species.	These	
results	highlight	a	major	disadvantage	of	standard	broad-range	16S	rDNA-PCR	in	that	
only	the	dominant	sequence	is	identified.	NGS	of	4	samples	identified	the	same	
species	as	obtained	by	Sanger	sequencing	and	in	addition	identified	10	more	species	
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of	differing	proportions	in	each	of	the	4	samples,	including	known	gut	commensals	
(Bifidobacteriaceae,	Lactobacillaceae),	Staphylococcaceae	and	Streptococcaceae.	This	
was	the	first	published	application	of	deep	sequencing	to	investigate	microbial	
translocation	in	HIV200.		
It	would	thus	appear	that	microbial	translocation	may	occur	in	approximately	1	in	10	
HIV	infected	children	in	London.	We	hypothesized	rates	could	be	higher	in	children	in	
Africa,	where	environmental	enteropathy	is	likely	to	be	more	prevalent.		
	
8.6 Summary	
	
Although	ART	has	revolutionised	the	management	of	the	HIV	pandemic,	we	face	new	
challenges	in	supporting	children	with	perinatal	HIV	infection	through	a	lifetime	of	
therapy.	To	minimise	the	risk	of	comorbidities	in	the	future	for	these	children,	efforts	
must	be	made	to	investigate	potential	causes	of	those	morbidities	such	as	immune	
activation.	It	is	hypothesised	that	HIV	damages	GALT,	allowing	translocation	of	gut	
microbiota	and	microbial-associated	products,	with	increased	circulating	levels	of	LPS	
and	bacterial	ribosomal	DNA.	This	could	drive	immune	activation	and	T-cell	
dysregulation,	and	may	increase	morbidity	and	mortality	in	patients	with	and	without	
ART.	This	effect	is	thought	to	be	so	important	that	clinical	trials	are	underway	to	
reduce	microbial	translocation	aiming	to	reduce	immune	activation	and	improve	
clinical	outcome155,157,201-203.			
	
In	summary	analysing	the	results	of	work	undertaken	to	date,	a	number	of	issues	
arise:		
	
1. Most	studies	have	been	cross-sectional,	not	prospective100,204-206.		
Translocation	may	be	due	to	severe	HIV	disease/immunological	non-response,	
and	not	causally	implicated207.	
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2. Many	studies	utilise	quantitative	PCR	(qPCR)	to	quantify	the	16S	rDNA	subunit	
to	measure	translocating	bacteria.	16S	rDNA	PCR	is	subject	to	artefact	from	
endogenous	and	exogenous	bacterial	products167-169	and	therefore	without	
sequencing	the	PCR	product,	there	is	concern	that	results	may	not	be	due	to	
gut-derived	organisms.			Sequencing	the	16S	rDNA	has	so	far	yielded	results	
compatible	with	environmental	contamination	rather	than	recognised	gut	
commensals100,141,176.	
	
3. Some	studies	have	failed	to	find	evidence	of	microbial	translocation	at	all,	or	
report	conflicting	results	depending	on	markers	used144,145,202.		
	
4. There	are	few	data	from	Africa:	one	major	African	longitudinal	study	found	no	
significant	increase	in	markers	of	microbial	translocation	or	circulating	
cytokines	during	untreated	disease	progression	in	adults144.	
	
5. Data	in	children	are	limited	and	conflicting:	two	small	studies	showed	an	
association	between	LPS,	16S	rDNA	and	virological	response,	while	another	
failed	to	demonstrate	a	relationship73,152,208.	
	
Whilst	microbial	translocation	is	a	plausible	hypothesis,	and	potentially	amenable	to	
therapeutic	interventions,	there	are	potential	pitfalls	with	technology	used	to	date	
and	inconsistent	data.	Furthermore,	few	studies	have	investigated	microbial	
translocation	in	HIV-infected	children,	and	none	in	Africa.	It	is	unclear	if	and	how	
microbial	translocation	affects	outcome	in	HIV-infected	children.	
8.7 Aims	of	the	Thesis	
	
The	key	aims	of	the	thesis	were:	
	
1. To	assess	the	level	of	microbial	translocation	defined	as	identification	of	
bacterial	DNA,	occurring	in	HIV-infected	African	children	by	both	HIV-infected	
		
61	
ART-naïve	and	ART-experienced,	compared	with	HIV-uninfected	African	
controls	
2. To	determine	the	effect	of	ART	on	microbial	translocation	by	comparing	levels	
detected	in	ART-naïve	and	ART-experienced	children,	and	changing	levels	over	
time	on	ART.	
3. To	determine	the	impact	of	environment	on	microbial	translocation	by	
comparing	levels	in	ART-naïve	HIV	infected	children	in	urban	versus	rural	
settings	at	baseline	and	over	time	on	ART.	
4. To	investigate	the	relationship	between	microbial	translocation,	gut	damage,	
and	clinical	events	in	HIV	infected	children	in	Uganda.	
8.7.1 Primary	Hypothesis	
1. HIV	infected	ART	naïve	children	have	higher	levels	of	microbial	translocation	
than	age	matched	HIV-uninfected	controls.		
	
8.7.2 Secondary	Hypothesis	
1. ART	can	reduce	microbial	translocation	in	HIV-infected	children	during	the	
first	72	weeks	of	therapy.	
2. Environment	(rural	versus	urban)	has	a	significant	impact	on	microbial	
translocation	in	HIV-infected	children.	
3. There	is	a	significant	relationship	between	microbial	translocation,	gut	
damage,	nutritional	status,	and	clinical	events	in	HIV-infected	children	on	ART.		
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9 Chapter	9	Materials	and	Methods		
9.1 Study	Population		
	
The	study	population	comprised	196	HIV-infected	Ugandan	children	(median	age	3	
years;	range	2	months	to	11	years)	enrolled	in	the	CHAPAS-3	trial,	a	three-arm	phase	
II/III	open-label	randomised	trial	comparing	toxicity	and	pharmacokinetics	of	three	
fixed-dose	combination	ART	regimens	in	children	in	Uganda	and	Zambia	
(ISRCTN69078957).		The	trial	enrolled	480	ART-naïve	and	ART-experienced	children	
and	randomized	them	to	either	stavudine	(d4T),	zidovudine	(AZT)	or	abacavir	(ABC)	
with	lamivudine	(3TC)	and	either	efavirenz	(EFV)	or	nevirapine	(NVP)	(Figure	15).	The	
trial	results	were	published	in	February	2016,	and	showed	good	clinical,	virological	
and	immunological	responses	in	all	three	arms	with	low	toxicity209.	
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Figure	15	Trial	Profile	from	CHAPAS	3	reproduced	under	Creative	Commons	License	from	Mulenga	et	al.	2016209	
ART:	antiretroviral	treatment.	*Includes	one	not	seen	after	randomisation.	†One	participant	started	stavudine	and	substituted	zidovudine	at	12	weeks,	two	started	abacavir	and	did	not	change	(both	
prescribing	errors).	‡Two	started	zidovudine	and	did	not	change	(one	prescribing	error	and	one	child	changed	regimen	to	match	twin	sibling).		
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To	be	eligible	for	enrolment,	ART	experienced	children	had	to	have	been	stable	on	
d4T-containing	first	line	ART	for	at	least	two	years	with	a	viral	load	at	screening	<50	
copies/ml,	stable	CD4	T	cell	counts/%	and	no	signs	of	lipodystrophy.	All	children	
initiated	cotrimoxazole	if	they	were	not	already	on	it	(dapsone	was	used	as	an	
alternative	if	necessary).	Age,	ART,	laboratory	tests,	anthropometric	measurements	
(weight,	height	and	BMI-for-age	Z-scores)	and	co-morbidities	were	recorded	
longitudinally	until	01/14.	Weight-for-age,	height-for-age	and	BMI-for-age	z-scores	
were	calculated	using	UK	1990	cohort	data	as	WHO	z-scores	did	not	cover	the	age	
range	of	CHAPAS-3	children	for	weight210.		
	
Children	were	reviewed	every	6	weeks	by	a	nurse	and	every	12	weeks	by	a	doctor	for	
clinical	review,	and	checking	self-reported	adherence.	Haematology,	biochemistry	
and	CD4	T	cell	tests	were	performed	at	weeks	6,	12,	24	and	then	24-weekly	(results	
available	to	clinicians),	and	plasma	saved	for	viral	load	which	was	performed	
retrospectively	(viral	load	measurements	were	not	part	of	standard	care	at	the	time;	
results	not	available	to	clinicians	in	real	time).	ART	substitutions	for	toxicity	or	
switching	to	second	line	for	ART	failure	was	at	the	managing	physician’s	discretion.	
The	primary	outcome	was	grade	2	or	greater	clinical	adverse	events,	confirmed	grade	
3	laboratory	adverse	events	or	any	grade	4	laboratory	events.	Adverse	events	were	
reported	by	local	trial	teams	to	MRC	CTU	and	clinical	adverse	events	were	
adjudicated	by	an	endpoint	review	committee	blinded	to	randomisation.		Viral	load	
was	tested	on	stored	samples	with	the	Roche	COBAS	Ampliprep/Taqman	version	2.0	
and	run	with	a	1/5	dilution	of	Basematrix	53	giving	a	lower	limit	of	detection	of	100	
copies/ml.	If	children	needed	to	be	admitted	to	hospital,	an	additional	form	was	filled	
out	by	a	nurse	to	document	the	events	of	the	admission	as	available	from	the	local	
hospital.	Any	additional	microbiological	samples	(e.g.	blood	cultures	or	ear	swabs)	
taken	by	the	doctors	or	nurses	in	the	trial	clinic	were	also	recorded.	
	
In	terms	of	the	samples	used	for	this	study,	samples	were	collected	from	141	HIV-
infected	Ugandan	children	from	the	Joint	Clinical	Research	Centre	(JCRC)	Kampala	
(urban)	and	55	from	Gulu	(rural):	at	study	enrolment	119/55	were	ART-naïve	and	
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22/0	were	ART-experienced	with	suppressed	HIV	viral	load.	Children	had	frozen	
plasma	and	pellets	stored	at	baseline	then	12	weekly.		Pellets	and	plasma	were	
separated	by	centrifugation	within	two	hours	of	collection	at	1500g	for	15	minutes,	
and	then	stored	at	-80°C.	Any	discard	of	blood	taken	for	diagnosis	of	acute	illness	was	
stored.		Also	included	were	a	cross-sectional	sample	of	109	HIV-uninfected	children	
from	community	clinics	in	Kampala,	age-matched	to	the	HIV-infected	Kampalan	
children,	who	were	enrolled	as	a	parallel	cohort	in	CHAPAS-3,	assaying	a	single	time	
point	using	0.5	ml	of	10	mL	frozen	plasma.			
9.1.1 Sample	Size	Calculations	
	
The	sample	size	for	Aim	1	(primary	objective)	was	119	ART-naïve	HIV-infected	
children	and	90	HIV-uninfected	age	matched	controls	and	22	ART-experienced	
children	with	20	age	matched	HIV-uninfected	controls,	all	from	Kampala.	This	
provided	>80%	power	to	detect	15-20%	differences	in	prevalence	of	microbial	
translocation	between	ART-naïve	HIV-infected	and	uninfected	children	based	on	
previous	estimates211;	power	was	lower	for	children	already	on	ART.	For	aim	2,	
plasma	already	stored	from	three	time	points	was	assessed	for	HIV-infected	children:	
weeks	-2,	12,	and	72	after	enrollment	in	CHAPAS	3/initiation	of	ART.	Aim	3	compared	
55	HIV-infected	ART-naïve	children	from	Gulu	with	119	equivalent	urban	children	
from	Kampala	(JCRC	site),	which	provided	≥80%	power	to	detect	differences	of	20-
25%,	determining	if	results	from	Kampala	were	broadly	representative	of	other	
populations	or	if	there	were	major	effects	of	environment/diet.		
	
9.2 Ethical	Considerations	
The	study	was	approved	by	both	UCL	Research	Ethics	Committee	(reference	
5019/001)	and	the	Ugandan	National	Council	for	Science	and	Technology	(reference	
HS	1559).	Informed	consent	was	obtained	for	the	storage	and	use	of	samples	for	
studies	investigating	the	pathogenesis	of	HIV.	
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9.3 DNA	Extraction	for	Molecular	Testing	
	
Pellets	were	spun	from	1	ml	of	whole	blood	as	per	section	9.1.	The	whole	sample	
available	was	used.	200	µL	of	lysis	buffer	was	added	and	extracted	using	a	Qiagen	
QIAamp	DNA	Mini	Kit	with	additional	bead	beating	step.	The	final	elution	volume	was	
200	µL.	Plasma	samples	(200	µL)	were	extracted	using	EZ1	robot	and	EZ1	Virus	Mini	
Kit	v2.0	again	with	additional	bead	beating	step	and	eluted	to	a	volume	of	150	µL.	All	
samples	were	extracted	on	first	thaw,	had	an	internal	positive	control	(IPC,	mouse	
genomic	DNA,	non-coding	region)	added	prior	to	the	bead-beating	step.	Negative	
extractions	were	included	with	each	batch	as	a	negative	control.		
	
9.4 Quantitative	PCR		
	
The	steps	undertaken	to	design,	test	and	use	novel	qPCR	primers	were	as	follows:		
i. Identification	of	target	organisms	
ii. Identification	of	target	genes	for	amplification	
iii. Designing	primer	and	probe	sets	specific	for	the	target	gene,	incorporating	
variability	within	genus/class	while	excluding	other	non-target	organisms	
iv. Testing	the	primer	probe	mix	on	samples	with	known	bacterial	strains	
v. Testing	experimental	samples	using	the	primer	probe	mixes	
	
9.4.1 Identification	of	Target	Organisms	
	
Target	organisms	were	identified	using	previously	published	human	microbiome	data.	
Organisms	were	selected	in	descending	order	of	priority:		
i. Previously	identified	in	blood	in	studies	of	microbial	translocation	in	people	
with	HIV	
ii. Previously	identified	in	other	body	tissues	in	studies	of	microbial	translocation	
in	people	with	HIV	
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iii. Previously	identified	in	stool	in	studies	of	microbial	translocation	in	people	
with	HIV	OR	identified	in	blood/other	body	tissues	in	other	inflammatory	
diseases	where	microbial	translocation	is	implicated	in	pathogenesis	
iv. Previously	identified	in	studies	of	malnutrition	in	children	in	African	settings	
v. Previously	identified	as	important	components	of	the	healthy	human	
microbiome		
9.4.2 Identification	of	Target	Genes	for	Amplification	
	
The	primary	strategy	for	identifying	target	genes	was	to	identify	a	gene	that	is	specific	
only	for	the	intended	organisms	and	find	well	conserved	ubiquitous	regions	within	
that	gene	as	this	minimises	overlap	with	other	species.	A	secondary	strategy	if	the	
first	failed	was	to	target	a	ubiquitous	gene	(such	as	the	16S	rDNA	gene)	and	identify	
an	area	within	the	gene	that	is	specific	for	the	intended	organism.		
9.4.3 Designing	Primer	Probe	Sets	
	
Once	target	genes	were	identified,	multiple	sequences	from	different	bacterial	
species	within	the	target	genus	were	aligned	using	MegAlign	(Lasergene10,	DNAStar).	
Conserved	areas	were	then	entered	into	Primer	Express	(Thermofisher),	altering	
parameters	to	allow	a	minimum	amplicon	length	of	100	base	pairs	(to	allow	
sequencing).	If	no	suitable	matches	were	found	using	the	most	stringent	settings,	
parameters	were	relaxed	to	allow	different	melting	and	annealing	temperatures.		
	
9.4.4 Testing	Primer	Probe	Sets	on	Samples	with	Known	Bacterial	Strains	
		
The	following	primer	probe	sets	were	used:	
Table	1	Bifidobacterium	(xfp)	primer	probe	set	
Forward	(244-263)	 5’	CAGCTBTCCGAGCACCAGAT	
Reverse	(325-343)	 5’	TCCTTCGTWCACGTGATCG	
Probe	(270-285)	 5’	FAM-	CTTCCTCGAGGWCTAC-MGB	
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Table	2	Lactobacillus	(hsp60/GroEL	gene)	primer	probe	set	
Forward:	223-238	16bp	 5’	GCTGASGCHATGGAAA	
Probe	(casei):	242-256	15bp	 5’	FAM-TTGGSCASGATGGTG-MGB	
Probe	(acidophilus):	242-256	15bp	 5’	FAM-TTGGTMACGATGGTG-MGB	
Reverse	(casei):	301-322	22bp	 5’	GTAGTTGAAGGTATGCAATTSG	
Reverse	(acidophilus):	301-322	22bp	 5’	GTTGTTGAAGGDATGCAATTSG	
	
Table	3	Clostridiales	primer	probe	set	
Target	 Primer	 Sequence	
Clostridium	leptum	subgroup212	 sg-Clept-F	 5’	GCACAAGCAGTGGAGT	
sg-Clept-R3	 5’	CTTCCTCCGTTTTGTCAA	
Clostridium	coccoides	group213	 g-Ccoc-F		 5’	AAATGACGGTACCTGACTAA	
g-Ccoc-R	 5’	CTTTGAGTTTCATTCTTGCGAA	
	
	
Reaction	mix	1	(Bifidobacterium):		10μL	Taqman®	Real	Time	PCR	Master	Mix	(Life	
Technologies),	1μL	of	each	of	forward	and	reverse	primers	and	probe	(10	pM)	and	
7μL	sample	using	a	7500	Fast	Real	Time	PCR	system	(Life	Technologies).	Cycling	
conditions	were	95°C	for	5	minutes	then	45	cycles	of	95°C	for	30	seconds	and	60°C	for	
30	seconds.		
Reaction	mix	2	(Lactobacillus):	10μL	Taqman®	Real	Time	PCR	Master	Mix	(Life	
Technologies),	1μL	forward	primer	and	0.5μL	each	of	the	reverse	primers	and	probes	
(10	pM)	and	7	μL	sample	using	a	7500	Fast	Real	Time	PCR	system	(Life	Technologies).	
Cycling	conditions	were	95°C	for	5	minutes	then	45	cycles	of	95°C	for	30	seconds	and	
60°C	for	30	seconds.		
	
Reaction	mix	3	(Clostridiales):	12.5μL	Power	SYBR®	Green	PCR	Master	Mix,	0.5μL	
forward	and	reverse	primers	(20μM)	and	10.5μL	PCR	grade	water	(Bioline)	to	make	a	
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total	volume	of	25μL.	Cycling	conditions	were	95°C	for	10	min	1	cycle,	then	95°C	for	
15s	&	50°C	for	1	min	(repeated	40	times),	then	final	dissociation	stage	95°C	15s	50°C	
1	min	95°C	15s.	
	
9.4.5 Testing	Experimental	Samples	using	the	Primer	Probe	Mixes	
	
Reaction	mixes	for	individual	assays	were	made	up	as	below,	with	2uL	of	molecular	
grade	water	(Bioline),	10μL	of	Quantifast	Multiplex	PCR+R	master	mix	(Qiagen)	and	
5μL	of	sample.		All	assays	were	performed	on	an	Applied	Biosystems	7500	Real-Time	
PCR	System™	(Thermofisher)	according	to	the	Fast	protocol.	Pellets	were	found	to	
have	significantly	higher	cycle	thresholds	for	the	internal	positive	controls	than	the	
plasma	samples	(Two-tailed	p	value<0.0001)	which	indicates	template	inhibition.		
Therefore	they	were	run	at	a	10-fold	dilution.		
	
Table	4	Reaction	constituents	for	qPCR	reactions	
Target	 Reagent	 Sequence	 Sensitivity	
(CFU/	
reaction)	
Concentration/	
Volume	
Mix	1	
Staphylococcus	aureus	
214	
coa-F	 5’-GTAGATTGGGCAATTACATTTTGGAGG	 0.1-1	 0.15uM	
coa-R	 5’-CGCATCTGCTTTGTTATCCCATGTA	 0.15uM	
coa-Probe	 5’FAM-	TAGGCGCATTAGCAGTTGCATC-
BHQ1	
0.15uM	
Streptococcus	
pyogenes215		
csrR-F	 5’-TGGATGTGGTTGCAGGTTTAGAC	 0.1-1	 0.3uM	
csrR-R	 5’-	CGGGCAAGTAGTTCTTCAATGG	 0.3uM	
csrR-Pr	 5’-JOE-	
CGGTGCAGACGACTATATTGTTAAACC-
BHQ1	
0.2uM	
IPC215	 Mus	 5’-GGACACTATGCCCCTCCTTAGA	 	 0.1uM	
Mus	 5’-AGCTCCAAACTCCGTCTCTGTAA	 	 0.1uM	
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Mus	 5’Cy5-
TTGGGAACAAAACACCCATGGAAGGA-
BHQ2	
	 0.1uM	
Mix	2	 	 	 	 	
Enterobacteriacae215	 F		dnaK	 5’	ACCTGGGTACWACCAACTCTTGTGT	 1-10	 0.25uM	
R	dnaK	 5’	GTCACTGCCTGACGTTTAGC	 0.25uM	
Probe	dnaK	 5’-JOE-
AGGATGGTGAAACTCTGGTWGGTCAGCC-
BHQ1*	
0.25uM	
Staphylococcus	species	
215	
F	tuf	 5’	CATTCCAACTCCAGAACGTGAYT	 1-10	 0.1uM	
R	tuf	 5’-CACGACCAGTGATTGAGAATACG	 0.1uM	
Probe	tuf	 5’-CY5-
TGAYAAACCATTCATGATGCCAGTTGAGG-
BHQ2	
0.1uM	
Mix	3	
Fusobacterium	spp.216	 F			 5’	GGATTTATTGGGCGTAAAGC	 0.5-5	 0.1uM	
R		 5’GGCATTCCTACAAATATCTACGAA	 0.1uM	
Probe		 JOE	5’CTCTACACTTGTAGTTCCG	BHQ1	 0.1uM	
Mix	4		
Bifidobacterium	spp.	 xfp-F	 5’	CAGCTBTCCGAGCACCAGAT	 0.5-5	 0.5uM	
xfp-R	 5’	TCCTTCGTWCACGTGATCG	 0.5uM	
xfp-Pr	 5’	FAM-	CTTCCTCGAGGWCTAC-MGB*	 0.5uM	
Mix	5	
Lactobacillus	spp.	 F			 5’	GCTGASGCHATGGAAA	 1.3-13	 0.5uM	
R	(casei)	 5’	GTAGTTGAAGGTATGCAATTSG	 0.25uM	
R	
(acidophilus)		
5’	GTTGTTGAAGGDATGCAATTSG	 0.25uM	
Probe	(casei)		 5’	FAM-TTGGSCASGATGGTG-MGB	 0.25uM	
Probe	
(acidophilus)		
5’	FAM-TTGGTMACGATGGTG-MGB	 0.25uM	
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Table	5	Cycling	conditions	for	qPCR	reactions	
95°C	 5	minutes	 1	
95°C	 30	seconds	 45	
60°C	 30	seconds	
	
9.5 Broad	Range	16S	rDNA	PCR	
	
The	reaction	mix	consisted	of	5μL	sample,	10.5μL	PCR	grade	water	(Bioline),	12.5μL	
Power	SYBR	Green	master	mix	(Life	Technologies)	and	0.5μL	785F	(5’	
GGATTAGATACCCBRGTAGTC,	20pM)	and	1175R	(5’	ACGTCRTCCCCDCCTTCCTC,	20pM)	
amplifying	the	V5	–	V7	region	of	the	16S	rDNA	gene200.		Each	run	included	multiple	
dilutions	of	a	standard	of	known	concentration	and	negative	controls	in	triplicate.		
Pellets	were	run	at	a	10-fold	dilution	as	per	section	9.4.5.	Cycling	conditions	were	as	
follows:	
1. 95°C	for	10	mins	
2. 95°C	for	15s,	60°C	for	1	min	(40	cycles)	
3. Dissociation:	95°C	for	15s,	60°C	for	1	min,	95°C	for	15s	
By	extrapolation	from	standards	of	a	known	concentration	(Escherichia	coli),	bacterial	
load	defined	as	colony	forming	units	per	PCR	reaction	(5μL)	were	calculated	(CFU/PCR	
reaction).		CT	values	generated	by	negative	extraction	samples	or	negative	controls	in	
each	run	were	taken	as	a	cut	off	of	zero,	meaning	that	any	samples	with	a	higher	CT	
value	were	considered	negative	as	the	assay	had	reached	its	limit	of	detection.	By	this	
method,	the	sensitivity	of	the	assay	was	calculated	as	a	bacterial	load	of	5-50	
CFUs/PCR	reaction.	
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9.6 Sanger	Sequencing	
Amplicons	were	sequenced	using	the	Big-Dye	v.3.1	cycle	sequencing	kit	
(Thermofisher)	and	analyzed	on	the	3130	genetic	analyzer	(Thermofisher).	The	
sequences	obtained	were	compared	to	those	on	the	GenBank	database	using	the	
BLAST	program	available	at	the	National	Center	for	Biotechnology	Information	
(www.ncbi.nlm.nih.gov).	The	sequence	was	classified	to	species	level	if	there	was	>	
98%	homology	with	two	or	more	GenBank	sequences	from	the	same	species,	
submitted	by	independent	laboratories,	and	the	percentage	identification	was	lower	
for	all	other	species.	
	
9.7 Next	Generation	Sequencing	
	
Library	preparation	used	reagents	as	per	Table	6	using	the	same	primers	with	
individual	12-bp	error	correcting	barcodes/indices	(different	for	forward	and	reverse	
to	allow	paired-end	sequencing),	and	Illumina	compatible	adaptor,	pad	and	linker	
sequences	(See	Appendix	B	Tables	of	barcoded	primer	sequences	for	NGS	)198,217.	
Negative	extractions	and	negative	controls	were	included	for	quality	control	as	well	
as	mock	communities	(obtained	through	BEI	Resources,	NIAID,	NIH	as	part	of	the	
Human	Microbiome	Project:	Genomic	DNA	from	Microbial	Mock	Community	A	(Even,	
Low	Concentration),	v3.1,	HM-278D,	and	Microbial	Mock	Community	B	(Staggered,	
Low	Concentration),	v5.2LHM-783D	(Appendix	A	Species	in	Microbial	Mock	
Communities)	
Primer	sequences	were	checked	against	16S	rRNA	gene	sequences	of	species	within	
microbial	mock	communities	using	Megalign™	to	ensure	no	primer	bias	against	these	
species.		
Cycling	conditions	were	as	per	Table	7.	
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Table	6	Reagents	for	NGS	library	amplification	
Reaction	component	 Final	Concentration	 Per	25	uL	reaction	
PCR	grade	water	 -	 15.2	-16.2	uL	
Molzym	PCR	buffer	 1X	 2.5	uL	
dNTPs	 200pmol/ul	(25pmol/ul	working	
concentration)	
0.2	uL	
Forward	primer	(with	barcode	attached,	
different	for	every	sample)	
0.4pmol/ul	(10pmol/ul	working	
concentration)	
0.5-1	uL	
Reverse	primer	(with	barcode	attached,	
different	for	every	sample)	
0.4	pmol/ul	(10pmol/ul	working	
concentration)	
0.5-1	uL	
Moltaq	 0.025pmol/ul	(5pmol/ul	working	
concentration)	
0.125	uL	
Template	DNA	 -	 5	uL	
	
Table	7	Cycling	conditions	for	NGS	library	amplification	
Step	 Temperature	 Time	 Number	of	Cycles	
Initial	denaturation	 94C	 3	min	 1	
Denaturation	 94C	 30	sec	 35	cycles	
Annealing	 60C	 40	sec	 	
Extension	 72C	 90	sec	 	
Final	extension	 72C	 10	min	 1	
Cooling	 10C	 HOLD	 1	
	
The	resulting	amplicon	was	cleaned	and	pooled	in	96	wells	using	SequalPrep	
normalization	plate	kits	(Invitrogen)	and	AMPure	XP	beads	(Beckman	Coulter)	both	as	
per	manufacturer’s	protocol.	Ratios	of	beads	used	varied	from	0.6	to	1.6:1,	and	both	
plate	and	columnar	magnets	were	used,	both	prior	to	and	after	SequalPrep	
normalization	(See	section	10.2	and	14.3	for	details).	The	pooled	96	well	plates	were	
diluted	to	a	2nM	final	library	after	quantification	using	a	Qubit	2.0	(Life	technologies),	
a	KAPA	library	quantification	kit	(KAPA	Biosystems),	and	an	Agilent	high	sensitivity	
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DNA	kit	(hsDNA)	using	a	Bioanalyser	or	an	Agilent	2200	TapeStation	Instrument.	The	
library	was	loaded	onto	a	MiSeq	(Illumina)	as	per	manufacturer’s	protocol	for	500	
cycle	V2	kits	with	the	addition	of	custom	sequencing	primers	using	a	10-50%	PhiX	
spike.			
	
Table	8	Custom	Sequencing	Primers	
Read	1	sequencing	primer	 	 	
Padding	 785F	primer	 	 	
TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 R1Seq	
Read	2	sequencing	primer	 	 	
Padding	 1175R	primer	 	 	
AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 R2Seq	
Index	2	sequencing	primer	 	 	
Reverse	complement	of	1175R	primer	 Reverse	complement	of	Read	2	padding	
GAGGAAGGHGGGGAYGACGT	 TAAAACGTGTT	 	 In2Seq	
	
The	resulting	FASTA	files	were	analysed	using	QIIME198	(Section	19.3,	Appendix	B).	
Paired-end	sequenced	reads	from	each	MiSeq	run	were	merged	using	FLASH217	and	
demultiplexed,	pooled	and	assigned	OTUs	using	QIIME	v1.8.01.	OTUs	were	clustered	
at	97%	similarity	and	assigned	taxonomy	against	the	Greengenes	database	(v.13.5)2.		
OTUs	occurring	at	a	count	fraction	of	<0.001	were	filtered	out	(minimum	count	
fraction	or	MCF),	and	a	single	random	rarefaction	carried	out	to	produce	an	even	
sampling	depth	across	all	samples	(1000	sequences	per	sample).	Further	analyses	on	
both	rarefied	and	unrarefied	results	were	carried	out	in	R	Studio	(v.0.99.896)	using	
Phyloseq	(v.1.10.0).	In	a	secondary	analysis	OTUs	seen	in	experimental	negative	
controls	were	removed	from	both	rarefied	and	unrarefied	results	in	Phyloseq.	
	
	
	
9.8 Assessment	of	Gastrointestinal	Tract	Injury	and	Anthropometry	
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All	samples	were	assayed	on	first	thaw	using	the	commercial	ELISA	kit	(Hycult)	with	
plasma	diluted	1	in	10	as	per	protocol.	The	measurable	concentration	range	of	the	
assay	was	20-5000	pg/mL.	100μL	of	standards	and	diluted	samples	were	incubated	
for	an	hour	in	supplied	microwell	plates	at	room	temperature.	They	were	washed	4	
times	using	provided	wash	buffer	and	100μL	of	diluted	tracer	added	to	each	well,	
incubated	for	an	hour	and	the	wash	repeated.	100μL	of	diluted	streptavidin	
peroxidase	was	then	added	followed	by	another	hour	incubation	and	a	further	wash.	
100μL	tetramethylbenzidine	substrate	was	then	added,	the	plate	covered	with	tin	foil	
and	incubated	for	half	an	hour	before	100μL	stop	solution	was	added.	The	plate	was	
read	using	plate	reader	(Infinite	F2000,	Tecan)	at	450nm	within	30	minutes.	
Standards	were	run	in	duplicate	and	samples	in	singlicate	owing	to	limited	volume	of	
sample	available.	The	mean	absorbance	for	each	set	of	standards	and	samples	was	
calculated,	and	samples	giving	absorbance	>15%	of	the	mean	for	that	set	were	
considered	suspect	and	retested,	as	were	samples	which	were	undetectable.	If	the	
mean	absorbance	of	the	blank/zero	standard	was	>0.4,	the	run	was	repeated.	
Absorbance	of	the	blank/zero	standard	was	subtracted	from	the	absorbance	of	the	
samples	prior	to	standard	curve	fitting.	A	standard	curve	was	fitted	using	Microsoft	
Excel®	for	Mac	2011	(version	14.6.6),	and	R2	>0.99	were	considered	acceptable.	
Anthropometric	measurements	were	compared	with	molecular	test	results	over	time	
as	a	proxy	markers	of	intestinal	dysfunction3,4.	
	
9.9 Comparison	of	Clinical	Events	to	Molecular	Test	Results	
	
Clinical	events	were	collated	from	a)	adverse	event	reports	b)	reports	of	admission	
completed	by	trial	nurses	if	a	child	needed	hospital	admission	c)	microbiological	
investigation	performed	by	trial	team.	A	comparison	was	made	with	children	who	had	
a	high	result	from	a	molecular	test	(qPCR/16S	broad	range	PCR	result	>1000	CFU	
Equivalents/PCR	reaction,	or	successful	sequencing	with	NGS)	within	four	weeks	of	
the	event,	those	who	did	not	have	a	high	test	result	or	successfully	sequenced	with	
NGS	and	had	a	study	sample	available	within	four	weeks	of	the	event,	and	those	who	
had	a	clinical	event	but	had	no	study	sample	available	within	four	weeks	of	the	event.	
The	comparison	investigated	the	frequency	and	types	of	event	recorded	in	each	
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group.	The	molecular	test	results	at	the	nearest	time	point	for	children	who	had	
either	a	confirmed	urine	or	blood	culture	positive	were	also	documented,	even	if	
these	fell	below	the	threshold	of	a	PCR	result	>1000	CFU	Equivalents/PCR	reaction.		
	
9.10 Statistical	Analysis	
	
Statistical	analysis	was	carried	out	in	R	Studio	(v.0.99.896).	Descriptive	analysis	
included	simple	tabulations	and	percentages	alongside	chi-squared	and	Fisher’s	exact	
test	for	binary	data	(depending	on	sample	numbers	available),	and	Wilcoxon	paired	
tests	and	Mann-Whitney-U	tests	for	numeric	data.	Correlation	calculations	were	
carried	out	to	calculate	Spearman’s	rho.	Comparisons	were	made	between	ART	
groups	(experienced,	naïve,	naïve-matched	controls,	experienced-matched	controls,	
Gulu	(rural	group,	ART-naïve)	and	experimental	controls	where	appropriate.	
Comparisons	were	also	made	between	the	results	from	different	assays	(e.g.	between	
NGS	and	qPCR	results).	For	analyzing	the	NGS	results,	principal	coordinates	analysis	
was	carried	out	in	R	Studio	(v.0.99.896)	using	Phyloseq	(v.1.10.0)	and	the	Unifrac	
method.	
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10 Chapter	10	Assay	Development	Results	
10.1 QPCR	Assay	Development	
10.1.1 Identifying	Target	Organisms	
	
The	literature	review	prioritised	studies	that	documented	the	prevalence	of	genera	
affected	by	HIV	infection	when	studying	the	gut	microbiome5-7,	or	when	investigating	
microbial	DNA	in	the	bloodstream	of	those	infected	with	HIV8,9.	These	studies	
identified	Enterobacteriales,	Lactobacillales,	Pseudomonandales,	Burkholderiales	and	
Bacillales	as	key	genera.	In	particular,	Bifidobacteria	and	Lactobacillales	numbers	
appeared	to	be	adversely	affected	while	the	proportion	of	Pseudomonandales	
increased	in	adults	with	HIV	infection	versus	controls10.		
	
Few	studies	were	identified	where	detected	bacterial	DNA	in	the	blood	stream	of	
people	with	HIV	was	sequenced,	so	the	choice	of	targets	was	further	informed	by	
available	literature	documenting	sequenced	bacterial	DNA	identified	from	stool	
samples.		Ellis	et	al.	investigated	differences	in	faecal	microbiota	in	HIV,	comparing	
order	abundances	with	patient	clinical	status	and	evidence	of	immune	activation	in	
the	gut	itself5.		Microbial	DNA	was	extracted	from	faeces	and	subjected	to	16S	rDNA	
qPCR	in	order	to	quantify	pan-bacterial	loads	and	relative	abundances	of	
Enterobacteriales,	Bacteroidales,	and	Clostridiales.		Increased	Enterobacteriales	
detected	in	stool	was	positively	associated	with	duodenal	CD4	T	cell	depletion5.			
	
Considering	evidence	from	humans	uninfected	with	HIV,	but	affected	by	malnutrition,	
Smith	et	al.	investigated	differences	in	gut	microbiota	from	Malawian	twin	pairs,	
some	healthy	and	some	discordant	for	kwashiorkor.	DNA	was	obtained	from	fecal	
samples	and	subjected	to	multiplex	shotgun	pyrosequencing.11	Similarly,	they	found	
predominance	of	Bacteroides,	Bifidobacterium,	Clostridiales,	Escherichia	coli,	
Ruminococcus,	Lactobacillus,	and	Enterococcus.11	Significant	changes	were	seen	in	
the	microbiota	of	gnotobiotic	mice	with	associated	weight	loss	after	receiving	fecal	
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microbiotal	transplant	from	twins	discordant	for	kwashiorkor,	and	on	exposure	to	
Malawian	diet	versus	ready	to	use	therapeutic	food11.	
	
Data	from	healthy	humans	included	sequencing	of	16S	rDNA	clones	obtained	from	10	
cycle	PCR	from	stool	samples	from	a	healthy	40	year	old	man.	This	demonstrated	95%	
OTUs	obtained	were	from	3	groups:	the	Bacteroides	group,	the	Clostridium	coccoides	
group,	and	the	Clostridium	leptum	subgroup.12	Changes	in	gut	microbiota	occur	with	
age:	Bifidobacterium,	Streptococcus,	Lactococcus,	and	Lactobacillus	dominate	the	
infant	gut	microbiota,	with	lower	numbers	of	Bacteroidetes,	Firmicutes,	and	
Archaea13.	A	further	study	investigated	a	more	broad	population	from	differing	
geographic	locations.	Similar	results	were	obtained,	although	Enterococcaceae	were	
overrepresented	in	Malawian	versus	Amerindian	infant	microbiota13.			
	
Different	bacterial	loads	and	profiles	within	different	areas	of	the	gut	were	taken	into	
account.	In	a	study	taking	mucosal	biopsies	at	different	locations	in	the	gut	and	
comparing	bacterial	diversity	of	PCR-amplified	16S	rDNA	clone	libraries,	the	jejunal	
samples	were	dominated	by	species	related	to	Streptococcus	(67%)	while	more	
distally,	the	sequences	from	the	distal	ileum,	colon	and	rectum	were	dominated	by	
Bacteroidetes	(27-49%)	and	Clostridium	clusters	XIVa	(20-34%)	and	IV	(7-13%).14		
	
To	summarise,	the	following	bacteria	were	identified	as	important	potential	targets	
qPCR	targets:	Lactobacillus	(genus),	Bifidobacterium	(genus),	Clostridiales	(order),	
Enterobacteriaceae	(family),	Staphylococcus	aureus,	Staphylococcus	epidermidis,	
Streptococcus	pyogenes,	and	Fusobacterium.	Assays	for	the	following	were	already	in	
use	prior	to	the	study:	Enterobacteriaceae	family	(target	gene	DnaK)15,	
Staphylococcus	aureus	(target	gene	CoA)16,	Streptococcus	pyogenes	(Target	gene	
csrR)15,	Fusobacterium	(16S	rDNA)17,	Staphylococcus	species	(target	gene	tuf)15.	
Assays	for	Lactobacillus	(genus),	Bifidobacterium	(genus),	Clostridiales	(order)	were	
lacking.	
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10.1.2 Identification	of	Target	Genes	for	Amplification	
	
Bifidobacterium	
For	Bifidobacterium,	targets	considered	included	the	unique	fructose-6-phosphate	
phosphoketolase	pathway	used	to	ferment	carbohydrates,	genes	involved	in	the	
stress	response	to	bile,	temperature	and	acid18;	colonisation	genes	such	as	the	type	
IVb	tight	adherence		(Tad)	pilus-encoding	gene	cluster	tad200319;	and	
immunomodulation	genes	that	encode	serpin-like	protease	inhibitors	that	interact	
with	human	neutrophils	and	pancreatic	elastases20.	After	checking	ubiquity	among	
Bifidobacterial	species	and	sequence	homology,	the	most	promising	target	was	the	
xfp	gene	which	encodes	the	D-xylulose	5-phosphate	⁄	D-fructose	6-phosphate	(X5P	⁄	
F6P)	phosphoketolase	(Xfp),	the	key	enzyme	of	the	F6P-phosphoketolase	pathway	in	
bifidobacteria21,22.	Phosphoketolases	(EC	4.1.2.9,	EC	4.1.2.22)	are	thiamine	
diphosphate	(ThDP)-dependent	key	enzymes	of	the	pentose	phosphate	pathway	
lactic	acid	bacteria	and	of	the	d-fructose	6-phosphate	(F6P)	shunt	of	Bifidobacteria23.		
	
Lactobacillus	
Acid,	osmotic	and	bile	salt	stress	resistance	genes	were	screened	along	with	cell	
surface	adhesion	genes	(which	were	too	variable)	24,25.	Metabolic	genes	such	as	those	
involved	in	amino	acid	synthesis	were	also	screened26,	along	with	quorum	sensing	
genes,	but	given	that	these	had	the	potential	for	horizontal	transfer	they	were	judged	
unlikely	to	be	sufficiently	specific27.	The	most	promising	gene	was	a	two	component	
regulatory	system	LBA1524HPK-LBA1525RR	2CRS	associated	with	resistance	to	acid	
stress26.	The	HPK	gene	had	36%	identity	with	HPK	in	lisRK	in	Listeria	monocytogenes.28	
This	gene	was	subjected	to	the	screening	processes	described	below	with	design	of	a	
primer-probe	set.	However,	on	testing	the	set	with	isolates	of	Lactobacillus	reuteri,	
Lactobacillus	rhamnose,	Lactobacillus	casei,	Lactobacillus	plantarum	and	Lactobacillus	
gasseri	the	reaction	failed	and	this	primer	set	was	abandoned.		After	further	
literature	review	and	discussion	with	experts	in	the	field,	it	was	decided	to	target	a	
ubiquitous	house	keeping	gene	groEL	(coding	heat	shock	protein	60:	
hsp60)29(personal	communication	Dr	Makarova,	4.10.13).	Sequences	were	collated	
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from	key	branches	of	Lactobacillus	families	as	well	as	possible	overlaps	(with	
Streptococcus	pneumoniae,	S.	agalacticae,	S.	pyogenes,	S.	thermophiles	and	
Lactococcus	spp)	to	ensure	specificity29.	Owing	to	sequence	divergence	between	
families,	the	primer	set	were	designed	with	one	forward	primer,	2	reverse	and	2	
probes	to	cover	the	families	including	Lactobacillus	casei	and	Lactobacillus	
acidophilus	most	effectively.	
	
Clostridiales	
Potential	conserved	genes	screened	included	spore	forming	genes30-32	and	butyrate	
producing	genes	as	butyrate	appears	to	have	a	role	in	moderating	the	inflammatory	
process	of	gut	disease	(for	example	Crohn’s	disease	and	Ulcerative	Colitis)	and	as	an	
energy	source	for	the	colonic	epithelium33-35	both	of	which	were	found	to	be	
insufficiently	conserved.	Primers	have	previously	been	designed	for	the	butyryl-CoA	
CoA	transferase	but	when	compared	in	a	multiple	sequence	alignment	using	
MegAlign	(Lasergene10,	DNAStar)	they	were	very	degenerate	and	also	had	a	
relatively	low	sensitivity	when	tested	using	isolates-	which	is	a	much	more	
challenging	for	samples	likely	to	have	a	low	bacterial	load	(such	as	plasma)	than	for	
assessing	faecal	samples36.		Primers	targeting	the	16S	rDNA	gene	were	assessed	and	
trialed	in	the	absence	of	another	well-conserved	gene.	This	is	unsurprising	given	the	
size	and	diversity	of	the	Clostridiales	family	as	well	as	frequent	taxonomic	
reassignments.		
	
10.1.3 Designing	Primer	and	Probe	Sets	
	
Primer	probe	sets	were	designed	for	Bifidobacterium,	Lactobacillus	and	Clostridiales	
as	per	section	9.4.3.		
	
Clostridiales	
Widely	used	primer	sets	for	Clostridiales	have	been	targeted	to	a	conserved	area	of	
the	16S	rDNA	gene,	with	two	sets	developed	to	target	two	broad	groups	of	Clostridia	
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using	a	SYBRgreen	assay.	These	were	the	Clostridium	leptum	group	(including	
Eubacterium	siraeum,	Clostridium	cellulosi,	Clostridium	orbiscindens,	Clostridium	
sporosphaeroides	and	Eubacterium	desmolans)	and	the	Clostridium	coccoides	group	
(including	Ruminococcus	lactaris,	Butyrivibrio	fibrisolvens,	Clostridium	clostridioforme,	
and	Clostridium	nexile)37,38	39.	When	comparing	the	primer	sets	from	Matsuki	et	al.	
and	Rintilla	et	al.	using	MegAlign	they	were	found	to	target	overlapping	regions	so	
only	the	Matsuki	et	al.	sets	were	trialed	as	they	appeared	to	target	more	conserved	
regions.		
	
10.1.4 Testing	Primers	against	Target	Strains	
	
Bifidobacterium			
These	primers	were	tested	using	the	reaction	conditions	described	in	Section	9.4.4	
(reaction	1),	using	1.0	μL	of	forward	and	reverse	primers.	The	limit	of	detection	for	
Bifidobacterium	longum,	Bifidobacterium	adolescentis	and	Bifidobacterium	infantis	
was	0.5	CFU/μL.	No	Lactobacillus,	Clostridiales	or	Streptococcal	species	were	
detected,	nor	Escherichia	coli	or	Staphylococcus	aureus.		
	
Lactobacillus	
These	primers	were	tested	using	the	reaction	conditions	described	in	Section	9.4.4	
(reaction	2),	using	1.0	μL	of	forward	and	0.5μL	of	reverse	primers.	Cycling	conditions	
as	per	section	9.4.4.	Owing	to	reduced	sensitivity	for	L.	reuteri	with	this	mix,	the	assay	
was	re-run	using	just	the	acidophilus	probe	and	reverse	primer	with	resultant	
improved	sensitivity.	
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Table	9	Sensitivity	of	assay	for	detecting	different	Lactobacilli	
Species	 Limit	of	detection	(cfu/PCR	reaction)	
L	Casei	 1.3-13	
L	Rhamnose	GG	 1.4-14	
L	Reuteri	(using	R	and	P	acidophilus	)	 5.1-51	
L	plantarum	 Undetected	
Bifidobacterium,	Clostridiales	or	Streptococcal	species	were	not	detected,	nor	
Escherichia	coli	or	Staphylococcus	aureus.		
	
Clostridiales	
Reaction	conditions	as	described	in	Section	9.4.3	(reaction	3).	Isolates	included	were:	
Clostridium	butyricum,	Clostridium	sordelli,	Clostridiaceae	bacterium,	Clostridium	
orbiscindens,	Lachnospiraceae,	Clostridium	clostridioforme,	Clostridium	aldenense,	
Clostridium	hathewayi,	Clostridium	citroniae	and	Streptococcus	mitis.	The	C.	coccoides	
primer	set	detected	C.	butyricum	at	10-100	CFU/PCR	reaction	but	none	of	the	other	
strains.	The	C.	leptum	set	detected	Streptococcus	mitis	at	the	same	frequency	as	any	
of	the	Clostridial	strains.	At	this	stage,	given	the	lack	of	sensitivity	and	specificity	of	
this	primer	probe	mix	and	the	high	chance	of	futility	given	the	diversity	of	the	
Clostridiales	genus,	it	was	decided	to	focus	on	broad	range	techniques	for	detection	
rather	than	specific.		
	
10.1.5 Testing	Experimental	Samples	
	
Two	primer	sets	targeted	entire	bacterial	families	(Enterobacteriaceae	and	
Staphylococcae)	and	so	were	more	vulnerable	to	contamination	than	those	which	
were	species	specific,	as	demonstrated	both	by	Tann	et	al.	and	in	this	study	(negative	
controls	and	negative	extract	samples	crossing	the	cycle	threshold	between	35-40	
cycles)15.		Therefore	a	lower	CT	cut	off	was	set	for	these	assays.	In	order	to	draw	
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comparisons	between	assays,	each	of	which	is	subject	to	some	degree	of	variability	as	
well	as	distinct	sensitivities	and	specificities,	a	schema	was	drawn	up	to	enable	
comparison	between	these	heterogenous	assays.	Where	samples	were	positive	for	
more	than	one	sample,	the	codes	were	summed	to	enable	crude	but	standardised	
comparison	between	results.	See	Section	11	for	full	results.		
Table	10	Scheme	for	interpretation	and	comparison	of	PCR	results	
Normal	Cut	off	
PCRs	
Low	Cut	off	PCRs	
(Ent/TUF)	
CFU	equivalent	 Ranking	 Coded	
>40.1	 >35.1	 0	 Negative	 0	
37.0-40	 32.0-35	 1-10	 Very	low	 1	
34.0-36.9	 29-31.9	 10.1-100	 low	 2	
31.0-33.9	 26-28.9	 100.1-1000	 moderate	 3	
28.0-30.9	 22.0-25.9	 1000.1-10000	 high	 4	
<28	 <22	 >10000.1	 Very	high	 5	
	
	
10.2 Next	Generation	Sequencing	Assay	Development	
	
Initial	assay	development	involved	using	blood	samples	from	5	healthy	volunteers.	
These	were	used	in	triplicate-	once	as	whole	EDTA	blood,	once	as	EDTA	plasma	and	
once	as	a	cell	pellet	in	order	to	compare	results	depending	on	sample	constituents,	
alongside	controls	as	per	section	9.7.	Samples	were	extracted	as	per	section	9.3.	
Library	preparation,	normalisation,	sequencing	and	analysis	were	carried	out	as	per	
section	9.7.	
	
10.2.1 Contamination	of	Barcoded	Primers	
On	analyzing	the	results	of	the	initial	assay	development	run,	it	was	noted	that	the	
most	prevalent	organism	was	Sphingomonas,	with	nearly	2	million	reads.	It	appeared	
in	every	sample	and	was	the	most	abundant	sequence	found	in	the	greater	part.	The	
next	most	prevalent	was	Porphyrymonas	gingivalis	with	a	read	count	of	400000,	
limited	to	only	two	samples	previously	demonstrated	to	have	contained	this	
organism.	Having	ruled	out	all	other	reagents	as	a	source	of	contamination,	the	
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barcoded	primer	sets	were	tested	by	using	them	as	template	in	a	standard	16S	rDNA	
PCR	and	sequencing	any	resulting	amplicons	as	per	sections	9.5	and	9.6.	The	resulting	
sequences	were	found	to	be	>98%	homologous	with	Sphingomonas	spp.	The	
sequence	obtained	was	then	aligned	using	MegAlign	with	sequences	from	the	NGS	
run	and	found	to	be	identical.			
	
10.2.2 Primer	Dimer	
	
After	sourcing	new	primers,	sample	preparation	of	study	samples	was	carried	out	as	
per	Sections	9.3	and	9.7	the	same	method	was	used	with	samples	from	this	study.	
However	there	were	problems	with	discrepant	quantification	results	post-pooling	and	
cleaning	using	the	Qubit	such	that	two	runs	failed	due	to	over-	and	under-loading	of	
the	MiSeq	(the	library	although	appearing	to	be	10pM	was	either	too	concentrated	or	
too	dilute	to	successfully	sequence).	To	overcome	this	quantification	with	a	KAPA	
library	quantification	kit	(KAPA	Biosystems)	was	used	at	several	stages	during	the	
normalizing	and	pooling,	and	directly	before	loading	the	library.	Despite	using	the	
KAPA	quantification	kit,	difficulties	were	still	encountered	in	determining	the	correct	
loading	concentration.	The	use	of	the	Agilent	high	sensitivity	DNA	kit	(hsDNA)	on	the	
Bioanalyser	revealed	the	presence	of	a	high	concentration	of	primer	dimer	(Figure	16)	
which	explained	the	previous	inaccuracy	in	library	quantification.	Comparisons	of	the	
relative	results	using	the	KAPA	quantification	kit,	the	Qubit	and	the	Agilent	hsDNA	kit	
on	four	96	well	plates	post	normalization	and	cleaning	using	AMPure	beads	are	in	
Table	11.		
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Table	11	Comparison	of	Qubit	and	KAPA	results	for	library	quantification	
	 Qubit	 KAPA	Quantification	kit	
		 Conc	(nM)	 Conc	(nM)	
Plate	1	 155741	 28633	
Plate	2	 196185	 29893	
Plate	3	 144875	 27480	
Plate	4	 130388	 		
	
	
Figure	16	Agilent	hsDNA	kit	results	demonstrating	primer	dimer	in	four	plates	of	library	preparation	
A	large	primer	dimer	peak	can	be	seen	at	150bp	in	all	4	plates	at	a	much	higher	concentration	than	the	amplicon	peak	at	502bp	
	
The	plates	in	Figure	16	were	subjected	to	3	repeat	size	selections	using	AMPure	XP	
beads	at	a	ratio	of	0.8:1	beads	to	sample	(Beckman	Coulter)	to	reduce	the	relative	
concentration	of	primer	dimer	to	amplicon.	A	ratio	of	0.6:1	beads	to	sample	was	
trialled	to	see	if	further	reduction	of	the	primer	dimer	could	be	achieved	but	this	was	
found	to	give	similar	results	with	a	more	pronounced	loss	of	amplicon	(Figure	17).	
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Figure	17	Comparison	of	0.8:1	(top	panel)	and	0.6:1	(second	panel)	AMPure	beads	to	sample	ratio	in	reducing	
primer	dimers	in	plate	numbers	2,	3	and	4	
	
After	pooling,	attempts	to	run	this	library	both	with	a	10%	and	a	50%	PhiX	spike	
failed.	Repeating	the	pooling	of	the	four	plates	and	analysing	on	an	Agilent	2200	
TapeStation	Instrument	gave	a	peak	molarity	of	385	pmol/L	for	the	primer	dimer,	and	
108	pmol/L	for	the	amplicon.	At	this	stage,	this	library	was	abandoned	as	80%	of	the	
potential	sequencing	capacity	would	be	lost	even	if	the	sequencing	was	successful.	
	
The	library	amplification	was	repeated	in	an	attempt	to	reduce	the	primer	dimer	
generation	and	remove	it	more	effectively.	Firstly,	only	samples	with	CFUs/PCR	
reaction>100	using	the	qPCR	were	selected	to	maximize	the	potential	for	successful	
amplification.	Halving	the	concentration	of	primer	at	the	library	amplification	stage	
using	controls	was	found	to	give	satisfactory	amplification.	Therefore	the	
amplification	was	performed	using	the	primers	at	a	concentration	of	0.2pmol/μL.	The	
post	amplification	normalization	was	altered	so	size	selection	using	AMPure	beads	
(ratio	0.8:1	beads	to	sample)	and	a	plate	magnet	so	each	sample	was	subjected	to	
size	selection	prior	to	pooling.	This	was	followed	by	using	the	SeqPrep	normalization	
kit,	and	several	further	size	selections	using	AMPure	beads,	initially	at	a	ratio	of	1.8:1	
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and	then	0.8:1	beads	to	sample.	The	resultant	amplicon	to	primer	dimer	peaks	are	
shown	in	Figure	18.	
	
	
Figure	18	Amplicon	versus	primer	dimer	peaks	using	Agilent	Bioanalyser	in	4	plates	of	pooled	library	post-size	
selection	and	altering	method	of	normalisation	
	
After	pooling	of	all	4	plates,	the	concentrations	of	amplicon	and	primer	dimer	were	
740	pmol/L	and	949	pmol/L	giving	a	ratio	of	amplicon	to	primer	dimer	of	0.78.	This	
library	failed	to	sequence.	Therefore,	plate	1	(top	left	in	Figure	18)	which	had	the	
highest	concentration	of	amplicon	(1323	pmol/L,	primer	dimer	concentration	408	
pmol/L,	ratio	3.24)	was	chosen	to	sequence	in	isolation,	abandoning	the	other	3	
plates	which	contained	a	much	lower	proportion	of	amplicon.	This	plate	(which	
mostly	contained	cell	pellet	samples)	sequenced	successfully	generating	8.2M	reads	
prior	to	analysis.	
Four	further	96	well	plates	of	samples	were	amplified	using	the	same	protocol	and	a	
similar	pattern	emerged	(Figure	19)	
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Figure	19	Results	of	amplification	of	four	further	96	well	plates	labelled	p1-p4	using	Agilent	Bioanalyser	
demonstrating	primer	dimer	and	amplicon	peaks	
	
Table	12	Comparison	of	Primer	dimer	to	amplicon	concentrations	and	Qubit	results	for	second	library	
amplification	
Name	 Primer	dimer	(pmol/L)	 Amplicon	(pmol/L)	 Qubit	nM	 Ratio	Amplicon:	
Primer	dimer	
Plate	1	 4871	 2721	 7.24	 0.56	
Plate	2	 2466	 669	 2.44	 0.27	
Plate	3	 2072	 780	 2.92	 0.38	
Plate	4	 965	 734	 1.65	 0.76	
	
	
Repeated	size	selections	were	performed	on	Plate	1	(Table	13)	to	attempt	to	increase	
the	ratio	further.	
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Table	13	Table	demonstrating	relative	reduction	in	both	primer	dimer	and	amplicon	concentration	using	repeat	
size	selection	with	AMPure	beads	
	
Number	of	
0.8	size	
selections	
Primer	
Dimer	
pmol/L	
Ratio	reduction	
by	size	
selection	
Amplicon	
pmol/L	
Ratio	reduction	
by	size	
selection	
Ratio	
Amplicon:	
primer	dimer	
2	 9318	 		 3283	 		 0.35	
3	 4871	 0.52	 2721	 0.83	 0.56	
4	 2220	 0.46	 1830	 0.67	 0.82	
5	 1420	 0.64	 1010	 0.55	 0.71	
6	 743	 0.52	 719	 0.71	 0.97	
7	 67	 0.09	 390	 0.54	 5.82	
	
This	plate	was	sequenced	successfully	generating	4.8M	reads	prior	to	analysis.		
One	further	attempt	was	made	to	improve	the	output	from	NGS.	The	barcoded	
primers	were	redesigned	using	IDT’s	oligoanalyser	programme	(Integrated	DNA	
Technologies)40	to	have	a	higher	melting	temperature	(Tm).		The	padding	sequence	
length	was	increased	and	the	barcodes	were	exchanged	for	Nextera™	(Illumina)	
barcodes	which	are	8	bp	as	opposed	to	12	bp41,	which	increased	the	Tm	from	~62°C	
to	~68°C	(Appendix	B	Tables	of	barcoded	primer	sequences	for	NGS,	Table	40).		
The	94	samples	with	the	highest	CFUs/PCR	reaction	(as	per	16S	rDNA	PCR	using	the	
SYBRgreen™	assay)	were	amplified	with	the	redesigned	primers	as	per	conditions	
above,	and	immediately	post	library	amplification	were	quantified	using	the	Agilent	
2200	TapeStation™.	Only	6	samples	had	an	amplicon	peak.	The	relative	size	of	the	
amplicon	to	the	primer	dimer	peak	was	quantified	as	per	Table	14.	
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Table	14	Comparison	of	Relative	Primer	Dimer	to	Amplicon	Concentrations	using	redesigned	primers	as	
assessed	by	Agilent	2200	TapeStation	
Sample	
Identifier	 Molarity	(pmol/L)	 	
%	total	
	
	
primer	dimer	 amplicon	 primer	dimer	 amplicon	
C1	 14000	 12300	 17	 54	
D2	 38200	 2360	 56	 12	
C3	 37500	 3010	 54	 15	
C9	 74600	 1710	 65	 5	
C10	 38000	 2960	 35	 10	
B11	 17000	 14700	 18	 56	
	
Only	2	samples	contained	amplicon	in	sufficient	concentrations	that	post	
normalization	and	clean	up	they	were	likely	to	sequence	successfully.	These	two	
samples	also	generated	high	numbers	of	OTUs	using	the	previous	primer	set.	
Therefore	minimal	increase	in	data	is	likely	to	be	generated	by	proceeding	with	
further	library	amplification	with	the	redesigned	primers.		
	
	
10.3 Assay	Development	Discussion	
10.3.1 Quantitative	PCR	Assay	Development	
	
The	key	assay	development	issues	with	regards	to	qPCR	primer	design	were	the	
challenges	of	designing	primers	for	a	family	such	as	the	Clostridiales	which	have	a	
high	degree	of	diversity	between	species.	Even	using	previously	published	primers,	a	
high	degree	of	overlap	was	found	between	Streptococcus	mitis	and	Clostridial	
species,	meaning	that	primers	targeting	this	family	were	not	sufficiently	specific	to	
amplify	only	Clostridial	species.	As	the	main	advantage	of	qPCR	assays	is	their	
specificity,	we	took	the	decision	to	focus	on	broad	range	assays,	such	as	broad	range	
16S	rDNA	PCR	with	NGS	to	detect	these	diverse	families	of	bacteria.	Two	other	primer	
		
91	
sets	were	used	to	detect	whole	families	(Enterobacteriaceae	and	Staphylococcae),	
and	these	assays	are	therefore	more	vulnerable	to	contamination	as	demonstrated	
here	and	in	previous	studies15.	A	lower	CT	value	was	used	to	determine	positive	
samples	with	these	assays	than	in	the	other	species	specific	assays,	and	a	scheme	was	
drawn	up	to	enable	comparison	between	these	assays.	As	the	assays	are	
heterogenous	and	will	have	some	degree	of	variability,	it	is	important	that	results	
such	as	precise	CFUs	are	not	over-interpreted.	The	developed	schema	(Table	10)	aims	
to	enable	broad	comparison	between	assays	while	accounting	for	that	variation.		
When	samples	had	positive	results	for	more	than	one	assay,	the	code	derived	was	
summed	to	enable	a	crude	comparison	between	assays.	This	was	for	hypothesis	
generation	e.g.	investigating	whether	samples	positive	for	several	different	species	
also	had	a	higher	result	using	a	broad	range	16S	rDNA	PCR.	This	approach	is	
somewhat	crude	and	has	its	limitations,	but	does	allow	a	basic	standardised	
comparison	between	assays.		
	
10.3.2 NGS	Assay	Development	
	
A	number	of	issues	were	encountered	in	the	development	of	the	NGS	assay.	First	was	
the	discovery	that	the	barcoded	primers,	obtained	from	a	commercial	source,	were	
contaminated	with	Sphingomonas	sp.	This	waterborne	bacterial	species	is	only	rarely	
found	in	clinical	samples,	usually	in	immunocompromised	individuals.	The	
Sphingomonas	sp.	detected	during	the	first	NGS	run	was	identical	to	that	identified	by	
Sanger	sequencing	an	amplicon	derived	from	using	the	primers	themselves	as	a	
template,	which	appears	to	demonstrate	that	the	primers	themselves	were	the	
source	of	the	contamination.	On	reviewing	previous	runs	performed	in	the	same	
laboratory	using	this	primer	set,	Sphingomonas	sp.	was	also	noted,	albeit	
proportionally	lower	as	previously	tested	samples	had	a	higher	a	priori	bacterial	load.	
The	risk	of	reagent	contamination	using	NGS,	particularly	from	low	biomass	samples,	
has	been	noted	by	others,	with	various	techniques	suggested	to	remove	
contamination42,43.	As	yet	there	is	no	clear	consensus	about	how	best	to	avoid	
contamination,	although	UV	irradiation	of	reagents	such	as	water	should	be	used	
whenever	possible43.	
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The	second	major	issue	was	of	the	difficulties	encountered	when	attempting	to	
accurately	quantify	the	pooled	library	prior	to	MiSeq	loading.	Initially,	a	KAPA	
quantification	kit	was	used.	The	advantage	of	the	KAPA	method	is	that	it	aims	to	
calculate	the	concentration	of	the	amplified	library	only	rather	than	all	of	the	DNA	
present	in	the	sample,	allowing	increased	accuracy.	However,	the	MiSeq	loading	
concentration	is	calibrated	using	the	Qubit	to	determine	total	DNA	content	of	the	
sample,	rather	than	just	the	amplified	library,	as	the	assumption	is	that	that	the	
amount	of	other	DNA	present	will	be	minimal.		In	this	case,	as	the	KAPA	method	
targets	the	Illumina®	adaptor	sequences,	it	may	be	that	primer	dimer	was	also	
amplified,	which	would	interfere	with	the	final	calculation	of	DNA	concentration.		
It	was	necessary	to	use	the	Agilent	hsDNA	kit	to	identify	the	primer	dimers	which	
contributed	to	the	overall	DNA	concentration	and	rendered	quantification	by	both	
Qubit™	and	KAPA™	methods	inaccurate.	The	primer	dimers	possibly	interfered	with	
binding	sites	on	the	flowcell,	in	particular	as	the	primer	dimer	concentration	was	so	
much	higher	than	that	of	the	amplicon.	This	was	seen	even	when	the	spike	of	PhiX	
was	increased	to	50%:	cluster	generation	on	the	flow	cell	was	insufficient	likely	due	to	
primer	dimer	interference.		
	
To	overcome	this,	first,	I	prioritised	using	samples	which	contained	higher	bacterial	
loads	on	screening	with	a	broad	range	16S	rDNA	PCR.	Secondly,	I	used	half	the	
volume	of	primers	in	the	initial	library	preparation.	Thirdly,	I	introduced	a	number	of	
steps	to	remove	the	primer	dimer	during	the	normalisation	process.	These	included	
using	a	plate	magnet	with	AMPure	XP	beads	prior	to	sample	pooling	with	the	
SequalPrep	kit,	and	numerous	further	clean	ups	of	pooled	samples	using	the	AMPure	
XP	beads	post	pooling	alongside	quantification	with	the	Agilent	hsDNA	assay	on	a	
Bioanalyser	and	Tapestation™	instrument.	As	the	amplicon	was	already	at	a	low	
concentration,	a	threshold	was	reached	whereby	further	clean-ups	would	
proportionally	reduce	the	amplicon	more	than	the	primer	dimer	and	sequencing	
would	be	likely	to	fail	(Table	12).	This	threshold	differed	between	samples	and	pooled	
plates	dependent	on	the	success	of	the	initial	library	amplification	so	in	the	future,	
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performing	individual	hsDNA	assays	using	the	Tapestation™	instrument	prior	to	
library	clean	up	and	pooling	is	likely	to	be	the	most	productive	way	of	identifying	
samples	that	are	likely	to	be	sequenced	successfully.		The	final	attempt	to	improve	
output	was	to	amend	the	primers	and	increase	their	melting	temperatures	(Tm).	A	
higher	Tm	will	be	better	suited	to	the	high	temperatures	of	sequencing	and	should	
improve	the	performance	of	the	sequencing	primers41,44.		The	final	methods	used	for	
broad	range	16S	rDNA	PCR	with	NGS	are	described	in	the	following	chapters.	
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11 Chapter	11	Description	of	Study	Cohort	
11.1 Background	
This	study	was	carried	out	using	samples	from	the	CHAPAS-3	trial	(ISRCTN69078957)	
as	described	in	section	9.1.	In	order	to	fully	interpret	the	biological	impact	of	the	
results	described	in	subsequent	chapters,	it	is	necessary	to	first	describe	the	children	
enrolled	in	more	detail.		
11.2 Study	Population	
See	section	9.1	
11.3 Methods	
Statistical	analysis	was	carried	out	as	per	section	9.9	
11.4 Results	
	
CHAPAS-3	enrolled	480	children	from	Uganda	and	Zambia,	randomising	156	to	d4T,	
158	to	AZT	and	164	to	ABC	(2	excluded	due	to	randomisation	error).	The	overall	
results	showed	good	clinical,	immunological	and	virological	results	in	all	three	groups	
with	low	and	comparable	toxicity	rates	in	each	arm45.	There	were	19	deaths,	all	in	
ART-naïve	children,	9	of	which	occurred	in	the	first	12	weeks	of	ART.	
	
The	cohort	for	this	study	included	305	children	altogether:	119	ART	naïve,	22	
experienced,	89	controls	age	matched	to	ART-naïve	children,	and	20	controls	age	
matched	to	ART-experienced	children	all	from	the	urban	(Joint	Clinical	Research	
Centre	(JCRC)	Kampala	site,	and	55	ART-naïve	children	from	the	rural	Gulu	site.	At	
enrolment,	the	ART-experienced	group	had	spent	a	median	duration	of	4	years	on	
ART	(IQR	2.6-4.3).	Demographics,	baseline	CD4	T	cell	counts	and	percentages,	viral	
loads,	percentage	of	HIV-infected	children	in	each	group	with	a	fully	suppressed	viral	
load	at	week	96	of	follow	up	and	anthropometric	data	are	presented	in		 	
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Table	15.	ART	naïve	children	tended	to	be	younger,	have	lower	CD4	T	cell	counts	and	
percentages	at	baseline,	and	lower	anthropometric	markers	at	baseline	than	ART-
experienced	children	(Figure	20,	Figure	22).		They	also	experienced	greater	
improvement	over	time	in	terms	of	CD4	T	cell	count/percentage	and	anthropometric	
markers	over	the	course	of	the	study	than	the	ART-experienced	group	(Figure	20,	
Figure	23).	In	comparison	with	controls,	the	ART	naïve	group	were	younger	than	the	
age-matched	controls	(median	age	2.8	years,	95%	CI	2.6-3	versus	median	age	3.3,	
95%	CI	3-3.6,	p<0.001),	but	the	ART-experienced	group	were	similar	in	age	(median	
6.5	years,	95%	CI	5.6-7.3	versus	6.3,	95%	CI	5.3-7.3,	p=0.12).	Both	HIV-infected	groups	
had	lower	CD4	T	cell	percentages	than	controls,	though	the	ART-naïve	group	more	
markedly	so	(Figure	20).	The	ART	naïve	group	had	lower	anthropometric	markers	
than	controls,	but	the	ART-experienced	group	were	more	comparable	with	their	age-
matched	peers	(Figure	22).		
	
The	Gulu	group	were	slightly,	though	not	significantly,	younger	than	the	ART	naïve	
children	from	JCRC,	and	had	higher	baseline	CD4	T	cell	counts	with	borderline	lower	
viral	loads	at	baseline	(Figure	20).	They	had	the	lowest	rate	of	viral	suppression	at	96	
weeks	(67%	below	100	copies/ml)	although	this	did	not	reach	statistical	significance	
in	comparison	with	the	other	two	groups	(Figure	21).	In	terms	of	anthropometry,	they	
were	broadly	similar	in	baseline	characteristics	and	improvement	over	time	to	the	
JCRC	ART-naïve	group	(Figure	22,	Figure	23).	
	
There	were	6	deaths	in	the	cohort,	all	in	ART	naïve	children	(3	from	JCRC,	3	from	
Gulu).	Age,	cause	of	death	and	duration	of	follow	up	at	date	of	death	are	in	Table	17.	
Two	died	early	within	6	weeks	of	enrolment,	and	the	remaining	four	had	at	least	24	
weeks	follow	up.	Four	patients	(3%)	were	lost	to	follow	up	by	week	72	from	the	ART-
naïve	group.	Of	these	four,	one	only	had	baseline	samples,	while	the	other	three	had	
both	baseline	and	week	12	samples.	Three	were	lost	to	follow	up	(5%)	from	the	Gulu	
(ART-naïve)	group,	one	within	6	weeks	of	randomisation	and	the	other	two	between	
week	12	and	week	72.	All	children	from	the	ART-experienced	group	had	samples	
available	at	week	72.		 	
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Table	15	Demographics,	CD4	T	cell	counts,	viral	loads	and	anthropometric	data	compared	by	ART	group	
ART	group	 Naïve	 Experienced	 P	value	
naïve	
versus	
experienced	
Naïve	
Controls	
Experience
d	Controls	
P	value	
cases	
versus	
controls	
Gulu	 P	value	
(Gulu	vs	
naïve	
cases)	
Number	 119	 22	 	 89	 20	 	 55	 	
Male	Sex	(%)	 58	(49)	 10	(45)	 0.82	 40	(44)	 12	(60)	 0.65	
(naïve)	
0.56	
(exp)	
27(49)	 0.99	
Age	
(years)(median,	
IQR)	
2.8	
1.7-4	
6.45	
5.9-9.2	
	
<0.001	 3.3	
2.4-4.4	
	
6.3	
5.7-8.9	
	
0.006	
(naïve)	
0.89	
(exp)	
2	
1.7-3.5	
	
0.12	
Age	range	 0.3-5	 5.1-11.2	 	 0.6-7.4	 5.1-11.8	 	 0.6-4.8	 	
Baseline	CD4	T	
cell	count	
(mm3)	(median,	
IQR)	
925	
637-
1451	
1188	
927-1813	
0.02	 1333	
1036-1707	
1010	
856-1343	
<0.001	
(naïve)	
0.11	
(exp)	
1031	
674-
1602	
0.51	
Baseline	CD4	T	
cell	percentage	
(median,	IQR)	
20	
14-24	
35	
31-39	
<0.001	
	
38	
34-43	
40	
35-45	
<0.001	
(naïve)	
0.06	
(exp)	
30	
22-41	
	
<0.001	
Baseline	Viral	
Load	
(copies/ml)	
(median,	IQR)	
401200	
161300-	
1021000	
<100	 NA	 NA	 NA	 NA	 267400	
130100-
746300	
0.047	
CD4	T	cell	
count	change	
baseline-Week	
96	(mm3)	
(median,	IQR)	
314		
-41-657	
-157	
-438-59	
	
<0.0001	 NA	 NA	 NA	 NA	 NA	
CD4	T	cell	%	
change	
baseline-Week	
96	(mm3)	
(median,	IQR)	
17	
12-22	
	
3	
0-6	
	
<0.0001	 NA	 NA	 NA	 NA	 NA	
Suppressed	VL	
at	Week	96	(%)	
95%CI	
84/110	
(76%)	
67-83%	
19/21	
(91%)	
70-99%	
0.243	 NA	 NA	 NA	 30/45	
(67%)	
51-80%	
0.23	
Weight	for	age	
z	score	
Baseline	
(median,	IQR)	
-2.0		
-3.2-	-0.9	
-1.5	
-2.1-	-0.4	
0.06	 -0.6	
-1.2-	0.1	
-1	
-2.1-	-0.1	
<0.0001	
(naïve)	
0.54	
(exp)	
-1.8	
-3.1-	-1.0	
	
0.85	
Height	for	age	z	
score	Baseline	
(median,	IQR)	
-2.5	
-3.5-	-1.3	
	
-1.5	
-2.1-	-1.1	
	
0.02	 -0.8	
-2.1-	0	
	
-1.3	
-2.5-	-0.3	
	
<0.0001	
(naïve)	
0.52	
(exp)	
-2.4	
-4.6-	-1.6	
	
0.24	
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BMI	for	age	z	
score	Baseline	
(median,	IQR)	
-0.5	
-1.2-0.5	
-0.3	
-1-	-0.5	
0.73	 -0.1	
-0.7-	0.8	
0	
-0.9-	-0.4	
0.01	
(naïve)	
0.48	
(exp)	
0	
-0.9-	1	
	
0.07	
Weight	for	age	
z	score	change	
Baseline-	W96	
(median,	IQR)	
1	
0.2-1.9	
-0.1	
-0.2-	0.0	
	
<0.0001	 NA	 NA	 NA	 0.6	
0.18-1.3	
0.23	
Height	for	age	z	
score	change	
Baseline	W96	
(median,	IQR)	
0.8	
0.2-1.3	
	
-0.1	
-0.3-	-1.4	
	
<0.001	 NA	 NA	 NA	 0.8	
-0.2-	1.8	
	
0.97	
BMI	for	age	z	
score	change	
Baseline	W96	
(median,	IQR)	
0.6	
-0.1-	1.6	
	
-0.1	
-0.4-0.1	
	
0.001	 NA	 NA	 NA	 0.2	
-1.1-	1.1	
	
0.08	
	
The	ART	randomisations	for	the	HIV	infected	groups	are	shown	in	Table	16.	
	
Table	16	ART	randomisation	for	HIV	infected	children	
Arm	 Received	 Total	 JCRC	(urban)	ART-
Naïve	
JCRC	(urban)	ART-
Experienced	
Gulu	(rural),	ART	
naive	
1	 D4T	 66	 42	 7	 17	
2	 AZT	 57	 35	 7	 15	
3	 ABC	 73	 42	 8	 23	
4	 Controls	 109	 0	 0	 0	
NNRTI	1	 EFV	 48	 46	 2	 	
NNRTI	2	 NVP	 93	 73	 20	 	
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Figure	20	Boxplots	of	CD4	T	cell	counts	and	percentages	over	time	by	ART	group	
	
0
1000
2000
3000
4000
Na
ive
Ex
per
ien
ced
Co
ntr
ol N
aiv
e
Co
ntr
ol E
xpe
rien
ced
Gu
lu (
nai
ve)
ART
Ba
se
lin
e 
CD
4 
ce
ll c
ou
nt
 (m
m
3)
ART
Naive
Experienced
Control Naive
Control Experienced
Gulu (naive)
Baseline CD4 Cell Count (mm3)
by group
0
20
40
60
Na
ive
Ex
per
ien
ced
Co
ntr
ol N
aiv
e
Co
ntr
ol E
xpe
rien
ced
Gu
lu (
nai
ve)
ART
Ba
se
lin
e 
CD
4 
ce
ll p
er
ce
nt
ag
e
ART
Naive
Experienced
Control Naive
Control Experienced
Gulu (naive)
Baseline CD4 Cell Percentage
by group
−2000
−1000
0
1000
2000
Naive Experienced
ART
CD
4 
ce
ll c
ou
nt
 (m
m
3)
 ch
an
ge
ART
Naive
Experienced
CD4 cell count
change by group at Week 96
−10
0
10
20
30
Naive Experienced
ART
CD
4 
ce
ll p
er
ce
nt
ag
e 
ch
an
ge
ART
Naive
Experienced
CD4 cell percentage
change by group at Week 96
		
99	
	
	
Figure	21	Histogram	of	viral	load	at	baseline	and	suppression	(<100	c/ml)	by	ART	group	at	week	96	
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Figure	22	Boxplots	of	anthropometric	markers	at	baseline	by	ART	group	
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Figure	23	Boxplots	of	changes	in	anthropometric	markers	by	ART	group	at	week	96	
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Table	17	Age,	ART	randomisation	and	causes	of	death	for	6	children	who	died	
ART	 Age	at	enrolment	
(years)	
Duration	of	
follow	up	
(weeks)	
Cause	of	Death	
ART-naïve		 1.3	 38	 Measles,	pneumonia	
Gulu	(ART-naïve)	 4.4	 5	 Pneumonia,	malnutrition,	
hyperglycaemia,	Gram	negative	sepsis	
ART-naïve	 3.1	 25	 Measles	
Gulu	(ART-naïve)	 1.33	 2	 Unknown,	died	at	home,	probable	
pneumonia	
Gulu	(ART-naïve)	 1.74	 94	 Unknown	
ART-naïve	 5	 56	 Kaposi's	sarcoma	
	
11.5 Discussion	
	
This	chapter	describes	the	demographic	and	clinical	features	at	enrolment	of	the	
children	in	the	study	cohort,	and	progress	over	time	in	the	HIV-infected	groups.	It	is	
reassuring	to	note	that	very	few	children	were	lost	to	follow	up	and	that	all	HIV-
infected	groups	had	a	high	overall	rate	of	viral	suppression	at	week	96	(Figure	21).		
The	number	of	deaths	over	96	weeks	for	the	whole	group	was	low,	3/119	(3%)	from	
the	ART-naïve	urban	group	and	3/55	(5%)	from	the	ART-naïve	rural	Gulu	group	(Table	
17).	Overall	within	CHAPAS-3,	there	was	minimal	difference	in	outcome	between	the	
trial	arms,	and	so	differing	impact	of	ART	randomisation	has	not	been	further	
explored	here.45	
As	viral	load	suppression	was	a	precondition	of	enrolment	in	CHAPAS-3	for	ART-
experienced	children,	it	is	unsurprising	that	CD4	T	cell	count/percentage	and	
anthropometric	markers	were	higher	at	baseline	for	this	group	than	the	ART-naïve	
group.	The	ART-experienced	group	had	already	received	a	median	of	4	years	of	ART	
(IQR	2.6-4.3)	during	which	immune	recovery	and	growth	catch-up	occurred.	It	is	also	
unsurprising	that	the	ART-naïve	group	made	bigger	gains	in	CD4	T-cell	
count/percentage	and	anthropometric	markers	over	the	course	of	the	trial	follow	up.		
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The	Gulu	group	were	slightly	younger	than	the	ART-naïve	group,	had	higher	higher	
CD4	T	cell	percentage	(Gulu	group:	median	30%,	IQR	22-41,	JCRC	ART	naïve	group:	
median	20%,	IQR	14-24;	p<0.001)	and	slightly	lower	viral	load	(Gulu	group:	median	
264700,	IQR	130100-746300,	JCRC	ART	naïve	group:	median	401200,	IQR	161300-
1021000;	p=0.047).	These	findings	could	indicate	that	the	Gulu	children	were	brought	
for	medical	attention	slightly	earlier	in	their	disease	course	than	their	urban	peers.		
Anthropometric	markers	were	similar	in	both	ART-naive	groups.		
Considering	the	anthropometric	markers	in	more	detail,	the	only	group	with	a	
weight-for	age	or	height-for-age	z	score	of	0	fell	within	the	IQR	was	the	HIV-negative,	
ART-naïve	control	group.	The	other,	older	control	group	had	median	weight-for	age	
and	height-for-age	z	scores	of	-1	(IQR	-2.1-	-0.1)	and	-1.3	(IQR	-2.5-	-0.3),	and	all	HIV-
infected	groups	had	median	z	scores	<0	for	both	weight	and	height-for-age.	This	
indicates	a	base	level	of	stunting	within	the	study	population	compared	with	the	
reference	population,	but	the	reference	population	for	anthropometric	results	was	
UK	based	which	is	a	limitation	of	the	study46.	The	WHO	reference	population,	which	
itself	is	acknowledged	to	be	flawed	and	is	under	review,	did	not	include	weights	for	
the	whole	age	range	of	the	CHAPAS-3	children	and	so	could	not	be	used47.	The	gains	
seen	in	the	ART-naïve	groups’	anthropometric	markers	are	similar	to	those	gains	seen	
in	other	settings	when	initiating	ART48-50.	
In	general,	all	three	groups	of	children	with	HIV	did	well	over	the	course	of	the	study	
with	good	CD4	T	cell	recovery	and	relatively	high	rates	of	viral	suppression	at	96	
weeks.	This	is	in	line	with	outcome	data	from	previous	trials	in	similar	settings51-53	 	
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12 Chapter	12	Quantitative	PCR	for	the	Detection	of	Specific	Bacterial	Species	and	
Families	as	Indicators	of	Microbial	Translocation		
12.1 Background	
As	per	section	8.4.6.3,	qPCRs	have	the	advantage	of	being	less	vulnerable	to	
contamination	than	broad	rand	PCRs.	This	means	that	more	cycles	can	be	run	
rendering	them	more	sensitive.	However,	they	must	be	targeted	to	known	bacteria	
and	so	may	miss	unexpected	pathogens.	A	panel	of	assays	was	used	targeted	to	
bacteria	implicated	in	microbial	translocation.		
12.2 Study	Population	
See	section	9.1	
	
12.3 Methods	
Assays	were	run	as	per	section	9.4.5	using	appropriate	positive	and	negative	controls	
depending	on	primer	set	used.		Negative	to	strong	positives	were	calculated	by	
comparison	with	standards	of	known	CFUs	and	coded	into	discrete	groups	from	0-5	
as	per	Table	10	reproduced	here	for	reference.	Proportion	of	positive	and	negative	
samples	and	the	proportions	of	samples	falling	in	each	category	from	negative	to	
strong	positives	(coded	from	0-5)	were	compared	using	chi-squared	tests	for	each	
assay	between	ART	groups.	
Table	10	Scheme	for	interpretation	and	comparison	of	PCR	results	
Normal	Cut	off	
PCRs	
Low	Cut	off	PCRs	
(Ent/TUF)	
CFU	equivalent	 Ranking	 Coded	
>40.1	 >35.1	 0	 Negative	 0	
37.0-40	 32.0-35	 1-10	 Very	low	 1	
34.0-36.9	 29-31.9	 10.1-100	 low	 2	
31.0-33.9	 26-28.9	 100.1-1000	 moderate	 3	
28.0-30.9	 22.0-25.9	 1000.1-10000	 high	 4	
<28	 <22	 >10000.1	 Very	high	 5	
	
12.4 Results	
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Results	were	analysed	and	compared	between	assays	using	Table	10.	In	total,	668	
plasma	samples	were	available	as	per	Table	18.	132	plasma	and	pellet	samples	were	
matched,	with	8	unmatched	pellet	samples	and	no	unmatched	plasma	samples.	
	
Table	18	Sample	availability	by	group	at	different	time	points	
	 Baseline	 Week	12	 Week	24	 Week	72	
ART-naïve	
(plasma)	
112	 108	 7	 112	
ART-
experienced	
(plasma)	
22	 19	 0	 22	
ART-	naïve	
(pellet)	
118	 	 	 	
ART-
experienced	
(pellet)	
22	 	 	 	
Gulu	*	 52	 49	 3	 49	
Controls	(Age	
matched	ART-	
naïve)*	
93	 	 	 	
Controls	(Age	
matched	ART-
experienced*	
20	 	 	 	
		*Plasma	samples	only	available.	
In	terms	of	missing	samples,	the	ART-naïve	group	had	9/119	(8%)	samples	missing	
(not	available)	at	baseline,	and	in	the	Gulu	(ART-naïve)	group	4/55	(7%)	were	missing.	
The	control	groups	and	the	ART-experienced	group	were	missing	no	samples	
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(Appendix	D	Missing	samples	across	groups	and	time	points).	At	week	12,	the	
proportion	of	missing	samples	were	11/119	(9%)	(ART-naïve),	3/22	(14%)	(ART-
experienced),	and	5/53	(9%)(Gulu).	At	Week	72,	excluding	5	children	who	had	died	
and	4	who	were	lost	to	follow	up,	proportions	of	missing	samples	were	2/112	
(2%)(ART	naïve),	0/22	(ART	experienced)	and	7/51	(14%)(Gulu).	The	children	who	had	
missing	samples	were	similar	in	age	and	baseline	CD4	T	cell	counts	to	the	other	
children	in	their	groups.	There	were	no	assay	failures	in	this	group.	
	
The	majority	of	plasma	samples	were	negative	at	all	time	points	for	most	assays	
(Figure	24	-	Figure	27,	Table	19	-	Table	21).	The	exceptions	were	Enterobacteriaceae,	
S.	aureus	and	Staphylococcus	spp	although	the	levels	seen	tended	to	be	very	low	even	
in	these	assays.	Very	few	samples	recorded	strong	positive	results	(higher	CFU	
equivalents	or	code	4/5	as	per	Table	10)	at	any	time	point	(Figure	24	-	Figure	27).		
Samples	positive	for	Bifidobacterium,	Lactobacillus	and	Fusobacterium	were	seen	but	
were	extremely	rare.	At	baseline,	over	half	the	Gulu	samples	were	positive	for	S.	
aureus	(55%,	95%	CI	40-69%)(Table	19,	Table	22,	Figure	28),	but	this	high	proportion	
was	not	replicated	in	the	other	groups,	and	indeed		was	significantly	higher	than	the	
other	two	HIV-infected	groups	(Table	19).		
	
Approximately	one-third	of	the	ART-experienced	group	(38%,	95%	CI	21-48%)	and	the	
Gulu	group	(33%,	95%	CI	21-48)	had	positive	results	for	Enterobacteriaceae,	with	23%	
(95%	CI	16-32%)	of	the	ART-naïve	group	also	having	a	positive	result	(Table	23).	
However	those	that	were	positive	tended	to	be	in	the	lower	range	at	all	time	points	
and	across	all	groups	(Figure	24-Figure	27).	The	Gulu	samples	were	also	significantly	
more	likely	to	be	positive	in	more	than	one	assay	than	the	other	two	groups	
(p<0.0001),	with	13.5%	positive	for	S.	aureus	and	Staphylococcus	spp.	and	9.6%	for	
both	S.aureus	and	Enterobacteriaceae.	
	
In	comparison	with	of	the	ART-naïve	and	experienced	groups	with	age-matched	HIV-
uninfected	control	groups,	the	naïve-control	group	had	a	higher	proportion	of	
samples	positive	for	Enterobacteriaceae	than	the	HIV-infected	ART-naïve	group	(37%,	
95%	CI	27-48%	versus	23%,	95%	CI	16-32,	p=0.03)(Table	19)(Figure	29).	The	
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experienced	control	group	also	had	a	higher	proportion	of	positive	samples	but	this	
did	not	reach	significance	(55%,	95%	CI	32-77%	versus	38%,	95%	CI	18-62%,	p=0.09).	
There	were	no	other	significant	differences	between	the	case	and	control	groups	in	
either	proportions	of	positive	versus	negative	samples	or	in	proportions	coded	from	
negative	to	strong	positive,	although	there	was	a	trend	towards	the	ART-naïve	having	
a	higher	proportion	of	strong	positives	for	S.aureus	(p=0.06)	than	age-matched	HIV-
uninfected	controls.	
12.4.1 Plasma	Samples	over	Time	
	
Figure	28	and	Figure	29	summarise	changes	over	time	in	proportions	positive	of	the	S.	
aureus	and	Enterobacteriaceae	PCRs	within	the	HIV	infected	groups.		
	
At	week	12,	the	proportions	positive	for	S.	aureus	trended	towards	an	increase	in	ART	
naïve	children	from	9%	(95%	CI	5-17%)	to	17%	(95%	CI	11-26%),	but	had	fallen	from	
23%	(95%	CI	8-45%)	to	16%	(95%	CI	3-40%)	(ART-experienced)	and	in	the	Gulu	group	
had	fallen	significantly	from	55%	(95%	CI	40-69%)	to	16%	(95%	CI		7-31%)(Table	20,		
Figure	28).		
	
Proportions	positive	for	Enterobacteriaceae	had	also	increased	in	the	ART	naïve	group	
from	23%	(95%	CI	15-32%)	to	36%	(95%	CI	27-46%)(p=0.06)	and	decreased	in	both	
ART-experienced	(from	38%	(95%	CI	18-62%)	to	26%	(95%	CI	9-51%),	p=0.64)	and	in	
the	Gulu	group	from	33%	(95%	CI	21-48%)	to	18%	(95%	CI	9-31%)(p=0.12)(Table	
23)(Figure	29).	There	was	a	trend	towards	the	ART	naïve	group	having	a	higher	
proportion	of	samples	positive	for	Enterobacteriaceae	than	the	other	two	groups	at	
this	timepoint	but	this	did	not	reach	statistical	significance	(p=0.07).	There	were	no	
other	significant	differences	between	groups	at	this	point,	including	in	comparing	
negative	to	strong	positives	between	groups.	
Very	few	samples	were	available	at	week	24,	and	only	seven	in	the	ART-naïve	and	
three	in	the	Gulu	group.	Only	one	sample	was	positive	for	S.aureus	in	each	group	and	
one	for	Enterobacteriaceae	in	the	ART-naïve	group.	
At	week	72,	S.	aureus	results	tended	to	be	lower	in	all	three	groups	than	at	week	12	
and	baseline:	6%	(95%	CI	3-12%)	in	ART-naïve	(p=0.44	in	comparison	to	baseline),	5%	
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(95%	CI	0-23%)(p=0.188)	in	ART-experienced	and	7%	(95%	CI	1-19%)(p<0.0001)	in	the	
Gulu	group	(Table	21,	Table	22).	Enterobacteriaceae	were	also	present	in	31%	(95%	CI	
23-41%)	of	the	ART-naïve,	23%	(95%	CI	8-45%)	of	the	ART-experienced	and	32%	(95%	
CI	19-48%)	of	the	Gulu	group	(Table	23).	Again,	there	were	no	significant	differences	
in	the	negative	to	strong	positives	between	groups.		
	
In	general,	with	the	exception	of	S.aureus	at	baseline	in	the	Gulu	group,	proportions	
positive	of	both	S.aureus	and	Enterobacteriaceae	tended	to	fluctuate	non-
significantly	over	time	and	between	groups	(Figure	28,	Figure	29)	
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Figure	24	Baseline	qPCR	results	ranked	negative	to	strong	positive	by	ART	group	
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Figure	25	Week	12	qPCR	results	ranked	negative	to	strong	positive	by	ART	group	
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Figure	26	Week	72	qPCR	results	ranked	negative	to	strong	positive	by	ART	group	
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Figure	27	Control	qPCR	results	ranked	negative	to	strong	positive	by	ART	group	
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Table	19	qPCR	results	for	samples	at	baseline	comparing	proportions	of	positive	samples	by	ART	group		
	 Positive	
Naïve	
N	(%)	
n=112	
%	Positive	
Experienced		
N	(%)	n=22	
%	Gulu	
(Naïve)		
N	(%)	
n=52	
P	Value	
(Fisher’s	
exact,	
comparison	
across	3	
ART	
groups)	
%	
Control	
(naïve)	
N	(%)		
n=93	
%	Control	
(experienced)	
N	(%)		
	n=20	
P	Value	(Fisher’s	exact)	
proportion	positive	
/negative	cases	versus		
matched	controls	
	 	 	 	 	 	 	 Naïve	 experienced	
Bifidobacteria	 5	(4)	 0	 1	(2)	 0.71	 0	 0	 0.07	 1	
S.	aureus	 11(9)	 5	(23)	 29	(55)	 <0.0001	 4	(4)	 3	(15)	 0.42	 0.61	
S.	pyogenes	 0	 0	 0	 1	 1	(1)	 0	 0.45	 1	
Fusobacterium	 1	(1)	 0	 2	(4)	 0.47	 0	 0	 1	 1	
Enterobacteriaceae	 26	(23)	 8	(38)	 17	(33)	 0.23	 35	(37)	 11	(55)	 0.03	 0.35	
Staphylococci	 3	(3)	 0	 12	(23)	 <0.0001	 0	 0	 0.25	 1	
Lactobacillus	 0	 0	 0	 1	 1	(1)	 0	 0.45	 1	
	 	 	 	 	 	 	 	 	
Any	mixed	 	 	 	 <0.0001	 	 	 1	 0.49	
S.	aureus,	
Staphylococci,	&	
Fusobacterium	
1	(1)	 	 	 	 	 	 	 	
S.	aureus,	
Staphylococci	&	
Enterobacteriaceae	
	 	 1	(2)	 	 	 	 	 	
S.	aureus,	
Fusobacterium,	&	
Enterobacteriaceae	
	 	 1	(2)	 	 	 	 	 	
S.	aureus,	
Staphylococci	
	 	 7	(14)	 	 	 	 	 	
S.	aureus		
Enterobacteriaceae	
2	(2)	 2	(9)	 5	(10)	 	 2	(2)	 	 	 	
Bifidobacterium,		
Staphylococci	
1	(1)	 	 	 	 	 	 	 	
S.	aureus,&	
Fusobacterium	
	 	 1	(2)	 	 	 	 	 	
Staphylococci,	
Enterobacteriaceae	
	 	 2	(4)	 	 	 	 	 	
Bifidobacteria,	
Enterobacteriacea	
	 	 1	(2)	 	 	 	 	 	
Enterobacteriaceae,	
S.pyogenes	
	 	 	 	 1	(1)	 	 	 	
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Table	20	Week	12	qPCR	results	comparing	proportions	of	positive	samples	between	ART	groups.	
	 %	Positive	Naïve	
(Week	12)		
N	(%)		
n=108	
%	Positive	Experienced	
(Week	12)	
N	(%)		
n=19	
%	Gulu	(Naïve)	
(Week	12)		
N	(%)	
n=49	
P	Value	
(Fisher’s	exact)	
proportion	
positive/	
negative	across	
3	ART	groups		
Bifidobacteria	 3	(3)	 1	(5)	 1	(2)	 0.62	
S.	aureus	 19	(18)	 3	(16)	 8	(16)	 0.95	
S.	pyogenes	 2	(2)	 0	 0	 1	
Fusobacterium	 1	(1)	 0	 0	 0.62	
Enterobacteriaceae	 39	(36)	 5	(26)	 9	(18)	 0.07	
Staphylococci	 0	 0	 2	(4)	 0.15	
Lactobacillus	 0	 0	 0	 1	
	 	 	 	 	
Any	Mixed	 	 	 	 1	
Bifidobacteria,	S.	pyogenes,	
Fusobacterium,	&	Enterobacteriaceae	
1	(1)	 	 	 	
S.	aureus,	Staphylococci	 	 	 1	(2)	 	
S.	aureus		Enterobacteriaceae	 8	(7)	 1	(5)	 2	(4)	 	
	
	 	
		
115	
Table	21	Proportions	of	positive	qPCR	results	at	week	72	by	ART	group		
	 %	Positive	Naïve	
(Week	72)	
N	(%)	
n=112	
%	Positive	Experienced	
(Week	72)		
N	(%)		
n=22	
%	Gulu	(Naïve)	(Week	
72)		
N	(%)		
n=49	
P	Value	(Fisher’s	
exact)	proportion	
positive	across	3	ART	
groups	
Bifidobacteria	 0	 0	 2	(4)	 0.15	
S.	aureus	 7	(6)	 1	(5)	 3	(7)	 1	
S.	pyogenes	 0	 0	 0	 1	
Fusobacterium	 2	(2)	 1	(5)	 0	 0.47	
Enterobacteriaceae	 35	(31)	 5	(23)	 16	(32)	 0.65	
Staphylococci	 0	 0	 2	(4)	 0.15	
Lactobacillus	 0	 0	 0	 1	
	 	 	 	 	
Any	Mixed	 	 	 	 0.81	
S.	aureus,	Staphylococci	
&	Enterobacteriaceae	
	 	 1	(2)	 	
S.	aureus		
Enterobacteriaceae	
1	(1)	 	 	 	
Bifidobacteria,	
Enterobacteriacea	
	 	 1	(2)	 	
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Table	22	Change	in	proportions	positive	for	S.aureus	over	time	by	ART	group	
	 Baseline		(%,	
95%	CI)	
W12	(%,	
95%	CI)	
Fisher’s	exact	
test	of	
proportions	
positive	
(Baseline	versus	
W12)	
W72	(%,	95%	
CI)	
Fisher’s	exact	
test	of	
proportions	
positive	
(Baseline	
versus	W72)	
ART-naive	 9	
5-17	
18	
11-26	
0.118	 6	
3-12	
0.336	
ART-
experienced	
23	
8-45	
16	
3-40	
0.70	 5	
0-23	
0.185	
Gulu	(ART-
naïve)	
55	
40-69	
16	
7-31	
<0.0001	 7	
1-19	
<0.0001	
Matched	
naïve	
control	
4	
1-11	
	 	 	 	
Matched	
experienced	
control	
15	
3-38	
	 	 	 	
	
Table	23	Table	comparing	proportions	positive	for	Enterobacteriaceae	over	time	by	ART	group	
	 Baseline	(%,	
95%	CI)	
W12	(%,	
95%	CI)	
Fisher’s	exact	
test	of	
proportions	
positive	
(Baseline	versus	
W12)	
W72	(%,	95%	
CI)	
Fisher’s	exact	
test	of	
proportions	
positive	
(Baseline	
versus	W72)	
ART-naïve		 23	
16-32	
36	
27-46	
0.06	 31	
23-40	
0.26	
ART-
experienced	
38	
18-62	
26	
9-51	
0.64	 23	
8-45	
0.44	
Gulu	(ART-
naïve)	
33	
21-48	
18	
9-31	
0.12	 32	
19-48	
1	
Matched	
naïve	
control	
37	
27-48	
	 	 	 	
Matched	
experienced	
control	
55	
32-77	
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Figure	28	Change	in	proportions	positive	for	S.aureus	using	qPCR	assay	over	time	with	95%	CIs	by	ART	group	
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Figure	29	Change	in	proportions	positive	for	Enterobacteriaceae	using	qPCR	assay	over	time	with	95%	CIs	by	ART	group	
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12.4.2 Pellet	Samples	
	
There	were	140	pellet	samples	for	analysis,	118	from	ART-naïve	children	at	baseline,	
and	22	from	ART-experienced	children	(Table	24,	Figure	30).	The	proportions	of	
samples	positive	for	S.	aureus	and	Enterobacteriaceae	were	higher	in	both	groups	
than	in	the	plasma	samples,	and	there	were	more	samples	with	a	higher	quantity	of	
bacteria	recorded	although	levels	still	tended	to	be	low	(Figure	30).	For	ART	naïve	
52%	(95%	CI	42-61%)	were	positive	for	S.aureus	versus	10%	(95%	CI	5-17%)	in	plasma,	
and	for	Enterobactericeae	69%	(95%	CI	59-77%)	were	positive	in	pellets	versus	23%	
(95%	CI	15-32%)	in	plasma.	For	the	ART	experienced	group,	64%	(95%	CI	41-83%)	
were	positive	for	S.aureus	versus	23%	(95%	CI	8-45%)	in	plasma	samples,	and	59%	
(95%	CI	36-79%)	for	Enterobacteriaceae	versus	36%	(95%	CI	18-62%)	in	plasma,	
showing	a	trend	towards	higher	proportions	although	not	reaching	statistical	
significance.		
	
There	was	no	significant	difference	between	either	proportions	of	samples	positive	
between	the	two	groups	or	proportions	of	samples	testing	weakly	or	strongly	positive	
as	per	Table	10	(Table	24).		
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Figure	30	qPCR	results	at	baseline	comparing	pellet	with	plasma	samples	by	ART	group:	CFU	equivalents	as	
compared	with	CT	values	of	standards	with	known	CFU	quantity	and	categorised	from	negative	to	strong	
positive.	
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Table	24	Table	comparing	qPCR	results	for	cell	pellets	in	HIV-infected	children	at	baseline	by	ART	group	
	 Positive	Naïve	
(NA=1)		
N	(%)		
n=118	
%	Positive	
Experienced		
N	(%)		
n=22	
P	value	(2	sided	
Fisher’s	exact	test)	
comparing	positive	
versus	negative	
P	value	2	sided	
Fisher’s	exact	
test	proportions		
low-	high	CFUs	
Bifidobacteria	 3	(3)	 0	 1	 1	
S.	aureus	 61	(52)	 14	(64)	 0.36	 0.66	
S.	pyogenes	 0	 0	 1	 1	
Fusobacterium	 0	 0	 1	 1	
Enterobacteriaceae	 81	(69)	 13	(59)	 0.46	 0.06	
Staphylococci	 61	(52)	 9	(41)	 0.49	 0.09	
Lactobacillus	 0	 0	 1	 1	
	 	 	 	 	
Any	mixed	 72	(61)	 11	(50)		 0.35	 	
S.	aureus,	Staphylococci	&	
Enterobacteriaceae	
25	(21)	 4	(18)	 	 	
S.	aureus	&	Staphylococci	 14	(12)	 1	(5)	 	 	
S.	aureus	&	Enterobacteriaceae	 9	(8)	 2	(9)	 	 	
Bifidobacteria,	S.	aureus,	&	
Enterobacteriaceae	
1	(1)	 	 	 	
Staphylococci,	
Enterobacteriaceae	
22	(19)	 4	(18)	 	 	
Bifidobacteria,	Enterobacteriacea	 1	(1)	 	 	 	
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12.5 Discussion	
	
To	our	knowledge,	this	is	the	first	use	of	qPCR	for	specific	bacterial	species/families	to	
investigate	microbial	translocation	in	the	blood	of	children	with	HIV.	Our	aim	was	to	
add	sensitivity	(not	achievable	with	broad	range	16S	rDNA	PCR)	for	particular	
bacterial	species/families	such	as	Enterobacteriaceae	previously	implicated	in	
microbial	translocation	in	HIV	infection54,55,	or	known	gut	commensals	such	as	
Bifidobacterium	and	Lactobacillus,	the	levels	of	which	in	the	gut	microbiome	might	be	
affected	by	HIV	infection.		
However,	most	of	the	qPCR	plasma	assays	were	negative	or	very	low	at	most	time	
points,	including	Bifidobacterium,	Fusobacterium,	Lactobactillus,	and	S.	pyogenes.	S.	
aureus	and	Enterobacteriaceae	were	positive	in	more	samples,	with	the	highest	
proportion	of	positive	plasma	samples	being	recorded	in	the	Gulu	group	at	baseline	
(55%	for	S.aureus,	95%	CI	40-69%)	(Figure	24,	Table	22).	The	baseline	pellets	had	
significantly	higher	proportions	of	positive	results	than	plasma	for	both	S.aureus	and	
Enterobacteriaceae	in	the	ART	naïve	group,	with	a	trend	towards	higher	proportions	
in	the	ART	experienced	group	though	confidence	intervals	were	wide	(Figure	30).		
	
The	Staphylococcus	spp.	assay	covers	the	whole	family	and	was	more	vulnerable	to	
contamination	that	the	specific	S.aureus	qPCR,	as	evidenced	by	negative	extraction	
and	negative	control	samples	crossing	the	cycle	threshold	<40	cycles.	Therefore	the	
threshold	for	a	positive	result	in	this	assay	and	the	Enterobacteriaceae	assay	was	set	
lower	at	35	cycles	rather	than	40	cycles	as	for	the	other	assays.	The	loss	of	sensitivity,	
meant	that	some	samples	that	were	positive	for	the	S.	aureus	assay	were	not	for	the	
Staphylococcus	spp.	Similarly,	samples	positive	for	both	S.aureus	and	Staphylococcus	
spp.	are	likely	to	represent	the	presence	of	S.	aureus	alone.		This	is	seen	most	clearly	
in	the	results	from	the	pellet	samples	where	the	proportion	of	ART	naïve	samples	
positive	for	both	S.aureus	and	Staphylococcus	spp.	were	the	same	(52%,	95%	CI	42-
61%),	although	in	the	ART	experienced	group	the	proportions	positive	for	
Staphylococcus	spp.	were	lower	than	S.	aureus.	For	reasons	discussed	below	(Section	
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14.5),	pellet	samples	appear	to	have	been	more	likely	to	contain	bacterial	DNA	than	
plasma	samples,	but	it	should	be	noted	here	that	although	the	levels	of	DNA	detected	
were	higher	in	the	pellet	than	plasma	samples	(possibly	secondary	to	centrifugation),	
the	species	of	bacteria	identified	in	plasma	and	pellet	samples	were	broadly	similar.	
This	runs	counter	to	the	a	priori	hypothesis	that	different	bacterial	species	might	be	
preferentially	phagocytosed	during	the	process	of	microbial	translocation,	although	
might	indicate	phagocytosis	more	generally	of	bacterial	DNA	in	the	blood.		
	
In	comparison	with	controls,	it	is	interesting	that	there	appeared	to	be	significantly	
more	naïve-control	samples	positive	for	Enterobacteriaceae	than	in	the	naïve	group	
at	baseline	(37%,	95%	CI	27-48%,	versus	23%,	16-32%	p=0.03),	with	a	trend	towards	a	
similar	pattern	in	the	experienced	versus	experienced-control	(Figure	30).	There	was	
a	trend	towards	an	increase	in	the	proportion	of	positive	samples	in	the	urban	ART-
naïve	group	over	time	(31%	at	week	72,	95%	CI	23-40%,	p=0.26	in	comparison	with	
baseline)	but	this	did	not	reach	significance.	Overall	there	was	some	fluctuation	in	the	
proportion	of	positive	samples	for	Enterobacteriaceae	in	all	three	HIV-infected	groups	
but	no	significant	change	over	time	(Figure	29).	As	can	be	seen	in	Figure	29	the	95%	
confidence	intervals	around	the	proportions	were	wide	and	overlapping	between	
groups	and	over	time.	This	could	indicate	either	that	the	assay	is	working	at	the	limits	
of	detection	and	the	very	low	results	seen	are	in	fact	representative	of	
contamination,	or	alternatively	that	there	is	some	evidence	of	Enterobacteriaceae	
DNA	present	in	both	HIV-infected	and	uninfected	individuals	and	also	in	those	
established	and	initiating	ART.	The	latter	interpretation	could	fit	with	the	hypothesis	
that	some	baseline	microbial	translocation	occurs	ubiquitously,	but	as	there	was	little	
difference	between	groups,	it	may	be	that	host	response	is	more	important	
biologically	than	microbial	translocation	per	se.		
	
With	regards	to	the	S.	aureus	results,	the	Gulu	(rural)	group	supported	most	closely	
the	a	priori	hypothesis	of	microbial	translocation	being	reduced	by	effective	ART,	with	
a	significant	reduction	in	the	number	of	positive	samples	over	time	(baseline:	55%,	
95%	CI	40-69,	Week	72:	7%,	95%	CI	1-19%,	p<0.0001).	Results	from	the	two	JCRC	
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(urban)	groups	do	not	conform	to	this	hypothesis,	as	results	in	the	ART	naïve	group	
were	lower	than	both	other	groups	(p<0.001)	at	baseline,	and	although	there	was	a	
non-significant	increase	at	week	12,	remained	low	at	week	72	(6%,	95%	CI	3-
12%)(Figure	28).	However,	confidence	intervals	were	wide,	especially	around	
proportions	for	the	ART-experienced	group	due	to	small	group	size	(Table	19)(Figure	
28).	In	general,	with	the	exception	of	the	Gulu	group,	the	proportions	of	samples	
positive	for	S.aureus		appeared	to	fluctuate	non-significantly	over	time	with	
overlapping	95%	confidence	intervals	as	seen	in	Figure	28.	As	many	of	the	positive	
results	were	low,	these	assays	were	working	at	the	limits	of	detection,	and	so	the	
results	must	be	interpreted	with	caution.		Furthermore,	the	S.aureus	results	from	the	
rural	Gulu	population	raise	the	question	as	to	whether	this	is	microbial	translocation	
from	the	gut	or	from	skin	contamination	that	is	being	measured.	S.aureus	frequently	
colonises	skin,	and	appears	to	be	at	a	higher	prevalence	in	rural	than	urban	
communities56.	
	
Data	as	regards	previous	use	of	qPCRs	for	specific	bacterial	species	are	extremely	
limited,	so	external	comparisons	are	limited	to	the	results	of	sequencing	after	broad	
range	16S	rDNA	PCR.	Members	of	the	Enterobacteriaceae	family	have	previously	
been	sequenced	in	this	setting	subsequent	to	broad	range	16S	rDNA	PCR,	and	were	
identified	in	a	small	number	of	HIV-positive	samples	(6/12	ART-naïve	adults	with	
advanced	HIV,	5/7	with	poor	response	to	ART,	0/7	in	adults	with	a	good	response	to	
ART54).	However,	no	HIV	uninfected	controls	were	included,	and	the	numbers	were	
small.	In	a	similar	study	by	the	same	group	which	included	44	HIV	infected	patients	
and	13	HIV	uninfected	controls,	cloning	and	Sanger	sequencing	after	broad	range	16S	
rDNA	PCR	revealed	Enterobacteriaceae	in	up	to	75%	of	samples,	and	a	significant	
difference	in	Lactobacillus	sp.	and	Pseudomonas	sp.	prevalence	between	those	with	a	
good	immune	response	to	ART	and	those	without8.	No	samples	were	positive	by	
broad	range	16S	rDNA	PCR	for	the	HIV-uninfected	controls.	No	Staphylococcus	spp.	
was	identified	in	any	group.	However,	no	sensitivities	are	quoted	for	the	assay,	the	
broad	range	16S	rDNA	PCR	was	run	to	40	cycles,	which	would	increase	the	risk	of	
false	positives	due	to	contamination,	and	sequencing	identification	was	limited	to	
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family	level.	The	group	sizes	were	very	small	(between	4-8	at	different	time	points)	so	
the	results	must	be	interpreted	with	caution.	
	
Some	of	these	limitations	also	applied	to	this	study,	in	that	the	ART-experienced	
group	size	was	small,	meaning	many	results	have	wide	confidence	intervals.	There	
were	some	missing	samples,	although	in	relatively	low	proportions.	The	highest	
proportion	of	missing	samples	was	in	the	Gulu	group	at	week	72	(14%).	However,	in	
all	three	groups,	the	children	for	whom	samples	were	missing	were	similar	in	
characteristics	(age	and	CD4	cell	count/percentage)	to	those	for	whom	samples	were	
available.	The	higher	proportion	of	missing	samples	from	Gulu	may	be	a	question	of	
logistics,	in	that	samples	had	to	be	packaged	for	transport	twice,	once	from	Gulu	to	
Kampala,	then	again	from	Kampala	to	London,	meaning	there	were	additional	
opportunities	for	samples	to	be	lost.	Alternatively,	there	may	have	been	difficulties	
for	the	children	in	attending	follow-up,	so	some	visits	may	have	been	missed	without	
the	child	being	entirely	lost	to	follow	up	for	the	study.		
	
The	qPCR	assays	are	heterogenous	with	varying	degrees	of	specificity	and	sensitivity,	
limiting	direct	comparison	between	assays.	To	overcome	this	and	try	to	limit	over	
interpretation	I	used	a	ranking	scheme	to	compare	results	as	per	Table	10.	The	
biggest	limitation	is	that	it	appears	that	the	pellet	samples	had	a	higher	proportion	of	
positive	test	results	for	both	S.aureus	and	Enterobacteriaceae,	but	pellet	samples	
were	only	available	at	baseline	for	the	ART	naïve	and	experienced	groups	from	JCRC,	
so	no	comparison	was	possible	with	controls,	or	the	Gulu	group,	or	over	time.		
	
However,	the	overall	pattern	of	results	were	similar	between	pellets	and	plasma,	in	
that	most	assays	(Fusobacterium,	S.pyogenes,	Lactobacillus,	Bifidobacterium)	were	all	
negative,	with	S.aureus	and	Enterobacteriaceae	being	the	assays	that	yielded	the	
highest	numbers	of	positive	results	throughout.	Enterobacteriaceae	in	particular	have	
been	detected	in	the	blood	of	HIV-infected	individuals	in	previous	studies,	although	
they	present	challenges	in	terms	of	interpretation	as	the	family	contains	species	that	
are	both	potential	pathogens	such	as	Escherichia	coli,	and	environmental	species,	
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such	as	Serratia	spp,	that	are	rarely	isolated	from	humans	and	are	therefore	more	
likely	to	be	contaminants.8,15,57,58	The	family	has	undergone	frequent	reclassification	
as	sequencing	methods	evolve,	meaning	even	species	identification	can	be	
challenging57,58.			
	
These	results	should	be	interpreted	together	with	the	results	from	NGS	and	broad	
range	16S	rDNA	PCR	assays	(see	below).		In	summary	however,	despite	using	assays	
of	high	sensitivity	minimal	evidence	was	found	of	DNA	from	the	Bifidobacterium,	
Fusobacterium	,	S.	pyogenes	or	Lactobacillus	assays	in	the	blood	of	the	study	
population.	Although	Enterobacteriaceae	and	S.aureus	were	identified,	the	levels	
detected		were	low	in	plasma	samples	at	all	time	points	in	all	groups,	indicating	these	
assays	were	working	at	the	limit	of	detection	(Figure	24	to	Figure	27).	Furthermore,	
for	the	Enterobacteriaceae	assay,	there	was	no	consistent	difference	between	groups	
or	over	time	(Figure	29),	so	it	is	questionable	as	to	whether	these	results	have	
biological	significance.		The	S.	aureus	did	appear	to	decrease	in	the	Gulu	(ART-naïve)	
group	over	time	(Figure	28),	which	could	indicate	a	true	change	in	translocating	
bacterial	DNA	from	the	gut.	However,	S.aureus	is	a	common	skin	commensal,	the	
assay	is	very	sensitive,	and	levels	detected	were	low.	These	results	too	should	be	
interpreted	with	caution.	
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13 Chapter	13	Broad	Range	16S	rDNA	PCR	for	the	Detection	of	Bacterial	DNA	as	an	
Indicator	of	Microbial	Translocation	in	HIV-infected	and	Uninfected	Children.	
13.1 Background	
As	described	in	8.4.6.1	and	8.4.6.2	a	combination	of	broad	range	16S	rDNA	PCR	with	
NGS	to	identify	the	species	present	is	a	method	to	explore	more	comprehensively	the	
bacterial	DNA	present	in	a	sample,	including	rare	or	unexpected	species,	and	groups	
of	organisms	that	are	difficult	to	target	using	a	specific	qPCR	owing	to	high	levels	of	
genetic	diversity.		Furthermore	16S	rDNA	PCR	is	necessary	to	quantify	the	bacterial	
load	in	each	sample	prior	to	NGS	in	order	to	determine	relative	abundances	in	the	
NGS	data	generated.		This	chapter	documents	the	results	obtained	using	a	broad	
range	16S	rDNA	PCR	using	a	SYBR®	Green	dye.		
13.2 Study	Population	
See	section	9.1	
13.3 Method	
Samples	were	extracted	as	per	section	9.3	
Broad	range	16S	rDNA	PCR	was	carried	out	using	a	SYBR®	Green	assay	according	to	
section	9.5.	Analysis	was	carried	out	as	per	section	9.7.	As	a	log	scale	was	used	for	
graphical	representation,	a	constant	of	one	was	added	to	all	results	generated	by	the	
SYBR®	Green	broad	range	16S	rDNA	PCR.	When	considering	the	broad	range	16S	
rDNA	PCR	in	isolation,	CFU	equivalents	were	used	to	estimate	bacterial	load	which	
were	calculated	by	comparison	with	standards	of	known	CFUs.	When	comparisons	
were	made	with	other	assays	such	as	the	qPCRs	the	scheme	described	in	Table	10	
was	used	(see	Section	10.1.5).	Negative	to	strong	positives	were	calculated	by	
comparison	with	standards	of	known	CFUs	and	coded	into	discrete	groups	from	0-5	
as	per	Table	10.	Proportion	of	positive	and	negative	samples	and	the	proportions	of	
samples	falling	in	each	category	from	negative	to	strong	positives	(coded	from	0-5)	
were	compared	using	chi-squared	tests	between	ART	groups.	
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13.4 Results	
	
Sample	numbers	available	for	analysis	were	the	same	as	for	section	12.4	(Table	18).	
Samples	were	missing	in	the	same	proportions	as	per	the	qPCR	assays	with	the	
exception	of	one	extra	sample	missing	at	week	72	in	the	ART-naïve	group	(3/112,	3%)	
(Section	12.4	and	Appendix	D	Missing	samples	across	groups	and	time	points).		
13.4.1 Broad	Range	16S	rDNA	PCR	using	SYBR®	Green	Assay		
For	plasma	samples,	results	were	broadly	similar	across	groups	and	time	
points(Figure	31).		As	seen	in	Figure	32	there	was	some	fluctuation	in	levels,	but	IQRs	
of	median	CFU	equivalents	were	broad	and	overlapping.	Considering	comparisons	
with	controls,	baseline	results	were	very	similar	between	both	ART-naïve	and	age-
matched	controls	(median	CFU	equivalents	103	(IQR	21-205)	and	102	(IQR	45-148)	
respectively,	p=0.47)	and	ART-experienced	and	controls	(median	CFU	equivalents	133	
(IQR	77-185)	and	103	(IQR	53-152)	respectively,	p=0.25).		The	samples	from	Gulu	had	
a	significantly	lower	median	(37,	IQR	12-96)	when	compared	with	Wilcoxon	rank	sum	
tests	to	the	naïve	group	at	baseline	(p=0.0015),	but	there	were	no	other	significant	
differences	between	the	groups	at	any	time	point.		
	
Considering	changes	in	bacterial	load	of	samples	over	time,	paired	Wilcoxon	rank	sum	
tests	for	each	individual	over	time	revealed	some	evidence	of	difference	between	the	
Gulu	samples	at	baseline	and	week	12,	and	baseline	and	week	72	(Table	26).	
However,	Spearman	correlation	coefficients	(using	complete	observations)	were	
small	and	not	significant	and	there	appeared	to	be	minimal	relationship	between	
results	in	individuals	over	time	(Table	27).	
Comparing	pellet	with	plasma	samples,	as	with	qPCR	results,	the	bacterial	loads	in	the	
pellet	samples	were	significantly	higher	than	for	plasma	overall	(p<0.001	in	paired	
Wilcoxon	rank	sum	test	in	both	groups)	although	there	was	no	direct	relationship	
between	individual	paired	samples	i.e.	between	the	bacterial	load	detected	in	plasma	
and	pellet	samples	from	an	individual	(Spearman	Correlation	coefficient	0.07,	p=0.44	
in	ART	naïve,	Spearman	Correlation	coefficient	0.003,	p	value=1	in	ART	
experienced)(Figure	33).	Bacterial	loads	detected	in	ART	experienced	and	ART	naïve	
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patients	were	similar	as	demonstrated	by	boxplot,	also	showing	the	difference	
between	plasma	and	pellet	results	(Figure	33).		
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Figure	31	Boxplots	of	Bacterial	load	(CFU	equivalents	compared	with	standards	of	known	CFUs)	detected	by	broad	range	16S	rDNA	PCR	(SYBR®	Green)	by	ART	group	over	time	
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Table	25	Bacterial	load	(CFU	Equivalents)	results	by	broad	range	16S	rDNA	PCR	assay	(SYBR®	Green)	by	ART	
group	over	time	compared	using	unpaired	Wilcoxon	Rank	sum	tests	
	 Naïve	 Experienced	 P	value	naïve	
versus	
experienced	
Naïve	
Controls	
Experienced	
Controls	
P	value	
cases	
versus	
controls	
Gulu	 P	value	
(Gulu	vs	
naïve	
cases)	
Baseline	CFU	
equivalent	
(Median,	IQR)	
103	
21-205	
n=112	
133	
77-185	
n=22	
0.37	 102	
45-148	
n=93	
103	
53-152	
n=20	
0.47	
(naïve)	
0.25	
(exp)	
37	
12-96	
n=52	
0.0015	
W12	CFU	
equivalent	
(Median,	IQR)	
85	
24-173	
n=108	
93	
16-240	
n=19	
0.72	 NA	 NA	 0.55	
(naïve)	
0.99	
(exp)	
88	
47-124	
n=49	
0.94	
W24	CFU	
equivalent	
(Median,	IQR)	
87	
8-155	
n=7	
NA	 NA	 NA	 NA	 0.6	
(naïve)	
	
200	
100-219	
n=3	
0.47	
	
W72	CFU	
equivalent	
(Median,	IQR)	
94	
69-134	
n=112	
114	
78-144	
n=22	
0.36	 NA	 NA	 0.56	
(naïve)	
0.62	
(exp)	
104	
29-214	
n=44	
0.94	
	
	
	
Table	26	Paired	Wilcoxon	Rank	sum	tests	of	bacterial	load	(CFU	equivalents)	over	time	by	ART	group	
Paired	Wilcoxon	rank	sum	test	 ART	Naïve	p	value	 ART	Experienced	p	
value	
Gulu	(naïve)	p	
value	
PreRandomisation	 Week	12	 0.072	 0.8	 0.03	
PreRandomisation	 Week	24	 0.47	 NA	 0.5	
PreRandomisation	 Week	72	 0.09	 0.39	 0.02	
Week	12	 Week	24	 0.63	 NA	 1	
Week	12	 Week	72	 0.28	 0.98	 0.19	
Week	24	 Week	72	 0.25	 NA	 0.75	
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Figure	32	Change	in	bacterial	load	(median	CFU	equivalents	compared	with	standards	of	known	CFUs)	by	broad	range	16S	rDNA	PCR	over	time	by	ART	group	with	IQR	
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Table	27	Spearman	Correlation	Coefficients	by	ART	groups	over	time	
Spearman	Correlation	using	
complete	observations	
ART	Naïve	 ART	Experienced	 Gulu	(naïve)	
Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	
PreRandomisation	 Week	12	 0.14	 0.17	 -0.08	 0.75	 -0.12	 0.44	
PreRandomisation	 Week	24	 -0.07	 0.49	 NA	 NA	 -0.87	 0.33	
PreRandomisation	 Week	72	 0.14	 0.17	 0.19	 0.39	 -0.04	 0.81	
Week	12	 Week	72	 -0.07	 0.49	 0.02	 0.93	 -0.08	 0.63	
	
	
	
Figure	33	Comparisons	of	bacterial	load	(CFU	equivalents	compared	with	standards	of	known	CFUs)	in	pellets	
versus	plasma	samples	at	baseline	
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13.4.2 Comparison	of	Broad	Range	16S	rDNA	PCR	(using	SYBR®	Green	assay)	with	
qPCRs	
	
The	results	obtained	from	the	broad	range	16S	rDNA	PCR	(SYBR®	Green)	were	
compared	with	those	from	the	individual	qPCRs	using	the	scheme	set	out	in	Table	10	
(see	section	10.1.5),	categorising	results	into	discrete	groups	from	negative	to	very	
high	results	as	compared	with	standards	of	known	CFUs.		Very	few	samples	tested	
positive	for	Fusobacterium,	Bifidobacterium,	Lactobacillus,	or	S.pyogenes	and	very	
little	relationship	was	seen	between	the	results	of	these	assays	and	the	broad	range	
16S	rDNA	PCR	(SYBR®	Green)(data	not	shown).	With	S.	aureus	and	Staphylococcus	
spp.	there	was	minimal	relationship	between	assays,	but	with	Enterobacteriaceae	
there	appeared	to	be	an	inverse	relationship	between	the	results	obtained	by	qPCR	
and	broad	range	16S	rDNA	PCR	which	was	significant	when	comparing	proportions	of	
negative	to	positives,	although	the	decrement	was	small	(p=0.03	using	Fisher’s	exact	
test)	(Figure	34).	ART	group	appeared	to	impact	minimally	on	the	comparison	(data	
not	shown).		
	
As	regards	pellet	samples,	there	was	a	significant	positive	relationship	between	
samples	positive	for	S.	aureus	and	those	with	a	positive	result	via	broad	range	16S	
rDNA	PCR	(SYBR®	Green)	(Fisher’s	exact	test	p=0.023)(Figure	35).	However	there	was	
once	more	a	significant	negative	relationship	between	assays	positive	for	
Enterobacteriaceae	and	using	the	broad	range	assay	(Fisher’s	exact	test	p=0.02)	
(Figure	35).		
	
To	investigate	a	possible	relationship	between	16S	broad	range	PCR	results	(SYBR®	
Green)	and	qPCR	samples	which	were	either	strongly	positive	for	one	assay	or	tested	
positive	with	more	than	one	qPCR	assay,	a	comparison	was	made	as	per	Section	
10.1.5.		No	significant	relationship	was	seen,	although	there	was	a	trend	towards	a	
positive	relationship	in	the	pellet	samples	(data	not	shown).		
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Figure	34	Scatterplots	of	qPCRs	compared	with	broad	range	16S	rDNA	PCR	(high	number	of	positive	qPCRs),	comparing	
ranking	of	negative	to	high	positives	
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Figure	35	Comparison	of	qPCR	versus	broad	range	16S	rDNA	PCR	for	pellet	samples,	comparing	ranking	of	negative	to	high	
positives	
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13.5 Discussion	
	
Interpreting	the	results	from	the	broad	range	16S	rDNA	PCR	(SYBR®	Green)	assay	in	
this	study	presents	some	challenges.	Broad	range	16S	rDNA	PCR	has	been	used	with	
and	without	subsequent	sequencing	as	a	marker	of	microbial	translocation	in	HIV	and	
SIV	infection8,54,59-66.	In	most	previous	studies,	the	quantification	has	been	recorded	
as	16S	rDNA	copies/μL	as	opposed	to	CFU	equivalents/PCR	reaction	in	comparison	
with	standards	of	known	CFUs,	and	the	ranking	scheme	of	negative	to	high	positives	
used	here.		A	disadvantage	of	the	former	method	is	that	as	the	16S	rRNA	gene	has	
variable	copy	numbers	between	bacterial	species,	presenting	the	result	as	a	single	
figure	could	lead	to	over-interpretation,	especially	in	the	absence	of	downstream	
sequencing	to	identify	bacterial	species	present.	This	means	that	differences	of	less	
than	one	log	in	copies/μL	might	be	artifactual	and	due	to	the	species	of	bacteria	
present	as	opposed	to	the	quantities.	Owing	to	this	assay’s	vulnerability	to	
contamination,	care	must	be	taken	to	ensure	that	results	are	presented	with	
concomitant	provisos	that	even	between	runs	within	the	same	study	comparisons	
may	be	inaccurate.	Hence	I	opted	for	a	cautious	interpretation	of	quantification	by	
comparison	with	CFUs	of	a	known	standard	as	an	estimate	of	bacterial	load,	and	
performed	NGS	to	confirm	the	presence	of	bacteria	likely	to	be	associated	with	
microbial	translocation	as	opposed	to	artifact	and	contamination.		
	
As	a	broad	summary,	it	appears	that	there	was	minimal	difference	between	results	
obtained	from	the	cases	and	controls,	or	the	cases	over	time	(Figure	31,	Figure	32).	
Interquartile	ranges	were	very	wide	and	overlapping	for	all	groups	and	over	time	as	
seen	in	Figure	32.	This	could	indicate	that	there	is	genuinely	no	difference	in	the	
levels	of	bacterial	DNA	detected	in	these	samples,	or	could	indicate	that	the	assay	has	
reached	the	limits	of	detection	when	used	without	sequencing.	Due	to	concern	about	
the	assay’s	vulnerability	to	contamination,	results	were	interpreted	conservatively:	
the	limit	of	detection	was	determined	by	the	lowest	CT	value	of	negative	extraction	
and	negative	control	samples	even	if	this	was	lower	than	the	threshold	indicated	by	
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the	standards.	This	means	the	sensitivity	(5-50	CFUs/PCR	reaction)	was	lower	than	for	
specific	qPCRs	and	so	there	may	have	been	some	false	negative	samples.		
In	terms	of	external	comparison,	the	sensitivity	of	the	assay	equates	to	a	sensitivity	of	
80-800	copies/μL67.	This	is	much	lower	than	the	sensitivity	of	5	copies/μL	quoted	in	
Jiang	et	al.	which	is	the	method	used	in	several	subsequent	papers	59,61,65,66,68.	The	
median	levels	in	HIV	infected	individuals	detected	in	these	papers	vary	from	5-400	
copies/μL,	and	in	one	study,	adults	with	chronic	HIV	had	levels	between	500-9000	
copies/μL63.	With	the	exception	of	Chevalier	et	al.,	the	levels	generated	by	the	assay	
of	Jiang	et	al.	tend	to	be	lower	than	in	this	study	(converting	from	CFU	equivalents	to	
median	copies/μL	of	1600-4180),	but	it	is	important	to	note	that	straightforward	
comparisons	are	unlikely	to	be	useful	owing	to	variability	in	the	assay	and	the	
contrasting	quantification	methods	used.	Also,	the	method	described	by	Jiang	et	al.	
does	not	include	sequencing,	and	uses	45	thermal	cycles,	more	than	used	in	this	
study59.		An	alternative	method	described	by	Kramski	et	al.	uses	a	shrimp	nuclease	to	
decrease	contaminant	DNA	prior	to	amplification64.	This	modified	assay	has	a	quoted	
sensitivity	of	10	copies/reaction,	and	reported	500-2500	16S	rRNA	copies/mL	in	HIV-
infected	adults	from	Australia64.	A	further	method	(again	with	no	sequencing)	used	in	
a	cohort	of	children	in	Spain	found	medians	of	630	and	3162	copies/μL	in	HIV	
uninfected	and	infected	children	respectively69,70.	It	can	be	seen	there	is	considerable	
variation	in	levels	generated	by	different	assays,	and	in	copy	numbers	detected	even	
in	using	similar	assays	in	different	studies.	In	summary,	considering	the	difference	(or	
lack	of	difference)	between	groups	within	this	study	are	likely	to	be	more	useful	than	
external	comparators,	owing	to	different	methods	used.	In	the	absence	of	an	external	
assay	calibrator	or	standard,	the	usefulness	of	interstudy	comparison	of	quantitative	
data	is	limited.	
	
The	apparent	negative	relationship	seen	between	the	Enterobacteriaceae	assay	and	
the	broad	range	16S	rDNA	PCR	(SYBR®	Green)	could	be	due	to	the	fact	that	the	
Enterobacteriaceae	assay	is	also	vulnerable	to	contamination	and	so	is	similarly	
limited	in	terms	of	its	sensitivity	and	that	the	apparent	association	is	spurious	(Figure	
34).	It	may	be	that	there	is	some	form	of	sample	inhibition	that	impacts	on	one	assay	
more	than	the	other,	although	this	pattern	did	not	extend	to	the	S.aureus	assay	
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(Figure	34),	and	internal	positive	control	results	did	not	indicate	inhibition.		Another	
explanation	is	that	all	PCR	primers	have	inherent	bias,	and	so	the	broad	range	primers	
used	in	the	SYBR®	Green	assay	could	be	more	biased	towards	Gram	positive	bacteria	
such	as	S.aureus,	and	away	from	Enterobacteriaceae.	Additionally,	
Enterobacteriaceae	have	variable	copy	numbers	of	the	16S	rRNA	gene,	from	1	to	11	
copies	depending	on	the	species71.	Even	within	species	there	can	be	variation72.	By	
contrast,	the	DnaK	gene	targeted	by	the	Enterobacteriaceae	qPCR	is	a	single	copy	
gene73.	The	broad	range	16S	rDNA	PCR	may	therefore	give	less	accurate	
quantification	of	Enterobacteriaceae.	Furthermore,	the	Enterobacteriaceae	PCR	was	
designed	for	use	in	a	clinical	setting,	and	so	targeted	towards	clinically	significant	
bacteria	such	as	Escherichia	coli15.	The	16S	rDNA	PCR	primers,	while	also	aiming	to	
target	clinically	significant	bacteria,	are	subject	to	more	constraints	due	to	the	need	
to	cover	as	broad	a	range	of	bacteria	as	possible.	Therefore	compromises	have	to	be	
made	such	that	for	a	diverse	family	such	as	Enterobacteriaceae,	contaminant	rather	
than	biologically	significant	species	may	be	preferentially	sequenced.		
	
A	broad	comparison	was	made	between	the	broad	range	16S	rDNA	PCR	(SYBR®	
Green)	and	samples	which	were	either	strongly	positive	in	one	qPCR	assay	or	positive	
with	several	qPCR	assays	for	the	purposes	of	hypothesis	generation.	This	comparison	
was	to	investigate	whether	there	was	any	similarity	between	the	numbers	of	CFU	
equivalents	detected	by	the	broad	range	assay	and	across	the	panel	of	specific	assays.	
With	the	plasma	samples,	no	similarity	was	seen	but	there	was	a	trend	towards	a	
relationship	in	the	pellet	samples.	This	is	likely	to	be	driven	by	the	positive	association	
seen	between	broad	range	assay	results	and	the	S.	aureus	assay	(Figure	35).	
	
In	summary,	the	results	for	the	bacterial	load	as	detected	by	a	broad	range	16S	rDNA	
PCR	were	very	similar	between	HIV-infected	groups	and	controls,	and	over	time	
within	HIV	infected	groups,	with	the	one	exception	of	the	rural	group	having	a	
significantly	lower	bacterial	load	at	baseline.	This	suggests	that	the	low	levels	of	
bacterial	DNA	as	detected	by	this	assay	are	unlikely	to	play	a	significant	biological	role	
in	this	setting.	Although	results	tended	to	be	higher	than	those	detected	in	other	
studies,	there	is	considerable	variability	both	in	methods	used	elsewhere	and	in	
		
140
bacterial	levels	detected	which	undermines	the	usefulness	of	external	comparison.	
These	results	should	be	interpreted	together	with	those	of	Chapters	12	and	14.	
	 	
		
141	
14 Chapter	14	Next	Generation	Sequencing	subsequent	to	Broad	Range	16S	rDNA	
PCR	to	Identify	Bacterial	DNA	involved	in	Microbial	Translocation	in	HIV-
infected	and	Uninfected	children.	
14.1 Background	
As	discussed	in	sections	8.4.6.1	and	8.4.6.2,	without	sequencing,	it	is	difficult	to	
determine	whether	results	from	broad	range	16S	rDNA	PCR	are	artefact	as	the	assay	
is	vulnerable	to	contamination.	NGS	offers	the	most	comprehensive	and	effective	
method	to	sequence	the	full	range	of	bacterial	species	which	may	be	present	in	a	
sample.			
14.2 Study	Population	
See	section	9.1	
14.3 Methods	
NGS	was	carried	out	according	to	section	9.7.	Barcoded	primers	(Table	39)	were	used	
at	a	concentration	of	0.2pmol/μL.	Post	library	amplification,	the	samples	were	initially	
cleaned	individually	using	AMPure	XP	beads	(Beckman	Coulter)	and	a	plate	magnet	at	
a	ratio	of	0.8:1	beads	to	sample.	They	were	then	normalised	and	pooled	using	
SequalPrep	normalization	plate	kits	(Invitrogen).	Several	further	steps	of	cleaning	
using	AMPure	XP	beads	(Beckman	Coulter)	at	a	ratio	of	0.8:1	were	carried	out	for	
each	plate	as	guided	by	quantification	with	an	Agilent	high	sensitivity	DNA	kit	(hsDNA)	
using	a	Bioanalyser,	comparing	the	ratio	of	primer	dimer	to	library	(see	section	
10.2.2).	The	libraries	only	successfully	sequenced	when	the	ratio	of	amplicon	to	
primer	dimer	was	at	least	3:1.	Final	library	quantification	was	carried	out	using	a	
Qubit	2.0	(Life	technologies)	and	10pM	library	loaded	onto	a	MiSeq	(Illumina)	as	per	
manufacturer’s	protocol	for	500	cycle	V2	kits	with	the	addition	of	custom	sequencing	
primers	and	a	10%	PhiX	spike.	Sequences	were	demultiplexed	and	filtered	and	OTUs	
assigned	using	QIIME	(v1.8.0)(section	19.3,	Appendix	B)	and	results	were	analysed	
using	R	Studio	(v.0.99.896)	using	Phyloseq	(v.1.10.0)	as	per	section	9.7.	
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14.4 Results	
	
Samples	available	for	analysis	were	the	same	as	in	section	12.4.	In	total,	176/808	
(22%)	samples	produced	sufficient	quantities	of	amplified	16S	library	to	be	
successfully	sequenced.	105/140	(75%)	pellet	samples	were	sequenced	along	with	
71/668	(11%)	plasma	samples	(Table	28).		None	of	the	113	control	samples	from	HIV-
uninfected	children	were	sequenced	successfully	as	insufficient	16S	library	was	
produced.	
Table	28	Table	of	distribution	of	samples	successfully	sequenced	using	NGS	by	ART	group	and	sample	time	
points	
	 Baseline	Pellet	 Baseline	Plasma	 Week	12	 Week	72	
ART	naïve	
95%	CI	
83/118	(70%)	
61-78	
53/112	(47%)	
38-57	
3/112	(3%)	
6-8	
0/112	(0%)	
0-3	
ART	experienced	
95%	CI	
22/22	(100%)	
85-100	
6/22	(27%)	
11-50	
1/22	(5%)	
1-23	
0/22	(0%)	
0-15	
Gulu	(ART	naïve)		
95%	CI	
NA	 0/52	(0%)	
0-7	
0/49	(0%)	
0-7	
7/49	(14%)	
6-27	
	
Eleven	controls	were	included:	two	mock	communities	(one	was	run	in	duplicate),	
two	other	positive	controls,	one	negative	extract	on	each	run	and	two	other	negative	
controls	on	each	run.		As	the	number	of	OTUs	generated	tended	to	be	low;	both	
rarefied	and	unrarefied	results	are	presented.		The	results	were	dominated	by	
Staphylococcus	spp.	and	Enterobacteriaceae	with	these	OTUs	also	appearing	in	the	
negative	experimental	controls	in	both	runs	(Figure	36,	Figure	37).	Similar	OTUs	
appeared	in	all	three	ART	groups	as	can	be	seen	from	the	phylogenetic	tree	node	
labels	(Figure	36,	Figure	37).		Furthermore	there	was	no	clustering	of	the	negative	
control	groups	within	principle	coordinates	analysis:	rather	there	was	representation	
of	all	groups	across	the	plot	regardless	of	ART	status(Figure	38).	
Some	species	included	in	the	mock	communities	were	from	families	missing	from	the	
sequencing	results:	Actinomyces	odontolyticus,	Deinococcus	radiodurans,	and	
Rhodobacter	sphaeroides.	On	checking	the	alignment	of	the	primers	with	the	16S	
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rRNA	gene	of	these	species,	there	was	a	good	match	between	the	primers	and	the	
relevant	regions	of	the	genes.	All	other	species	in	the	mock	communities	were	from	
families	identified	in	the	sequencing.
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Figure	36	Phylogenetic	Tree	by	ART	randomisation	(unrarefied):	showing	predominance	of	Staphylococcacea,	Enterobacteriaceae,	and	Sphingomonadaceae.	Negative	
experimental	control	samples	(coloured	blue)	can	be	seen	across	most	nodes		
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Figure	37	Phylogenetic	Tree	by	ART	Randomisation	(rarefied)	showing	predominance	of	Staphylococcacea,	Enterobacteriaceae,	and	Sphingomonadaceae.	Negative	experimental	
control	samples	(coloured	blue)	can	be	seen	across	most	nodes	
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Figure	38	Principal	Coordinates	Analysis	using	Unifrac	(rarefied)	showing	no	specific	clustering	by	sample	type	or	ART	randomisation.	Negative	experimental	control	samples	
(squares)	can	be	seen	dispersed	across	analysis	with	no	specific	clustering.		
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14.4.1 Removal	of	OTUs	in	Negative	Control	Samples	
Examining	the	results	using	principal	coordinates	analysis	(PCoA)	(Section	9.9)	
demonstrated	that	the	experimental	controls	were	distributed	across	the	results	
rather	than	clustered	together	(Figure	38).	Therefore	the	OTUs	contained	within	the	
controls	were	removed	and	the	samples	reanalysed	both	with	and	without	
rarefaction.		
Families	from	which	OTUs	were	removed	were:	Brevibacteriaceae,	Caulobacteraceae,	
Comamonadaceace,	Enterobacteriaceae,	Intrasporangiaceae,	Micrococcaceae,	
Moraxellaceae,	Propionibacteriaceae,	Pseudomonadaceae,	Sphingomonadaceae,	
Staphylococcaceae	and	Streptococcaceae.	After	removal	of	experimental	negative	
control	OTUs,	the	resulting	phylogenetic	trees	were	scanty	(Figure	39,	Figure	40).	
Staphylococci	and	Enterobacteriaceae	were	still	seen	across	both	ART-naïve,	ART-
experienced	and	Gulu	(ART-naïve)	groups	at	low	abundance	(Figure	39,	Figure	40).	
PCoA	showed	minimal	clustering	among	ART	randomisation	groups	or	timings	of	
sample	(Figure	41).	
OTUs	present	after	removal	of	those	seen	in	experimental	negative	control	samples	
include:	Staphylococcaceae,	Lactobacillaceae,	Veillonellaceae,	Clostridiaceae,	
Bacteroidaceae,	Porphyromonadaceae,	Enterobacteriaceae,	Neisseriaceae,	
Moraxellaceae,	Oxalobacteriaceae,	and	Helicobacteriaceae.		
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Figure	39	Phylogenetic	tree	by	ART	randomisation	after	removal	of	negative	control	OTUs	(unrarefied),	showing	sparse	OTUs	including	Staphylococcaceae	amongst	other	
families.	OTUS	derived	from	both	ART-experienced	and	ART-naïve	samples	distributed	across	phylogenetic	tree.	
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Figure	40	Phylogenetic	Tree	by	ART	randomisation,	Negative	Control	OTUs	removed	(Rarefied)	showing	sparse	OTUs	including	Staphylococcaceae	amongst	other	families.	OTUS	
derived	from	both	ART-experienced	and	ART-naive	samples	distributed	across	phylogenetic	tree.	
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Figure	41	PCoA	after	removal	of	negative	control	OTUs	(Rarefied):		no	clustering	by	sample	type	or	timing.	ART	naïve	and	ART	experienced	samples	distributed	throughout.	
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14.4.2 Comparison	of	NGS	Results	with	qPCR	and	Broad	Range	16S	rDNA	PCR	
	
The	PCoA	analysis	using	unifrac	was	repeated	to	look	for	associations	with	results	
from	a)	Broad	range	16S	rDNA	PCR	(SYBR®	Green)	and	b)	S.aureus	and	
Enterobacteriaceae	qPCR	assays	in	both	pellets	and	plasma	samples.	Minimal	
association	was	seen	prior	to	removal	of	negative	control	OTUs	(data	not	shown).	
After	removal	of	the	negative	control	OTUs,	there	did	appear	to	be	some	association	
in	both	the	broad	range	16S	rDNA	PCR	(SYBR®	Green)	and	the	S.aureus	PCRs	in	the	
pellet	samples	and	clustering	of	the	PCoA	(Figure	42),	in	that	more	strongly	positive	
samples	clustered	together,	as	did	negative	samples.	However	there	was	no	distinct	
clustering	seen	between	ART	naïve	and	ART-experienced,	and	minimal	relationship	
was	seen	in	the	plasma	samples	(Figure	43).	There	was	no	clustering	seen	between	
Enterobacteriaceae	results	and	the	PCoA	from	the	next	generation	sequencing	after	
removal	of	negative	control	OTUs	(Figure	42,	Figure	43).
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Figure	42	PCoA	of	Pellet	Samples	with	Negative	control	OTUs	removed	compared	with	other	PCRs:	broad	range	16S	rDNA	PCR,	Enterobacteriaceae	PCR	and	S.	aureus	PCR.	Some	
clustering	seen	by	negative	and	high	results	in	broad	range	16S	rDNA	PCR	and	S.aureus	PCR,	but	not	by	negative	or	high	results	in	Enterobacteriaceae	PCR.		
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Figure	43	PCoA	of	Plasma	samples	after	negative	control	OTUs	removed	compared	by	other	PCR	assays:	broad	range	16S	rDNA	PCR,	Enterobacteriaceae	PCR	and	S.	aureus	PCR.	
Minimal	clustering	seen	by	negative	or	high	results	in	any	of	the	three	assays.		
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14.5 Discussion	
	
This	study	has	demonstrated	the	challenges	of	NGS	when	analysing	samples	with	low	
bacterial	load.	The	assay	was	working	at	the	limit	of	detection,	as	seen	by	the	fact	
that	insufficient	library	was	generated	in	many	samples	to	sequence	successfully,	and	
even	in	the	successful	runs,	many	OTUs	generated	were	also	seen	in	negative	control	
samples	(Figure	36,	Figure	37).	On	removing	the	OTUs	seen	in	negative	controls,	the	
resulting	OTUs	generated	a	scanty	phylogenetic	tree	both	with	and	without	
rarefaction	(Figure	39,	Figure	40).	
	
That	many	OTUs	were	seen	in	negative	control	samples	highlights	that	16S	rDNA	PCR	
is	vulnerable	to	contamination	and	the	crucial	importance	of	sequencing	to	indicate	
whether	results	generated	are	artefact.	Of	previous	studies	using	16S	rDNA	PCR	to	
investigate	microbial	translocation	in	the	setting	of	HIV/SIV	infection,	only	two	have	
used	any	form	of	sequencing	on	plasma	samples8,54.	The	Sanger	sequencing	method	
used	in	these	two	studies	revealed	Enterobacteriaceae	and	Lactobacillaceae	which	
could	be	implicated	in	microbial	translocation	as	well	as	families	such	as	
Comamonadaceae,	and	members	of	the	Enterobacteriaceae	family	such	as	Rahnella	
sp.	which	could	be	contaminants.		
	
The	pilot	study	for	this	thesis	used	NGS	(Roche	454	platform®)	and	identified	families	
in	the	blood	of	HIV-infected	children	in	London	that	could	be	consistent	with	
microbial	translocation9.	These	included	Veillonellaceae	and	Lactobacillaceae.	
However,	the	numbers	of	samples	was	low	and	no	control	groups	were	available.	It	is	
possible	that	the	results	of	the	pilot	study	also	could	be	consistent	with	
contamination.		The	only	other	study	to	have	used	next	generation	sequencing	(also	
using	the	Roche	454	platform®)	involved	investigating	bacterial	DNA	found	in	the	
colon,	liver	and	mesenteric	lymph	nodes	of	SIV-infected	RMs	which	identified	certain	
families	within	the	phylum	of	Proteobacteria	to	translocate	preferentially	compared	
with	others,	and	members	of	the	Bacteroidetes	phylum62.	Interestingly	though,	the	
families	identified	to	have	preferentially	translocated	to	lymph	nodes	included	
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Sphingomonadaceae,	Caulobacteraceae,	and	Comamonadaceace,	all	of	which	were	
identified	in	negative	experimental	controls	in	this	study	and	removed.	It	is	
challenging	to	identify	which	species	might	be	genuine	indicators	of	microbial	
translocation	and	which	represent	artefact.		
	
Within	this	study,	of	the	families	that	were	identified,	some	might	be	implicated	in	
gut	translocation,	namely	Enterobacteriaceae	(as	seen	in	previous	studies8,59),	
Clostridiales,	Veilonella,	Lactobacillales	and	Bacteroides,	but	these	were	seen	at	low	
levels	and	represented	both	in	ART-naïve	and	ART-experienced	groups.	Other	families	
could	be	implicated	in	translocation	from	sites	other	than	the	intestine,	such	as	the	
nasopharynx	(Neisseriaceae,	Moraxallaceae,	Corynebacteriaceae	and	
Porphyromnodaceae),	although	some	species	are	also	represented	in	mouth	flora	
(Porphyromnodaceae	and	Fusobacterium).	The	Staphylococcaceae	and	
Streptococcaceae	are	difficult	to	interpret	as	they	could	have	been	derived	from	the	
skin,	therefore	representative	of	contamination,	but	are	also	seen	in	gut	flora.	Taken	
altogether,	as	these	families	are	seen	in	low	levels	in	both	ART-experienced	and	ART-
naïve	children,	this	could	be	representative	of	baseline	low	levels	of	ubiquitous	
translocation	that	may	be	seen	in	healthy	individuals,	rather	than	a	phenomenon	that	
is	unique	to,	or	at	least	more	severe	in	those	with	uncontrolled	HIV62,74-77.		
	
An	important	limitation	of	this	study	is	that	some	species	from	the	mock	communities	
were	not	identified	by	sequencing.	This	may	have	been	due	to	issues	with	the	mock	
communities	themselves	as	the	same	species	were	not	identified	in	the	mock	
communities	in	a	parallel	project	with	different	samples78.		It	should	be	noted	that	in	
any	case,	two	of	the	three	families	from	which	species	were	omitted,	namely	
Rhodobacter	and	Deinococcaceae	are	more	usually	associated	with	soil	and	are	not	
well	known	gut	commensals	or	pathogens78-80.	The	omission	of	Actinomyces	
odontolyticus	is	more	concerning	as	this	is	a	recognised	pathogen	and	can	be	found	in	
the	human	gut81.	However,	otherwise	coverage	of	the	mock	community	species	was	
reasonable.		
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Primer	bias	is	unlikely	to	be	the	cause	of	the	omission	of	the	three	mock	community	
species	as	the	primer	sequences	were	checked	relative	to	the	16S	rRNA	genes	of	the	
species	in	question.	However,	primer	bias	could	apply	to	species	present	in	
experimental	samples	that	have	also	not	sequenced	successfully.	This	is	an	issue	with	
any	PCR-based	reaction	which	is	that	all	primer	sets	can	be	biased	either	positively	or	
negatively	against	particular	bacterial	strains.	Use	of	alternative	primer	sets	such	as	
the	qPCR	assays	in	this	study	should	go	some	way	to	addressing	this,	but	these	assays	
were	also	working	at	the	limit	of	detection	and	are	narrow	in	their	targets.		
	
It	is	also	important	to	note	how	pellet	samples	were	more	likely	to	sequence	
successfully	than	plasma	samples,	a	pattern	also	seen	in	the	PCR	results	in	sections	12	
and	13.	This	meant	that	both	the	Gulu	group,	the	HIV-uninfected	control	group	and	
the	samples	at	different	time	points	when	no	pellet	samples	were	available	were	less	
likely	to	have	contributed	data	to	the	sequencing.	However,	47%	(95%	CI	38-57)	of	
the	ART-naïve	group	and	27%	(95%	CI	11-50)	of	the	ART	experienced	group	had	
plasma	samples	that	successfully	sequenced	at	baseline,	versus	3%	(95%	CI	6-8)	and	
5%	(95%	CI	1-23)	respectively	at	week	12,	and	none	at	week	72.	Also,	14%	(95%	CI	6-
27)	of	the	Gulu	samples	at	week	72	sequenced	successfully	but	none	at	any	other	
time	point.			
	
This	could	be	consistent	with	genuine	microbial	translocation	rather	than	
contamination.	However	if	this	were	so,	a	difference	between	the	ART	groups	would	
be	predicted.	It	is	more	likely	that	there	may	have	been	some	difference	in	the	
method	of	sample	collection	and	storage	at	these	time	points,	particularly	with	
regards	to	the	Gulu	samples.	The	Gulu	samples	had	to	undergo	two	stages	of	
transport,	firstly	from	Gulu	to	Kampala	and	then	on	to	London,	so	increasing	the	
chances	of	problems	in	the	cold	chain.	It	could	also	be	the	result	of	a	batch	effect.	In	
order	to	choose	samples	most	likely	to	successfully	sequence,	they	were	batched	
according	to	bacterial	load	by	16S	rDNA	PCR	(SYBR®	Green)	result	as	per	section	
10.2.2.	This	meant	that	for	the	most	part,	samples	were	not	batched	together	by	site	
or	by	time	point,	but	some	underlying	effect	cannot	be	ruled	out.		
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Considering	why	pellet	samples	might	be	more	likely	to	yield	higher	quantities	of	DNA	
across	all	three	assays,	this	might	be	a	true	representation	of	larger	quantities	of	
bacterial	DNA	present	in	the	sample,	potentially	as	a	result	of	phagocytosed	
intracellular	bacterial	DNA	in	host	cells	being	spun	into	the	pellet.	As	the	bacterial	
families	identified	in	pellets	and	plasma	were	similar	by	qPCR	and	NGS	(although	the	
levels	differed	between	sample	types),	it	appears	unlikely	that	different	species	were	
preferentially	phagocytosed	as	hypothesised	a	priori.	Furthermore,	although	the	
higher	levels	in	pellet	samples	might	be	due	to	translocating	bacteria	within	
phagocytes,	the	results	might	also	be	due	to	host	DNA	acting	as	carrier	DNA,	
increasing	the	proportion	of	recovered	bacterial	DNA	from	the	sample.	The	quantity	
of	host	DNA	has	been	demonstrated	in	previous	studies	to	be	important	in	successful	
recovery	of	microbial	DNA	in	PCR	assays82.	It	may	also	be	consistent	with	
contamination	at	collection,	as	any	bacteria	introduced	may	be	concentrated	within	
phagocytes	or	increased	in	pellets	due	to	centrifugation	
	
Although	the	OTUs	found	in	the	NGS	results	(largely	Staphylococci	and	
Enterobacteriaceae)	support	the	results	of	the	qPCR	assays,	there	was	minimal	
clustering	on	PCoA	analysis	by	high	or	low	results	according	to	these	assays	prior	to	
removal	of	the	OTUs	from	negative	controls	(data	not	shown).	After	removal	of	the	
negative	control	OTUs,	this	pattern	was	still	seen	both	with	the	plasma	samples	
versus	all	other	assays,	and	with	the	pellet	samples	for	the	Enterobacteriaceae	PCR	(		
Figure	42,	Figure	43).	This	indicates	that	there	was	not	a	consistent	association	
between	samples	with	high	numbers	of	Enterobacteriaceae	OTUs	and	those	with	a	
high	result	for	Enterobacteriaceae	on	qPCR.	This	again	indicates	that	these	assays	
were	at	the	limits	of	detection,	and	results	were	susceptible	to	contamination	and	
variability.		
There	was	some	clustering	of	high	S.aureus	assay	results	and	also	with	the	broad	
range	16S	rDNA	PCR	(SYBR®	Green)	results	for	the	pellet	samples	(		
Figure	42)	after	removal	of	the	negative	control	OTUs.	However,	there	was	no	
clustering	around	ART	groups.	Therefore,	it	is	difficult	to	extrapolate	biological	
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significance	from	this	result,	as	these	OTUs	were	identified	in	both	ART-naïve	and	
ART-experienced	children.	Also,	even	in	the	pellet	samples,	these	OTUs	were	seen	at	
very	low	levels.	It	is	possible	therefore	that	they	are	the	result	of	artefact,	whether	
during	sample	collection	(e.g.	from	the	skin	of	children)	or	from	the	reagents	(though	
this	is	less	likely	given	that	OTUs	seen	from	experimental	negative	controls	have	been	
removed).		
In	summary,	there	was	no	consistent	difference	seen	between	OTUs	generated	from	
samples	from	ART	naïve	or	ART	experienced	children,	and	overall,	the	number	of	
OTUs	generated	were	extremely	low.	Although	some	species	detected	by	NGS	might	
have	been	gut	derived,	the	levels	identified,	particularly	after	removal	of	negative	
control	OTUs,	were	very	low.	It	is	difficult	conclude	with	confidence	that	these	results	
are	not	artefact	as	the	assay	was	working	at	the	limit	of	detection.		
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15 Chapter	15	Assessment	of	Gastrointestinal	Tract	Injury	and	Anthropometry	in	
relation	to	Molecular	Markers	of	Microbial	Translocation	in	HIV	infected	and	
Uninfected	children.	
	
15.1 Introduction	
As	per	section	8.4.7	I-FABP	was	tested	in	all	plasma	samples	available	in	this	study	in	
order	to	investigate	differences	in	HIV-negative	versus	HIV	positive	children,	changes	
over	time	on	therapy	in	those	with	HIV	and	between	HIV	positive	children	living	in	
urban	(JCRC	Kampala)	versus	rural	(Gulu)	environments.	Anthropometric	measures	
were	compared	with	molecular	assay	results	in	order	to	investigate	differences	in	
between	groups	and	changes	over	time	on	therapy	in	those	with	HIV.	
15.2 Study	Population	
Please	see	section	9.1	
15.3 Methods		
Assays	were	carried	out	on	all	available	plasma	samples	as	per	section	9.8.	
Calculations	were	carried	out	to	compare	anthropometric	measures	with	assay	
results	including	I-FABP,	broad	range	16S	rDNA	PCR	results	and	qPCR	results	(as	per	
Table	10)	at	baseline	and	week	96	for	HIV-infected	groups.	Analysis	was	as	per	section	
9.10.			
15.4 Results	
	
For	the	I-FABP	assay,	at	baseline,	109	results	were	available	for	the	ART-naïve	group,	
20	for	the	ART	experienced	and	46	from	Gulu.	For	the	naïve	control	group,	89	results	
were	available	and	20	from	the	experienced	control	group.	At	week	12,	107	were	
available	for	ART	naïve,	19	for	ART	experienced	and	39	from	Gulu.	Eleven	samples	
were	available	from	week	24,	8	from	ART	naïve	and	3	from	Gulu.	At	week	72,	111	
ART-naïve	results,	21	ART-experienced	and	39	Gulu	results	were	available.	
Missing	results	at	baseline	were	as	follows:	ART-naïve	8%,	9	samples	missing	and	1	
assay	failure;	ART-experienced	9%,	2	samples	missing;	Gulu	16%,	8	samples	missing,	1	
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assay	failure;	control	groups-	none	missing	and	no	assay	failures	(Appendix	D	Missing	
samples	across	groups	and	time	points).	At	week	12,	10%	ART-naïve	were	missing	
results	(11	missing	samples,	1	assay	failure),	14%	ART	experienced	(all	missing	
samples)	and	19%	from	Gulu,	(15	missing	samples,	1	assay	failure).	At	week	72,	3%	
ART	naïve	(all	missing	samples),	5%	ART-experienced	(missing	samples)	and	22%	Gulu	
samples	were	missing	(10	missing	samples,	2	assay	failures).		
Gulu	samples	were	significantly	more	likely	to	be	missing	than	ART-naïve	or	ART-
experienced	groups	(p<0.001	for	both).		Age	and	baseline	CD4	T	cell	count	were	
similar	in	the	groups	for	whom	data	were	missing	and	those	who	had	complete	data.	
Baseline	anthropometric	measurements	were	available	for	all	children	except	one	
from	the	naïve	control	group.	In	the	HIV	infected	groups,	anthropometric	
measurements	at	week	96	were	available	for	108/120	(90%)	ART-naïve	children	
(urban),	21/22	(95%)	ART-experienced	children	and	40/55	(73%)	from	the	Gulu	group	
(rural,	ART-naïve)	(Figure	22).		For	the	comparisons	with	molecular	test	results,	I	
compared	three	anthropometric	measures	(weight-for-age,	height-for-age	and	BMI-
for-age	z-scores)	with	three	molecular	tests	(broad	range	PCR,	S.aureus	and	
Enterobacteriaceae	qPCR)	at	three	time	points	in	three	groups,	at	baseline	between	
five	groups	and	between	pellets	and	plasma	between	two	groups,	meaning	
3x3x3x3+5x3x3+2x3x3=	153	tests.	I	would	therefore	expect	there	to	be	7-8	tests	to	be	
positive	at	p=0.05	by	chance,	1-2	tests	at	p=0.01	and	<1	at	p=0.001.		
	
15.4.1 I-FABP	over	time	by	ART	Group	
	
At	baseline,	I-FABP	was	lower	in	the	ART-naïve	and	ART-experienced	groups	than	
both	control	groups	and	the	Gulu	(rural)	groups	(p<0.001	for	ART-naïve	compared	
with	controls	and	Gulu,	p=0.041	for	ART-experienced	versus	controls)	(Table	29,			
Figure	44).		By	week	12,	the	levels	of	I-FABP	in	the	ART	naïve	group	had	increased	to	
the	point	that	they	were	no	longer	different	from	controls	(p=0.45)	(Spearman	
correlation	coefficient	of	increase	in	ART	naïve:	0.19,	p=0.05)	but	were	still	
significantly	lower	than	the	Gulu	group	(p=0.009)(Table	29,	Figure	45).	The	I-FABP	
levels	in	the	ART-experienced	group	had	also	increased	to	be	no	longer	significantly	
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different	from	controls	(p=0.97,	Spearman	correlation	coefficient	versus	baseline	
0.46,	p=0.05)(Table	30).	By	Week	72,	the	levels	in	the	ART	experienced	group	had	
continued	to	increase	so	as	to	be	significantly	higher	than	in	the	ART-naïve	group	
(p=0.0003,	Spearman	correlation	coefficient	0.55	compared	with	baseline,	p=0.01).	
The	levels	in	the	Gulu	group	were	also	significantly	higher	than	in	the	JCRC	(urban)	
ART-naïve	group	(p=0.0001),	but	the	levels	in	the	Gulu	(rural)	group	did	not	change	
significantly	over	time	(Figure	45,	Table	30).	The	rate	of	increase	in	I-FABP	in	the	ART	
naïve	group	slowed	by	week	72	(median	at	week	12	140	pg/mL,	IQR	82-249;	median	
week	72	133	pg/mL,	IQR	83-193).			Subgroup	analysis	of	those	in	the	1st	quartile	(I-
FABP	<83	pg/mL	at	week	72)	revealed	no	significant	relationship	between	CD4	
percentage	at	baseline	or	week	96,	age	or	HIV	viral	suppression	at	week	96.		
	 	
		
162
Table	29	I-FABP	by	ART	group	over	time	(comparisons	using	unpaired	Wilcoxon	rank	sum	test)	
	 Naïve	 Experienced	 P	value	naïve	
versus	
experienced	
Naïve	
Controls	
Experienced	
Controls	
P	value	
cases	
versus	
controls	
Gulu	 P	value	
(Gulu	
versus	
naïve	
cases)	
Baseline	I-FABP	
(pg/ml)	
(Median,	IQR)	
74	
40-125	
n=109	
72	
53-111	
n=20	
0.79	 140	
75-222	
n=89	
160	
65-305	
n=20	
<0.0001	
(naïve)	
0.041	
(exp)	
249	
189-296	
n=46	
<0.001	
W12	I-FABP	
(pg/ml)	
(Median,	IQR)	
140	
82-249	
n=107	
111	
91-299	
n=19	
0.94	 NA	 NA	 0.45	
(naïve)	
0.97	
(exp)	
222	
137-279	
n=39	
0.009	
W24	I-FABP	
(pg/ml)	
(Median,	IQR)	
169	
75-263	
n=8	
n=0	 NA	 NA	 NA	 0.62	
(naïve)	
0.19	
(exp)	
55	
55-72	
n=3	
0.19	
W72	I-FABP	
(pg/ml)	
(Median,	IQR)	
133	
83-193	
n=111	
207	
153-323	
n=21	
0.0003	 NA	 NA	 0.87	
(naïve)	
0.10	
(exp)	
199	
154-296	
n=39	
0.0001	
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Figure	44	Boxplots	of	I-FABP	over	time	by	ART	group.	
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Figure	45	Change	in	Mean	I-FABP	over	time	by	ART	group	with	95%	Confidence	Intervals	
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Table	30	Spearman	Correlation	coefficients	comparing	I-FABP	at	different	time	points	by	ART	group	
Spearman	Correlation	using	
complete	observations	
ART	Naïve	 ART	Experienced	 Gulu	(naïve)	
Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	
PreRandomisation	 Week	12	 0.19	 0.05	 0.46	 0.05	 0.20	 0.26	
PreRandomisation	 Week	24	 -0.9	 0.85	 NA	 NA	 1	 1	
PreRandomisation	 Week	72	 0.02	 0.87	 0.55	 0.01	 0.01	 0.97	
Week	12	 Week	72	 -0.01	 0.95	 0.51	 0.02	 -0.13	 0.49	
	
15.4.2 I-FABP	compared	with	Broad	Range	16S	rDNA	PCR	(SYBR®	Green)	
	
Results	obtained	with	I-FABP	assay	were	compared	with	the	bacterial	load	(CFU	
equivalents)	generated	by	the	broad	range	16S	rDNA	PCR	using	SYBR®	Green.	There	
did	appear	to	be	a	borderline	significant	negative	relationship	between	I-FABP	and	
the	PCR	result	in	the	ART-experienced	group	at	week	12	(Spearman	correlation	
coefficient	-0.47,	p=0.04)(		
Figure	46,	Table	31).	No	other	significant	relationships	were	seen	in	any	ART	group	at	
other	time	points.			
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Figure	46	Scatterplot	comparisons	of	I-FABP	and	bacterial	load	(broad	range	16S	rDNA	PCR	using	SYBR®	Green)	by	ART	group	at	different	time	points	
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Table	31	Spearman	correlation	coefficients	between	I-FABP	and	Bacterial	Load	(CFU	equivalents	by	broad	range	16S	rDNA	PCR)	by	ART	group	over	time.	
Spearman	Correlation	
using	complete	
observations	
ART	Naïve	 ART	Experienced	 Naïve	Controls	 Experienced	Controls	 Gulu	(naïve)	
Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	
Baseline	I-
FABP	
Baseline	
CFU	
-1.1	 0.26	 -0.02	 0.95	 -0.18	 0.09	 0.21	 0.38	 -0.19	 0.22	
Week	12	I-
FABP	
Week	12	
CFU	
-0.02	 0.81	 -0.47	 0.04	 NA	 NA	 NA	 NA	 -0.22	 0.18	
Week	24	I-
FABP	
Week	24	
CFU	
0.24	 0.57	 NA	 NA	 NA	 NA	 NA	 NA	 0.5	 1	
Week	72	I-
FABP	
Week	72	
CFU	
-0.04	 0.64	 0.42	 0.06	 NA	 NA	 NA	 NA	 -0.11	 0.51	
		
168
15.4.3 Broad	Range	16S	rDNA	PCR	Results	versus	Anthropometric	Measures	
	
Baseline	and	week	72	bacterial	load	(CFU	equivalents	generated	by	broad	range	16S	
rDNA	PCR	using	SYBR®	Green)	results	were	compared	with	baseline	and	week	96	
anthropometry	measurements	by	ART	group	(		
Figure	47,			
Figure	48,	Table	32).	At	baseline,	there	was	a	significant	positive	correlation	between	
the	BMI-for-age-z	score	and	bacterial	load	(CFU	equivalents)	in	the	Gulu	group	
(rho=0.28,	p=0.05),	and	no	other	significant	correlation	seen	in	any	other	group.	At	
week	72,	the	positive	relationship	between	BMI-for-age-z	score	and	bacterial	load	
(CFU	equivalents)	in	the	Gulu	group	persisted	(rho=0.36,	p=0.03).	There	was	also	a	
significant	negative	relationship	between	the	height-for-age	z-score	in	the	ART-naïve	
group	and	bacterial	load	(CFU	equivalents)	at	week	72	(rho=-0.21,	p=0.03).	
	
Considering	the	pellet	samples,	there	was	no	significant	relationship	between	the	
bacterial	load	(CFU	equivalents)	and	weight-for-age	z-scores	in	either	the	ART-naïve	
group	at	baseline	(rho=0.05,	p=0.63),	or	the	ART-experienced	group	(rho=-0.24,	
p=0.29).	
	
Similarly	there	was	no	relationship	between	bacterial	load	(CFU	equivalents)	and	
BMI-for-age	z-scores	(ART-naïve	rho=0.01,	p=0.89;	ART-experienced	rho=0.21,	
p=0.34)	or	height-for-age	z-scores	(ART-naïve	rho=0.02,	p=0.82;	ART-experienced	
rho=0.36,	p=0.1).	
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Figure	47	Scatterplot	of	bacterial	load	(CFU	Equivalents	generated	by	broad	range	16S	rDNA	PCR	using	SYBR®	Green)	compared	to	anthropometric	measurements	at	Baseline	
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Figure	48	Scatterplot	of	week	72	bacterial	load	(CFU	Equivalents	generated	by	broad	range	16S	rDNA	PCR	using	SYBR®	Green)	compared	to	week	96	anthropometric	
measurements	
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Table	32	Correlation	coefficients	between	bacterial	load	(CFU	Equivalents	generated	by	broad	range	16S	rDNA	PCR	using	SYBR®	Green)	and	anthropometric	measurements	
	
	
	 	
Time	point	 Spearman	Correlation	using	complete	
observations	
ART	Naïve	 ART	Experienced	 Gulu	(naïve)	 Naïve-control	 Experienced-Control	
Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	
Ba
se
lin
e	
CFU	
equivalents	
Weight-for-age	Z	
score	
-0.07	 0.44	 -0.04	 0.87	 0.2	 0.16	 -0.12	 0.62	 -0.03	 0.75	
CFU	
equivalents	
Height-for-age	Z	score	 -0.06	 0.54	 0.17	 0.44	 -0.02	 0.86	 0.03	 0.8	 -0.08	 0.73	
CFU	
equivalents	
BMI-for-age	Z	score	 -0.09	 0.33	 -0.12	 0.61	 0.28	 0.05	 -0.09	 0.43	 -0.25	 0.29	
W
ee
k	
72
	(C
FU
	e
qu
iv
al
en
ts
)/
	W
ee
k	
96
	(a
nt
hr
op
om
et
ry
)	
CFU	
equivalents	
Weight-for-age	Z	
score	
-0.12	 0.24	 -0.15	 0.52	 0.04	 0.81	 	 	 	 	
CFU	
equivalents	
Height-for-age	Z	score	 -0.21	 0.03	 -0.11	 0.64	 -0.29	 0.08	 	 	 	 	
CFU	
equivalents	
BMI-for-age	Z	score	 0.11	 0.28	 0.10	 0.68	 0.36	 0.03	 	 	 	 	
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15.4.4 Comparison	of	S.aureus	and	Enterobacteriaceae	qPCRs	with	Anthropometric	
Measurements	
Baseline	and	week	72	qPCR	results	for	the	S.aureus	and	Enterobacteriaceae	(coded	
from	negative	to	strong	positive)	were	compared	with	baseline	and	week	96	
anthropometry	results	using	the	schema	in	Table	10.		
For	S.	aureus,	there	were	no	significant	associations	in	any	of	the	three	HIV-infected	
groups,	except	for	a	negative	association	between	the	Gulu	(rural,	ART-naïve)	group	
week	72	S.aureus	results	and	the	week	96	height-for-age	z-scores	(rho=-0.34,	p=0.04)	
(Table	33).	Correlation	coefficients	could	not	be	calculated	for	the	control	groups	due	
to	insufficient	finite	observations.		
Considering	the	Enterobacteriaceae	assays,	there	was	a	significant	negative	
relationship	between	the	height-for-age	z-scores	of	the	ART-experienced	group	at	
baseline	and	the	level	of	Enterobacteriaceae	(rho=-0.46,	p=0.03)(Table	34).	At	week	
72,	there	was	a	significant	negative	relationship	between	the	BMI-for-age	z-score	of	
the	ART-naïve	group	and	the	Enterobacteriaceae	levels	(rho=-0.20,	p=0.04).	Once	
more	correlation	coefficients	could	not	be	calculated	for	the	control	groups	due	to	
insufficient	finite	observations.	
Comparing	the	results	of	the	pellet	samples	with	the	anthropometric	measurements,	
for	Enterobacteriaceae,	no	relationship	was	found	for	the	ART-naïve	(rho=-0.01,	
p=0.9),	or	ART-experienced	(rho=0.31,	p=0.16).	There	was	similarly	no	significant	
relationship	between	the	S.aureus	results	and	anthropometric	measurements	for	
either	ART-naïve	(rho=0.03,	p=0.71)	or	ART-experienced	(rho=-0.22,	p=0.32).	
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Table	33	Correlation	coefficients	between	S.aureus	coded	negative	to	strong	positive	and	anthropometric	measurements	at	Baseline	and	week	72.	
	
	 	
Time	
point	
Spearman	Correlation	using	complete	
observations	
ART	Naïve	 ART	Experienced	 Gulu	(naïve)	
Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	
Ba
se
lin
e	
qPCR	result	
categorised	
from	negative	
to	strong	
positive	
Weight-for-age	Z	score	 -0.09	 0.33	 0.29	 0.19	 -0.09	 0.55	
Height-for-age	Z	score	 -0.05	 0.57	 0.17	 0.45	 -0.09	 0.51	
BMI-for-age	Z	score	 -0.14	 0.13	 0.46	 0.03	 0.03	 0.83	
W
ee
k	
72
	(q
PC
R	
re
su
lts
)/
	
W
ee
k	
96
	a
nt
hr
op
om
et
ry
	
	
Weight-for-age	Z	score	 -0.04	 0.65	 0.18	 0.42	 -0.06	 0.71	
Height-for-age	Z	score	 -0.02	 0.85	 0.3	 0.19	 -0.34	 0.04	
BMI-for-age	Z	score	 0.04	 0.7	 0.15	 0.52	 0.29	 0.08	
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Table	34	Correlation	coefficients	of	Enterobacteriaceae	coded	negative	to	strong	positive	versus	anthropometry	
	
	
	
Time	
point	
Spearman	Correlation	using	complete	
observations	
ART	Naïve	 ART	Experienced	 Gulu	(naïve)	
Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	 Correlation	
coefficient	
P	value	
Ba
se
lin
e	
qPCR	result	
categorised	
from	negative	
to	strong	
positive	
Weight-for-age	Z	score	 -0.03	 0.75	 -0.35	 0.12	 0.05	 0.75	
Height-for-age	Z	score	 -0.13	 0.17	 -0.36	 0.03	 -0.12	 0.39	
BMI-for-age	Z	score	 0.14	 0.14	 -0.13	 0.56	 0.21	 0.15	
W
ee
k	
72
	(q
PC
R	
re
su
lts
)/
	
W
ee
k	
96
	a
nt
hr
op
om
et
ry
	
	
Weight-for-age	Z	score	 -0.04	 0.65	 0.18	 0.4	 -0.05	 0.78	
Height-for-age	Z	score	 0.11	 0.25	 0.11	 0.63	 -0.05	 0.77	
BMI-for-age	Z	score	 -0.20	 0.04	 0.13	 0.58	 -0.07	 0.66	
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15.5 Discussion	
From	these	results,	it	appears	that	I-FABP	increased	significantly	with	time	in	both	
ART	groups,	but	to	a	greater	extent	and	in	a	more	sustained	fashion	(to	week	72)	in	
the	ART-experienced	group.	This	increase	over	time	brought	the	levels	in	both	HIV	
infected	groups	from	JCRC	(urban)	up	to	levels	seen	in	uninfected	controls	in	the	
same	community.	Interestingly,	the	Gulu	(ART-naïve)	group	from	a	rural	setting	had	
the	highest	levels	of	all	groups,	which	remained	consistently	high	over	time.	These	
results	appear	to	run	counter	to	the	a	priori	hypothesis	that	HIV	related	gut	damage	
would	cause	higher	levels	of	I-FABP	in	the	ART-naïve	group	compared	with	ART-
experienced	and	HIV	uninfected	children	as	has	been	seen	in	HIV-infected	adults	in	
developed	settings63,83,84.		In	Ugandan	HIV-infected	adults,	I-FABP	was	actually	lower	
in	rapid	progressors	than	slow	progressors,	with	no	significant	difference	between	
infected	adults	and	controls.	Indeed,	I-FABP	in	HIV	uninfected	adults	was	similar	to	
that	in	HIV-infected	adults	in	developed	settings.85	In	this	Ugandan	study,	the	median	
level	in	HIV-uninfected	adults	was	330	pg/mL	(IQR	68-2861),	and	in	HIV-infected	
adults	was	160	pg/mL	(100-1592),	tending	to	be	higher	than	the	urban	groups	in	this	
study	(baseline	median	in	ART	naïve	children	(urban)	74	pg/mL,	IQR	40-125,	in	ART-
experienced	72	pg/mL	IQR	53-111)	although	not	dissimilar	to	the	results	seen	in	the	
Gulu	(rural)	group	(median	at	baseline	249	pg/mL,	IQR	189-296).	I-FABP	levels	seen	in	
the	HIV-uninfected	control	groups	were	140	pg/mL	(IQR	75-222)	and	160	pg/mL	(IQR	
65-305)	in	age-matched	naïve	and	age-matched	experienced	respectively.		
	
In	terms	of	further	external	comparison	with	studies	from	developed	settings,	the	
levels	detected	in	27	HIV-infected	adults	in	a	French	study	(14	of	whom	had	initiated	
ART,	13	not	receiving	ART)	were	higher	6	months	after	HIV	infection	than	health	
donors,	with	levels	ranging	between	0-2000	pg/mL,	with	the	majority	having	levels	
>500pg/mL,	higher	than	those	recorded	in	any	group	in	this	study63.	Median	levels	of	
I-FABP	found	in	Italian	HIV-infected	adults	on	ART	were	721	pg/mL	and	868	pg/mL	in	
those	responsive	and	unresponsive	to	ART	respectively,	again,	higher	than	seen	in	
this	study86.		The	levels	seen	in	HIV-infected	adults	in	SMART	study	based	in	the	
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U.S.A.	were	more	comparable	to	those	seen	in	this	study	with	median	varying	from	
70-175pg/ml	depending	on	group.		
	
The	lower	overall	levels	of	I-FABP	in	comparison	with	those	seen	in	developing	
settings,	raises	the	question	as	to	whether	the	high	prevalence	of	gastrointestinal	
infections	(in	particular	parasitic	diseases)	in	resource-limited	settings	leads	to	a	
different	paradigm	of	enterocyte	turnover.	It	has	been	suggested	that	constant	
remodelling	of	the	gut	by	enterocyte	turnover	may	protect	the	gut	against	persistent	
parasitic	infection87.		The	results	presented	here	also	support	this	alternative	
paradigm,	that	a	higher	I-FABP	may	be	a	marker	of	a	healthier	gut	in	African	children	
as	seen	in	HIV-uninfected	controls.	Considering	that	the	children	from	Gulu	(rural)	
had	the	highest	levels,	this	might	indicate	a	higher	parasite	exposure	than	the	
children	from	JCRC	(urban)	and	so	a	greater	enterocyte	turnover	level.	The	children	
from	Gulu	were	of	similar	ages	with	similar	baseline	anthropometry	measurements	
and	gains	in	growth	after	ART	commencement	to	the	ART	naïve	group	from	JCRC	
(Figure	22,	Figure	23),	and	all	children	received	deworming	on	ART	initiation,	
indicating	that	the	relationship	between	I-FABP,	nutritional	status	and	gut	parasites	in	
HIV-infected	children	in	this	setting	is	likely	to	be	complex.	
	
In	comparing	I-FABP	to	bacterial	load	(CFU	equivalents	generated	by	broad	range	16S	
rDNA	PCR),	there	was	borderline	significance	of	a	negative	correlation	between	the	
two	markers	at	week	12	in	the	ART-experienced	group	(Spearman	correlation	
coefficient	-0.47,	p=0.04).	This	should	be	interpreted	with	caution	as	the	sample	size	
was	small	(n=19)	and	multiple	comparisons	have	been	made	so	there	is	a	possibility	
that	at	there	will	be	some	statistically	significant	associations	seen	due	to	chance.		
	
The	anthropometric	markers	over	time	were	compared	to	the	results	of	the	
molecular	assays.	Although	some	significant	associations	were	seen,	these	were	
limited	to	one	anthropometric	marker	and	one	time	point,	with	the	exception	of	a	
positive	relationship	between	CFU	equivalents	by	broad	range	16S	rDNA	PCR	and	the	
BMI-for-age	z-score	at	both	time	points.	As	has	been	previously	discussed,	these	
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molecular	assays	were	working	at	the	limits	of	detection,	and	sample	size	for	ART-
experienced	groups	and	even	the	Gulu	group	at	the	later	time	point	was	small.	The	
possibility	that	the	associations	seen	were	spurious	must	be	considered.	This	is	
particularly	to	be	considered	in	view	of	the	number	of	tests	being	carried	out.	As	
highlighted	above,	I	would	anticipate	7-8	tests	to	be	positive	at	p<0.05	due	to	chance	
alone.	No	significant	relationships	were	identified	at	a	level	of	p<0.01,	so	it	is	possible	
that	the	relationships	identified	between	anthropometric	markers	and	molecular	
assays	were	due	to	chance.		
	
In	terms	of	limitations	of	the	I-FABP,	as	with	the	other	assays,	the	sample	size	for	the	
ART-experienced	group	was	small.	Additionally	there	may	have	been	some	variation	
within	the	assay	itself	that	could	have	been	compensated	for	by	performing	the	assay	
in	duplicate.	However	the	volumes	of	samples	available	were	small	and	limited	
repetition.	In	comparison	to	the	molecular	assays,	this	ELISA	based	test	is	likely	to	be	
less	vulnerable	to	contamination	and	variability.	As	with	the	molecular	assays,	
samples	from	the	Gulu	group	were	significantly	more	likely	to	be	missing	than	the	
other	two	groups,	which	renders	the	Gulu	results	more	susceptible	to	bias.	As	the	
characteristics	of	the	children	for	whom	data	were	missing	were	similar	to	those	
without	missing	data,	this	bias	may	be	minimal	but	should	be	taken	into	account.		
	
In	terms	of	the	anthropometric	markers,	again,	the	Gulu	group	was	more	likely	to	
have	missing	data,	incorporating	a	potential	bias	into	the	results.	Furthermore,	there	
are	ongoing	challenges	about	the	most	representative	measures	and	reference	
groups	to	use	when	monitoring	the	growth	and	nutritional	status	of	HIV-infected	
children	in	these	settings88,89.	Z-scores	are	the	internationally	accepted	standard	(with	
provisos	as	regards	the	reference	population	as	previously	highlighted),	but	each	
measure	has	its	own	limitations	and	should	be	interpreted	together	with	other	
measures	if	available.	Furthermore,	trajectories	are	more	important	than	single	
measurements,	and	although	two	time	points	are	available	here,	further	monitoring	
of	both	I-FABP	and	the	growth	of	these	children	over	time	would	be	helpful	to	clarify	
the	relationship	between	growth	and	I-FABP	in	this	setting.	
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Overall,	it	appears	that	there	were	significant	differences	between	the	ART	groups	
over	time,	with	both	urban	groups	seeing	an	increase	in	I-FABP	over	time.	This	might	
be	explained	by	a	different	underlying	mechanism	of	change	in	this	population	of	HIV-
infected	and	uninfected	African	children	compared	with	HIV-infected	adults	in	
developed	settings.	Examining	the	relationship	between	anthropometric	markers,	
disease	progression	and	I-FABP	over	time	merits	further	specific	investigation.	
	
	 	
		
180
16 Chapter	16	Clinical	Events	in	HIV-infected	Children	during	the	Course	of	the	
Study	in	Relation	to	Molecular	Markers	of	Microbial	Translocation			
16.1 Background	
HIV-infected	children	are	known	to	be	at	high	risk	of	bacterial	infections,	despite	
ART90.	There	might	be	a	relationship	between	microbial	translocation	and	these	
infections.	In	order	to	investigate	this	potential	relationship,	and	to	investigate	the	
potential	relevance	clinically	of	positive	molecular	assay	results	obtained	in	this	study,	
the	relationship	between	clinical	events	and	assay	results	were	compared.			
16.2 Study	Population	
See	section	9.1	
16.3 Methods	
See	section	9.9.	Where	two	events	were	recorded	on	the	same	day,	the	primary	
event	name	only	was	included	(i.e.	if	the	patient	had	malaria	and	also	had	anaemia	
recorded	as	event	2,	only	malaria	was	recorded).	For	analysis	some	types	of	events	
were	combined.	These	were:	pyogenic	meningitis	and	meningitis-	other;	any	kind	of	
tuberculosis;	any	kind	of	pneumonia	(pneumonia-	other	bacterial,	pneumonia	–	
pneumococcal,	pneumonia	no	organism	identified);	rash	erythematous	and	rash	
maculopapular,	upper	respiratory	tract	infection	–	not	sinusitis	or	otitis	media	and	
other	acute	upper	respiratory	symptoms.	
16.4 Results	
There	were	386	events	reported	over	the	duration	of	the	trial,	including	hospital	
admissions,	adverse	events	as	defined	by	the	trial	protocol	and	microbiological	
investigations	sent	(Table	35).	29	of	these	occurred	in	children	who	also	had	either	a	
high	qPCR	/16S	rDNA	PCR	result	or	a	sample	successfully	sequenced	with	NGS	within	
four	weeks	of	the	event,	72	occurred	in	children	who	had	study	samples	taken	within	
four	weeks	of	the	event	but	assay	results	were	negative,	and	287	occurred	in	children	
who	had	no	study	samples	within	four	weeks	of	the	event.	The	most	frequent	events	
were	pneumonia	(89	events),	presumed	sepsis	or	bacteraemia	(64	events),	malaria	
(49	events)	and	upper	respiratory	tract	infections	(31	events).		
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To	take	first	the	comparison	between	children	who	had	study	samples	available	
within	four	weeks	of	the	clinical	event,	children	with	positive	assay	results	were	of	
similar	age	to	those	with	negative	results	(median	age	1.8	years,	IQR	1.2-2.3	versus	
median	2	years,	IQR	1.8-4)(Table	35).	The	children	with	positive	assay	results	were	all	
from	the	naïve	group,	unlike	those	with	negative	assay	results	of	whom	29	(40%)	
came	from	the	Gulu	group	and	one	(2%)	from	the	ART	experienced	group	(Fisher’s	
exact	test	p<0.001).	There	was	no	difference	in	the	proportion	of	children	admitted	
(p=0.52),	nor	in	the	overall	distribution	of	event	types	(p=0.13)	between	the	groups.	
Considering	those	who	did	not	have	a	study	sample	available	within	four	weeks	of	the	
event,	these	children	were	older	than	those	with	a	positive	assay	result	within	four	
weeks	of	the	event	(p=0.03)	and	came	from	all	three	HIV-infected	groups	(Fisher’s	
exact	test	p<0.001).	There	was	no	difference	in	the	proportions	of	children	admitted	
(p=0.01),	but	there	was	a	difference	in	the	distribution	of	event	types	(p<0.001).		
	
Looking	in	more	detail	at	the	events	which	occurred	within	1	month	of	a	high	positive	
test	result	or	successfully	sequenced	using	NGS,	22	(21	patients)	of	these	had	high	cell	
pellet	results	(>1000	CFU	equivalents	using	16S	rDNA	PCR	with	SYBR®	Green),	one	of	
which	also	had	a	high	plasma	result	using	16S	rDNA	PCR	and	a	high	positive	with	
S.aureus	PCR	(Table	36).	Six	further	events	took	place	within	a	month	of	a	sample	
having	successfully	sequenced	with	NGS.		
	
For	children	who	had	either	a	positive	blood	or	urine	culture	at	any	time	point,	the	
molecular	test	results	at	all	time	points	are	documented	in	Table	37.	There	were	no	
cerebro-spinal	fluid	results	recorded	within	the	study	population.		Positive	
blood/urine	cultures	included:	S.aureus,	Staphylococcus	sp.,	E.	coli,	Klebsiella	
pneumoniae,	Candida	albicans	and	Candida	sp.	The	episode	of	E.coli	bacteraemia	was	
at	week	60.	The	patient	had	low	levels	of	Enterobacteriaceae	(9	CFU	equivalents	by	
qPCR	in	baseline	pellet	sample,	and	4	CFU	equivalents	at	week	12),	but	the	week	72	
sample	was	negative.		The	episode	with	a	positive	blood	culture	for	S.aureus,	was	six	
days	after	a	negative	plasma	PCR	for	S.aureus	and	a	pellet	sample	that	had	a	CFU	
equivalent	result	of	80	(low	positive),	and	the	Staphylococcus	sp.	bacteraemia	
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episode	was	at	week	85,	preceded	at	week	72	by	negative	qPCRs.		The	Klebsiella	
pneumoniae	episode	was	at	week	88,	and	preceded	by	negative	qPCRs	apart	from	
one	low	level	positive	S.	aureus	PCR	in	a	baseline	pellet	sample.	There	was	one	event	
of	chronic	suppurative	otitis	media	with	an	ear	swab	result	positive	for	S.	aureus	with	
a	positive	qPCR	result	for	S.aureus	on	the	same	day.	However,	a	further	positive	swab	
result	for	S.	aureus	from	a	septic	ulcer	was	not	accompanied	with	a	positive	qPCR	
result,	although	there	were	staphylococcal	OTUs	in	the	NGS	result	(Table	36).		
	
To	compare	distribution	of	OTUs	amongst	children	who	had	a	clinical	event	versus	
those	who	did	not,	the	PCoA	plot	(using	unifrac)	was	repeated,	using	clinical	event	
versus	no	clinical	event	as	a	differentiating	feature	(Figure	49,	Figure	50).	No	
clustering	of	OTUs	was	seen	by	clinical	event/no	event.		
	
Table	35	Comparison	of	clinical	events	occurring	within	one	month	of	a	high	qPCR/16S	rDNA	PCR	result	or	
successful	NGS	sequencing	
	 SYBR/QPCR	positive	within	4	
weeks	of	event	
SYBR/QPCR	
negative	AND	
event	<4	weeks	
before/after	
study	sample	
timing	
P	value	event	&	
positive	sample	
versus	event	&	
negative	study	
sample	
No	study	
sample	<4	
weeks	of	
Event	
P	value	event	and	
positive	sample	versus	
event	and	no	study	
sample	available	
Number	 29	 72	 	 287	 	
Median	age	(IQR)	 1.8	(1.2-2.3)	 2	(1.3-3.7)	 0.48	 2.9	(1.8-4)	 0.03	
ART	group	 	 	 	 	 	
Naïve	 29	 42	 <0.001	 176	 <0.001	
Experienced	 0	 1	 	 24	 	
Gulu	(naïve)	 0	 29	 	 87	 	
Admitted	 15	(52%)	 32	(46%)	 0.52	 104	(36%)	 0.11	
	 	 	 	 	 	
Event	Name	 	 	 0.13*	 	 <0.001*	
Meningitis	 0	 0	 	 2	 	
Epilepsy-	fits-	convulsions	 0	 0	 	 2	 	
Toxoplasmosis	of	the	brain	 0	 2	 	 3	 	
Acute	otitis	media	 0	 4	 	 13	 	
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Chronic	otitis	media	 4	 1	 	 11	 	
Upper	Respiratory	Tract	
Infection	
1	 4	 	 27	 	
Tuberculosis		 0	 1	 	 6	 	
Pulmonary	Cryptococcus	 0	 1	 	 0	 	
Pneumonia	 7	 25	 	 57	 	
Conjunctivitis	 0	 1	 	 2	 	
Diarrhoea	 2	 9	 	 20	 	
Urinary	Tract	Infection	 1	 1	 	 9	 	
Candida	Balanitis	 0	 0	 	 1	 	
Herpes	Zoster	(Varicella	
Zoster)	-	cutaneous	
0	 1	 	 0	 	
Rash	-	erythematous	or	
maculopapular	
1	 0	 	 6	 	
Tinea	-	athletes	foot	-	fungal	
infection	of	foot	or	skin	
0	 0	 	 3	 	
Cellulitis	 0	 0	 	 2	 	
Impetigo	 0	 1	 	 1	 	
Folliculitis	-	furuncles	-	
carbuncles	
0	 0	 	 1	 	
Lymphadenopathy	 0	 1	 	 0	 	
Anaemia	with	clinical	
symptoms	
0	 1	 	 2	 	
Anaemia	with	no	clinical	
symptoms	
1	 0	 	 0	 	
Kaposi's	sarcoma	lymph	nodes	 0	 2	 	 0	 	
Malnutrition	 0	 1	 	 1	 	
Presumed	
septicaemia/bacteremia	-	not	
investigated/	no	organism	
6	 10	 	 54	 	
Malaria	 3	 4	 	 45	 	
Measles	 0	 0	 	 3	 	
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Acute	febrile	episode		-	
undiagnosed	
2	 2	 	 8	 	
Unknown	 0	 0	 	 1	 	
Not	available	 0	 0	 	 7	 	
	 *Comparing	whole	distribution	of	events	for	group	rather	than	individual	types	of	event	
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Table	36	Description	of	clinical	events	occurring	within	one	month	of	a	positive	test	molecular	test	result	(all	children	were	ART	naïve	and	from	the	JCRC	cohort)	
Age	 week	 Sample	
Date	
Pellet	
Bacterial	load	
(CFU	
Equivalent)	
Plasma	
Bacterial	
load	(CFU	
Equivalent)	
NGS	
success	
QPCR	
positive	
Clinical	event	within	4	weeks	of	positive	test	 Admitte
d	0=no,	
1=yes	
Episode	Date	
3.5	 -1	 24-Mar-
11	
1646	 		 Yes	 	 Presumed	Sepsis,	blood	culture	negative		 No	 13.4.11	
1.8	 0	 07-Jul-
11	
2294	 	 Yes	 	 Pneumonia,	diagnosed	1	month	later	with	Kaposi	Sarcoma.	
Blood	culture:	S.aureus.	Ear	swab	mixed	growth.	See	table		
Yes	 13.7.11	
0.8	 -1	 27-Sep-
11	
2874	 	 Yes	 	 Chronic	otitis	media,	not	admitted,	no	investigation	recorded	 No	 8.10.11	
3.5	 -1	 05-Oct-
11	
1268	 	 No	 	 Upper	respiratory	tract	infection	 No	 24.11.11	
1.8	 -2	 03-Oct-
11	
4868	 	 Yes	 	 Pneumonia,	No	investigation	recorded	 Yes	 27.10.11	
3.1	 -1	 24-Nov-
11	
1070	 	 Yes	 	 anaemia	 No	 12.12.11	
3	 -2	 30-Mar-
11	
2027	 	 Yes	 S.	
aureus	
Chronic	suppurative	otitis	media,	S.	aureus	on	ear	swab	 No	 30.3.11	
2.3	 -1	 05-May-
11	
1275	 5431	 Yes	 	 Undiagnosed	fever	 No	 12.6.11	
0.7	 -2	 15-Mar-
11	
1250	 	 Yes	 	 Diarrhoea	&	possible	urinary	tract	infection	 No	 4.4.11	&	1.4.11	
1.1	 -1	 04-Nov-
11	
4095	 	 Yes	 	 Pneumonia.	No	investigation	recorded	 Yes	 30.11.11	
4.4	 0	 09-Nov-
11	
1012	 	 Yes	 	 Plasmodium	falciparum		 No	 28.11.11	
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1.1	 -1	 13-Sep-
11	
1408	 	 No	 	 Presumed	sepsis	&	anaemia,	no	investigation	recorded	 Yes	 13.10.11	
3.3	 -1	 17-Jun-
11	
2251	 	 Yes	 	 Chronic	suppurative	otitis	media,	ear	swab	Proteus	mirabilis,		 No	 24.6.11	
0.8	 -4	 06-Jun-
11	
1830	 	 No	 	 Upper	respiratory	tract	infection.	No	investigation	recorded	 No	 1.8.11	
2.9	 -1	 14-Oct-
11	
1845	 	 Yes	 	 Bacteraemia,	No	investigation	recorded	 No	 2.11.11	
1.5	 -2	 28-Oct-
11	
5996	 	 Yes	 	 Pneumonia	 Yes	 25.11.11	
2.1	 -1	 04-Nov-
11	
3995	 	 No	 	 Presumed	sepsis		 No	 15.2.12	
3.1	 -1	 07-Sep-
11	
1468	 	 No	 	 Presumed	sepsis		 No	 26.10.11	
1.5	 -5	 30-Sep-
11	
1619	 	 No	 	 Pneumonia.	No	investigation	recorded	 Yes	 17.11.11	
1.8	 -5	 10-May-
11	
1759	 	 No	 	 Presumed	sepsis	 No	 26.6.11	
4.3	 -1	 19-Sep-
11	
6011	 6065	 No	 	 Chronic	suppurative	otitis	media.	No	investigation	recorded	 No	 8.11.11	
1.2	 12	 25-May-
11	
	 82	 Yes	 	 Acute	Diarrhoea.		No	investigation	recorded	 Yes	 11.4.11	
1.2	 -3	 8-Apr-11	 1272	 0	 Yes	 	 Plasmodium	falciparum	malaria	 Yes	 16.5.11	
4.4	 12	 2-May-
11	
	 	 Yes	 	 Septic	ulcer,	Staphylococcus	aureus	on	swab	 No	 2.5.11	
1.6	 -2	 30-Jun- 37	 	 Yes	 	 Pneumonia	 Yes	 1.8.11	
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	11	
3.6	 -2	 22-Jun-
11	
487	 	 Yes	 	 Pneumonia	 Yes	 8.7.11	
4.7	 -2	 14-Sep-
11	
	 	 Yes	 	 Plasmodium	falciparum	malaria	 Yes	 13.10.11	
		
188
Table	37	Assay	results	for	patients	with	positive	blood/urine	culture	
Age	
(yr)	
Naïve/	
Experienced	
Trial	
Week	
Blood/	
Urine	
Organism	 Presumed	
Diagnosis	
Admitted	 Test	time	point	 qPCR	CFU	
equivalents*	
16S	CFU	
equivalen
t	
I-FABP	
pg/mL	
NGS	
successful	
1.8	 Naïve	 1	 Blood	 Staphycocccus	
aureus	
Pneumonia,	
Kaposi	
sarcoma	
Yes	 baseline	pellet	 SA:	80	 2290	 	 Yes	
baseline	
plasma	
	 	 <20	
W12	 	 200	 80	
W72	 	 272	 58	
1.1	 Naïve	 85	 Blood	 Staphylococcus	
sp	(coagulase	
negative)	
Sepsis/	
Urinary	tract	
infection	
Yes	 baseline	pellet	 SA:	20,	Ent	6.6	 91	 	 Yes	
baseline	
plasma	
	 55	 368	
W12	 	 187	 132	
W72	 	 121	 98	
2.7	 Naïve	 60	 Blood	 Escherichia	coli	 Presumed	
Sepsis	
Yes	 baseline	pellet	 Ent:	9,	Tuf:	4	 110	 	 Yes	
baseline	
plasma	
	 208	 31	
W12	 Ent:	3	 60	 95	
W72	 	 123	 134	
10.7	 Experienced	 88	 Urine	 Klebsiella	
pneumoniae	
Pneumonia/	
Urinary	tract	
infection	
No	 baseline	pellet	 SA:	8.3	 2980	 	 Yes	
baseline	
plasma	
	 185	 <20	
W12	 	 	 <20	
W72	 	 97	 215	
1.3	 Naïve	 2.3	 Urine	 Candida	
albicans	
Pneumonia/	
Urinary	tract	
infection	
Yes	 baseline	pellet	 	 20	 	 Yes	
baseline	
plasma	
Bif:	76	 165	 162	
W12	 Bif:	6	 220	 61	
W72	 	 10	 153	
1.8	 Naïve	 32	 Urine	 Candida	sp.	 Pneumonia/	
Diarrhoea/	
presumed	
Yes	 baseline	pellet	 SA:	96,	Ent:	<	 2210	 	 Yes	
baseline	
plasma	
	 <5	 64	
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sepsis	 W12	 	 108	 137	
W72	 	 71	 62	
*Ent:	Enterobacteriaceae,	SA:	Staphylococcus	aureus,	Tuf:	Staphylococcus	spp.,	Bif:	Bifidobacterium	
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Figure	49	PCoA	of	Rarefied	Samples,	by	Clinical	Event/No	Event	using	unifrac	showing	no	clustering	according	to	whether	or	not	a	clinical	event	occurred.	
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Figure	50	PCoA	of	rarefied	samples	(unifrac),	negative	control	OTUs	removed	by	presence/absence	of	clinical	event,	showing	no	clustering	by	whether	or	not	a	clinical	event	
occurred	
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16.5 Discussion		
	
This	section	documents	the	type	and	frequency	of	clinical	events	experienced	by	
children	enrolled	in	the	cohort:	namely	adverse	events	as	defined	by	the	trial	
protocol,	hospital	admissions	and	any	positive	microbiological	test	results,	and	
compares	these	events	with	molecular	test	results.	First,	the	frequency	and	type	of	
clinical	event	was	compared	by	whether	or	not	the	child	had	also	had	a	high	positive	
qPCR	or	broad	range	PCR	result,	or	a	sample	that	successfully	sequenced	using	NGS	
within	a	month	of	the	event.	There	did	not	appear	to	be	a	significant	difference	
between	types	or	frequency	of	events	between	the	two	groups	for	whom	study	
samples	were	available	within	four	weeks	of	the	event,	although	the	children	who	
experienced	events	and	had	a	high	test	result	were	all	from	the	JCRC	ART	naïve	group	
(Table	35).	However,	when	considering	this	result,	it	should	be	seen	that	the	positive	
test	results	were	overwhelmingly	from	baseline	pellet	samples	which	were	not	
available	from	the	Gulu	children,	or	at	later	time	points,	and	the	ART	naïve	group	was	
larger	than	the	ART	experienced	group	(and	also	younger).	This	indicates	that	pellet	
sample	availability	is	likely	acting	as	a	confounding	factor,	as	the	pellet	samples	
tended	to	be	more	likely	to	have	a	high	result	across	all	molecular	assays	than	the	
plasma	samples	(Sections	12.4.2,	13.4.1	and	14.4).		
	
Confounding	also	applies	to	consideration	of	the	differences	seen	between	children	
whom	had	an	event	and	had	no	study	sample	available	within	four	weeks	of	the	
event,	in	that	they	also	were	more	likely	to	come	from	the	ART	experienced	or	Gulu	
groups	(neither	of	which	had	pellet	samples)	than	those	who	had	an	event	and	a	
positive	assay	result.	The	group	with	a	clinical	event	but	no	study	sample	available	
were	also	slightly	older,	and	had	a	different	distribution	of	event	types	(p<0.001)	to		
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those	with	a	positive	assay	result.	However,	commonly	occurring	events	such	as	
malaria,	pneumonia	and	diarrhoea	were	seen	in	both	groups	and	admission	rates	
were	similar	(p=0.11).	In	view	of	the	similarity	between	the	groups	for	whom	samples	
were	available,	it	is	unlikely	that	a	biologically	important	difference	has	been	missed	
in	comparing	those	experiencing	clinical	events	with	and	without	positive	assay	
results.		
	
The	assay	results	from	children	who	had	positive	blood	or	urine	cultures	at	any	time	
point	were	then	examined	to	look	for	any	relationship	between	the	organisms	found	
and	molecular	test	results	(Table	37).	There	was	no	apparent	close	relationship	
between	molecular	results	and	blood/urine	cultures,	though	this	comparison	was	
limited	by	sample	availability:	i.e.	samples	were	only	available	at	fixed	time	points	
that	in	several	cases	were	remote	from	the	event	itself.		
	
A	limitation	of	this	comparison	is	the	clinical	data	availability.	The	diagnoses	were	
taken	verbatim	from	codes	documented	in	the	trial	documentation	but	may	have	
been	subject	to	variability	and	diagnostic	uncertainty.	For	example,	many	events	
were	coded	as	“Pneumonia-	pneumococcal”	with	no	microbiological	evidence	that	
pneumococcal	pneumonia	had	been	confirmed.	By	combining	all	possible	codes	for	
pneumonia	(encompassing	“pneumonia-	other	bacterial”,	“pneumonia	–	
pneumococcal”	and	“pneumonia	no	organism	identified”)	I	attempted	to	minimise	
this	uncertainty,	but	a	degree	of	variability	is	likely	to	remain.	Similarly,	by	looking	
specifically	at	positive	culture	results	from	sterile	sites	(blood	and	urine)	I	used	the	
most	concrete	microbiological	evidence	available	in	the	comparison	rather	than,	for	
example,	using	urinalysis	results	that	are	subject	to	a	higher	degree	of	variability.	
Positive	microbiological	swab	results	from	other	sites	were	only	included	if	they	
coincided	with	an	adverse	event	(as	defined	in	the	trial	protocol)	or	an	admission,	in	
order	to	prioritise	clinically	significant	events	for	the	comparison.	
	
This	comparison	was	intended	as	broad	attempt	to	compare	clinical	events	with	
molecular	assay	results,	looking	for	high-level	trends	or	indications	that	there	might	
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be	a	relationship.	However,	although	sample	availability	(in	particular	only	having	
pellet	samples	in	the	JCRC	group	and	only	at	baseline)	is	a	major	limitation,	the	
relationship	between	assay	results	and	clinical	events	appears	to	be	small.	
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17 Chapter	17	Discussion	
The	aims	of	this	thesis	were:	
1. To	assess	the	level	of	microbial	translocation	defined	as	identification	of	
bacterial	DNA,	occurring	in	HIV-infected	African	children	by	comparing	HIV-
infected	ART	naïve	children	with	HIV-uninfected	African	controls	
2. To	determine	the	effect	of	ART	on	microbial	translocation	by	comparing	levels	
detected	in	ART-naïve	and	ART-experienced	children,	and	changing	levels	over	
time	on	ART.	
3. To	determine	the	impact	of	environment	on	microbial	translocation	by	
comparing	levels	in	ART-naïve	HIV	infected	children	in	urban	versus	rural	
settings	at	baseline	and	over	time	on	ART.				
4. To	investigate	the	relationship	between	microbial	translocation,	gut	damage	
and	clinical	outcome	in	HIV	infected	children	in	Uganda.	
In	my	final	discussion	I	will	examine	whether	we	have	found	evidence	of	microbial	
translocation	in	HIV	infected	children,	if	the	methods	developed	are	reliable	and	in	
the	light	of	my	results,	what	work	should	be	undertaken	in	the	future.			
		
17.1 Does	Biologically	Significant	Microbial	Translocation	Occur	in	Children	
with	HIV	
	
At	the	time	this	study	was	designed,	clinical	trials	were	underway	with	the	aim	of	
modifying	microbial	translocation	and	hence	improving	outcome	in	people	with	HIV.	
However,	on	closer	scrutiny	of	available	data,	the	evidence	for	microbial	translocation	
as	an	important	driver	of	immune	activation	was	by	no	means	conclusive.	Prior	
studies,	summarised	in	Table	38,	were	largely	small,	cross	sectional	and	based	in	
developed	settings,	and	only	four	studies	included	children.	Furthermore,	there	was	
no	consensus	on	the	best	method	of	quantifying	microbial	translocation.	The	assay	
used	to	quantify	LPS	is	subject	to	considerable	variability	and	plasma	inhibition,	even	
within	subjects	let	alone	between	studies91.	Additionally,	LPS	could	be	considered	a	
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Table	38	Summary	of	previous	studies	investigating	microbial	translocation	in	the	blood	of	humans	infected	with	HIV,	including	methods	used	for	quantification	and	study	results	(as	regards	
microbial	translocation)	
Population	 Country	 Median	age	in	
years	(range)	
Microbial	translocation	markers	measured	 Ref	
85	ART	experienced	children	over	
48	weeks	enrolled	in	the	Pediatric	
AIDS	Clinical	Trials	Group	Protocol	
P338,	adult	HIV-uninfected	
controls	
India	 Range	2-17	
Median	not	
given	
16S	rDNA	PCR,	sCD14,	LPS.	
	
All	higher	than	controls,	no	change	over	time.	
16S	rDNA,	CD4	T	cell	count	&	immune	
activation	associated,	no	association	with	LPS	
or	viral	load	
Pillakka	Kanthikiel	et	al.61	
54	HIV	infected	infants	in	the	
CHER	trial,	34	receiving	
immediate	ART,	20	deferring	ART	
until	CD4%<25%,	compared	with	
22	HIV	exposed,	uninfected	
infants.	
South	
Africa	
0-1	year	
(enrolled	at	
birth)	
LPS,	sCD14,	LBP.	
	
All	markers	and	T	cell	activation	were	higher	in	
those	deferring	versus	immediate	ART.	LPS	
higher	than	uninfected	controls.	No	LPS	in	
those	>6	months	of	age.	No	association	
between	LPS	and	T	cell	activation	
Papasavvas	et	al.92	
77	HIV	infected	children,	32	
controls;	Cross	sectional	study	
70%	of	HIV-infected	virally	
suppressed.	
Spain	 16.2	years	(13-
18.7)	
LPS,	16S	rDNA	PCR.	
	
T	cell	activation	associated	with	HIV	viraemia.	
No	association	between	LPS	or	16S	rDNA	with	
immune	activation,	although	levels	higher	than	
Madrid	et	al.70	
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HIV-uninfected	controls.	
33	ART	experienced	children	
commencing	PI-based	therapy	
over	96	weeks,	14	HIV-uninfected	
controls.	
U.S.A.	 HIV-infected:	
6.6	years(0.2-
17.7	
Controls:	1.4	
years	(0.4-15)	
LPS,	sCD14,	EndoCAb.	
	
10%	had	elevated	LPS,	associated	with	
increased	monocyte	activation,	but	no	
relationship	with	sCD14,	T	cell	activation,	CD4	
T	cell	count,	thymic	output	or	EndoCAb.	
Decrease	in	immune	activation	seen	with	
immune	recovery.	Healthy	infants	<	6	months	
also	had	raised	LPS.	
Wallet	et	al.	93	
205	HIV	infected	(50	acute	
infection,	30	“elite	controllers”	
with	undetectable	virus	and	no	
ART,	27	with	detectable	virus	and	
CD4	>250*,	7	with	AIDS	and	
CD4<250.	Cross	sectional.	
U.S.A.	
and	
France	
Adult	(age	not	
given)	
LPS,	sCD14,	LBP,	EndoCAb.	
	
Higher	LPS	in	HIV	infected	than	controls.	“Elite	
controller”	had	lower	sCD14	and	LBP,	and	
higher	EndoCAb	than	those	with	disease	
progression.	
Brenchley	et	al.	94	
Cross	sectional	study	of	mucosal	
integrity	in	19	HIV	negative,	15	
HIV	infected	untreated,	15	HIV	
infected	on	ART	CD4>500,	24	HIV	
infected	on	ART	CD4<350.	
U.S.A.	 45	years	(34-55)	 sCD14	
	
sCD14	linked	to	gut	mucosal	apoptosis.	
Somsouk	et	al.	(95)	
Cross	sectional	study	of	intestinal	
dysbiosis	in	18	HIV	infected	adults	
U.S.A.	 32	years	(22-58)	 LPS,	sCD14,	I-FABP,	LTA.	 Dillon	et	al.96	
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and	14	HIV	uninfected	controls.	 	
Plasma	LTA	significantly	associated	Bacteroides	
abundance	at	gut	mucosa.	PCoA	revealed	
association	of	microbiome	patterns	with	HIV	
infection	status,	LPS,	colon	and	peripheral	
blood	T	cell	activation	but	no	test	for	
association	independent	of	HIV	infection.	
Cross	sectional	study	of	intestinal	
dysbiosis	in	80	HIV	infected	(42	no	
ART,	40	on	ART)	and	40	HIV	
uninfected	controls.	
Uganda	 44	(on	ART)	(38-
49)	
29	(no	ART)	(24-
34)	
43	(controls)	
(38-48)	
sCD14	
	
sCD14	higher	in	HIV	infected	(CD4<200*)	than	
controls	or	HIV	infected	(CD4>200).	sCD14	
significantly	associated	with	HIV	viral	load.	144	
bacterial	taxa	in	stool	significantly	associated	
with	high	sCD14.	
Monaco	et	al.	97	
Longitudinal	study	of	intestinal	
dysbiosis	in	13	adults	with	acute	
HIV	infection	over	48	weeks	after	
ART	initiation.	
U.S.A.	 33	(21-55)	 LPS,	sCD14	
	
Increased	Lactobacillales	associated	with	lower	
sCD14,	higher	CD4	T	cell	percentage	and	lower	
viral	loads.	No	association	with	LPS	or	with	
immune	activation.	
Perez-Santiago	et	al.	7	
Cross	sectional	study	investigating	
invariant	natural	killer	T	(iNKT)	
cells,	gut	dysbiosis	and	gut	barrier	
U.S.A.	 50	(25-66)	(HIV)	
33	(23-59)	
sCD14,	LBP,	I-FABP.	
	
Paquin-Proulx	et	al.	98	
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function	in	23	HIV	infected	(13	on	
ART)	and	10	HIV	uninfected	
controls	
(controls)	 I-FABP,	sCD14	and	LBP	higher	in	HIV	infected	
than	controls.	Inverse	relationship	between	
iNKT	cells	and	microbial	translocation	markers.	
Cross	sectional	study	of	173	HIV	
infected	adults,	longitudinal	study	
of	54	adults	(48	weeks)	and	15	
HIV	uninfected	controls	
U.S.A.	 48	(40-54)	(HIV)	
26	(22-41)	
(controls)	
	
LPS,	16S	rDNA	PCR	
	
Higher	levels	in	HIV-infected	than	controls,	
associated	with	T	cell	activation.	Negative	
association	of	16S	rDNA	with	CD4	T	cell	
restoration	after	adjusting	for	viral	load	at	
week	48.	Those	on	ART	had	lower	16S	rDNA.	
Jiang	et	al.	59	
Longitudinal	study	of	44	HIV	
infected	adults	commencing	ART	
(48	weeks)	and	13	HIV	negative	
controls	
Italy	 38	(29-52)	(HIV)	
27	(25-32)	
(controls)	
sCD14,	LPS,	16S	rDNA	PCR	with	Sanger	
sequencing	
	
sCD14	higher	in	HIV	than	controls.	No	change	
in	LPS	or	sCD14	over	time	on	ART,	or	difference	
between	those	responsive/unresponsive	to	
therapy.	Higher	proportion	of	HIV	infected	
positive	for	16S	rDNA	PCR	than	controls.	Mixed	
sequencing	results	with	no	major	changes	over	
time	on	ART.		Minimal	difference	between	
responsive/unresponsive	to	therapy.	
Merlini	et	al.	8	
Longitudinal	study	of	420	HIV	
infected	adults	in	SMART	trial	and	
U.S.A.	
(90%),	
10%	
48	(40-56)(HIV)	
35	(controls)	
LPS,	sCD14,	EndoCAb,	16S	rDNA	PCR,	I-FABP.	
	
Sandler	et	al.	60	
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67	HIV	uninfected	controls	 from	32	
other	
countries	
range	not	given)	 Only	sCD14	associated	with	mortality.	I-FABP	
higher	in	HIV	infected	than	controls,	no	
difference	in	16S	rDNA	between	HIV	
infected/uninfected.	
Cross	sectional	study	of	60	HIV-
infected	adults	investigating	
association	of	endovascular	
markers	with	microbial	
translocation.	
Denmark	 47	(40-65)	 sCD14,	LPS	
	
sCD14	associated	with	increased	risk	of	
cardiovascular	events	but	not	LPS.	
Pedersen	et	al.	99	
Longitudinal	cohort	of	107	HIV	
infected	adults	without	ART.	
Uganda	 29	(23-43.3)	 sCD14,	LPS	
	
sCD14	and	immune	activation	markers	raised	
but	not	LPS.	No	change	in	LPS	over	time	
without	ART.	
Redd	et	al.100	
Cross	sectional	study	of	30	HIV	
infected	adults	on	ART	
investigating	gut	damage	and	
response	to	ART.	
Italy	 54	(43-71)	 sCD14,	LPS,	EndoCAb	
	
C-reactive	protein	related	to	disease	
progression	but	markers	of	microbial	
translocation	not	related	
Tincati	et	al.86	
Longitudinal	study	of	early	HIV	
infection	in	27	adults	
France	 Adult	(age	not	
given)	
16S	rDNA	PCR,	I-FABP	
	
Immune	activation	occurred	in	absence	of	
Chevalier	et	al.	63	
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microbial	translocation.	
Cross	sectional	study	of	adults	
with	HIV,	comparing	adults	
with/without	ART	and	
with/without	response	to	ART.	
Italy	 40	(30-69)	 16S	rDNA	PCR	with	Sanger	sequencing,	LPS	
	
LPS	lower	in	those	on	ART.	LPS	associated	with	
T	cell	activation	in	those	unresponsive	to	ART.	
Higher	proportion	of	samples	positive	with	16S	
rDNA	PCR	in	ART-naive/unresponsive	to	ART.	
Serratia	spp.	and	Rahnella	spp.	sequenced.	
Marchetti	et	al.	54	
*CD4:	CD4	T	cell	count	in	cells/μL	 	 	 	 	
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proxy	measure	of	microbial	translocation	and	as	it	is	a	component	of	Gram	negative	
cell	walls	means	that	Gram	positive	bacteria	would	not	be	quantified.	Finally,	the	
relationship	between	LPS,	immune	activation	and	disease	progression	in	HIV	has	not	
been	demonstrated	consistently	across	previous	studies	(Table	38).	The	relationship	
between	sCD14,	immune	activation	and	disease	progression	has	been	more	
consistently	demonstrated,	but	this	is	not	surprising	as	sCD14	is	itself	a	measure	of	
monocyte	activation,	which	could	be	driven	by	other	mechanisms	in	addition	to	
microbial	translocation	(section	8.4.5).	A	raised	sCD14	should	not	be	conflated	with	
microbial	translocation	as	it	too	is	a	proxy	marker.		Seven	previous	studies	have	used	
broad	range	16S	rDNA	PCR	to	quantify	microbial	translocation,	but	only	two	have	
used	sequencing	to	confirm	the	results	are	consistent	with	microbial	translocation	as	
opposed	to	artefact8,54.	Indeed,	the	bacteria	identified	(Serratia	spp.,	Rahnella	spp.,	
mixtures	of	Pseudomonadales	and	Burkholderiales)	could	be	consistent	with	
contamination	as	opposed	to	have	translocated	from	the	gut.		
This	thesis	set	out	to	determine	whether	microbial	translocation	occurs	in	HIV	
infected	children	in	an	African	setting,	and	whether,	if	present,	that	microbial	
translocation	is	of	biological	importance.	Aims	1-3	were	addressed	using	three	
molecular	methods:	a	panel	of	qPCRs,	a	broad	range	16S	rDNA	PCR	and	next	
generation	sequencing	(Sections	12.4,	13.4.1,	14.4)	in	140	HIV-infected	and	109	HIV	
uninfected	children	from	an	urban	environment	and	55	HIV-infected,	ART	naïve	
children	from	a	rural	environment.	This	was	the	first	time,	to	our	knowledge	that	NGS	
had	been	employed	to	provide	definitive	identification	of	any	bacterial	DNA	identified	
in	the	samples.	For	Aim	4,	gut	damage	was	assessed	by	measuring	I-FABP,	clinical	
events	occurring	in	the	trial	were	recorded	and	compared	with	results	of	molecular	
assays	and	anthropometric	markers	were	assessed	over	time	in	all	HIV-infected	
children,	and	at	a	single	time	point	in	uninfected	children.	
	
The	outcomes	of	investigating	aims	1-3	are	discussed	in	chapters	12-14.	In	general,	
markers	of	microbial	translocation	in	all	3	molecular	assays	were	low	in	all	groups	and	
at	all	time	points.	S.aureus	was	the	most	reliably	and	consistently	detected	bacterial	
species,	and	it	is	questionable	as	to	whether	this	DNA	is	derived	from	the	gut	
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secondary	to	microbial	translocation	or	from	another	source,	namely	skin	
contamination.	Previous	studies	have	not	used	sensitive	assays	such	as	the	S.aureus	
qPCR,	so	it	is	difficult	to	extrapolate	to	what	degree	previously	demonstrated	high	
levels	of	16S	rDNA	may	have	in	fact	been	due	to	skin	contamination	by	S.aureus	or	
other	skin	colonising	bacteria	as	opposed	to	translocated	DNA	from	the	gut.	Using	
NGS,	bacteria	were	identified	which	could	be	consistent	with	microbial	translocation	
from	the	gut	such	as	Veillonella	spp.	and	Fusobacterium	spp..	However,	they	were	
found	in	very	low	levels,	and	in	both	ART-naïve	and	experienced	children	at	baseline	(		
Figure	39).	It	is	important	to	note	that	I	was	unable	to	sequence	any	samples	from	
HIV-uninfected	controls,	which	may	mean	that	there	is	a	biologically	significant	
difference	in	the	quantities	of	bacterial	DNA	between	HIV	infected/uninfected	
groups.	Indeed,	several	previous	studies	have	also	found	no	evidence	of	bacterial	
DNA	using	a	broad	range	16S	rDNA	PCR	(without	sequencing)	in	HIV-uninfected	
controls54,59.	However	this	may	have	been	due	to	the	unavailability	of	pellet	samples	
for	the	control	groups:	and	both	with	the	qPCRs	and	the	broad	range	16S	rDNA	PCR	I	
was	able	to	identify	low	levels	of	bacterial	DNA	in	the	control	samples.		
Enterobacteriaceae	have	been	implicated	in	both	previous	studies	to	use	sequencing	
methods	on	the	blood	of	people	with	HIV8,54.	Although	in	this	study,	
Enterobacteriaceae	were	also	detected	using	the	qPCR	panel	and	the	NGS	method,	
the	levels	of	Enterobacteriaceae	detected	using	the	qPCR	assay	were	consistent	over	
time	in	all	HIV-infected	groups	(section	12.4.1),	indicating	that	the	results	may	be	due	
to	contamination	or	of	doubtful	biological	significance.	There	were	differences	
between	ART-naïve	and	HIV-negative	controls	at	baseline	(23%	versus	38%	positive,	
p=0.03),	but	the	proportions	of	positive	samples	were	higher	in	controls	than	HIV-
infected	children.		Furthermore,	in	the	context	of	numerous	significance	tests,	it	is	
possible	that	these	results	are	spurious,	particularly	when	taken	in	the	context	a)	of	
minimal	difference	between	other	groups	b)	understanding	the	inherent	variability	of	
the	assay	and	vulnerability	to	contamination.	There	was	also	minimal	association	
between	markers	of	microbial	translocation	and	clinically	significant	events	in	these	
children	over	time	as	discussed	in	chapter	16.	
This	is	the	most	comprehensive	study	to	evaluate	if	microbial	translocation	is	
occurring	in	HIV	infected	children.	To	conclude,	if	translocation	is	occurring,	it	is	at	
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very	low	levels	and	is	unlikely	to	be	of	clinical	significance.	Our	data	is	consistent	with	
previous	studies	and	together	they	raise	doubts	about	the	importance	of	microbial	
translocation	as	a	driver	of	immune	activation	in	people	with	HIV.		
	
The	results	for	Aim	4	are	discussed	in	Chapters	15-16.	Considering	the	results	of	the	I-
FABP	assay,	the	results	ran	counter	to	the	hypothesis	that	I-FABP	as	a	marker	of	gut	
damage	would	be	higher	in	ART-naïve	HIV-infected	children	than	ART-experience	
children	or	in	HIV-uninfected	controls.	Significant	increases	in	I-FABP	were	seen	in	
both	HIV-infected	urban	groups	over	time	on	ART,	bringing	the	levels	in	line	with	that	
seen	in	HIV-uninfected	controls	and	also	that	seen	in	HIV-infected,	ART-naïve	children	
from	a	rural	environment	(		
Figure	44,	Figure	45)	It	appears	that	in	this	setting,	I-FABP	may	be	a	marker	of	health	
gut	turnover	rather	than	gut	damage,	but	the	relationship	appears	to	be	complex	and	
further	research	is	needed.	An	adjusted	model	of	I-FABP	and	individual	predictor	
variables	could	contribute	to	understanding,	as	could	more	longitudinal	follow-up	and	
a	larger	sample	size.	Indeed,	I-FABP	is	only	one	marker	of	enteropathy.	A	panel	of	
other	markers	that	capture	permeability,	regeneration	of	the	epithelium,	
inflammation	of	the	gut	might	provide	more	information	about	the	extent	of	gut	
damage	and	its	relationship	to	microbial	translocation.	
	
17.2 Strengths	and	Limitations	
17.2.1 Assay	Limitations	
One	of	the	main	challenges	in	investigating	microbial	translocation	is	the	lack	of	
consensus	as	to	the	best	methods	of	quantification.	In	order	to	address	the	thesis	
aims	of	definitively	answering	the	question	as	to	whether	microbial	translocation	
occurs,	I	used	three	molecular	approaches.	The	assays	I	developed	were:	a	panel	of	
qPCRs,	a	broad	range	16S	rDNA	PCR	(SYBR®	Green)	and	next	generation	sequencing	
(NGS)	using	Illumina®	technology.	The	challenges	involved	in	development	of	these	
assays	are	described	in	Section	10.	It	became	clear	that	across	all	sample	types	from	
different	populations,	levels	of	bacterial	DNA	were	low,	and	these	assays	were	
working	at	the	limits	of	detection.	Methods	were	developed	accordingly	in	order	to	
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overcome	these	challenges,	particularly	with	regards	to	the	NGS.	The	discovery	that	
the	primers	were	contaminated	with	Sphingomonas	spp.	DNA	(section	10.2.1)	and	
also	identification	and	minimisation	of	the	primer	dimer	that	was	interfering	with	
successful	sequencing	(10.2.2)	led	to	development	of	a	workflow	that	allowed	the	
bacterial	16S	rDNA	present	in	22%	of	samples	to	be	amplified	to	a	level	that	
sequencing	was	possible.	However,	even	for	samples	that	were	successfully	
sequenced,	after	removal	of	OTUs	that	were	also	present	in	negative	experimental	
controls,	the	remaining	phylogenetic	trees	demonstrated	only	scanty	levels	of	
bacteria	in	both	ART	naïve	and	ART	experienced	children	(Section	14.4.1).	Although	it	
is	possible	that	these	bacteria	were	truly	the	result	of	microbial	translocation,	at	such	
low	levels	it	is	difficult	to	draw	definitive	conclusions.		
As	these	assays	were	working	at	the	limits	of	detection,	it	is	possible	that	they	were	
insufficiently	sensitive	to	identify	bacteria	that	had	translocated	from	the	gut	but	
were	present	at	very	low	concentrations.	In	this	study,	we	did	not	explore	other	
surrogate	markers	of	microbial	translocation	such	as	LPS	or	sCD14	which	might	have	
assisted	in	identification.	However,	LPS	is	a	variable	assay	in	itself,	with	widely	
divergent	results	demonstrated	in	different	studies,	and	no	overall	consensus	as	to	
what	should	constitute	a	strongly	positive	result60,61,100.	It	is	also	vulnerable	to	the	
effects	of	plasma	inhibition	depending	on	the	specific	patient	sample91.		Indeed,	LPS	
has	not	been	consistently	found	to	be	related	to	disease	progression	in	longitudinal	
studies	of	HIV69,70,100.	Although	the	evidence	of	association	of	sCD14	is	stronger	than	
LPS,	sCD14	is	a	marker	of	monocyte	activation	not	specifically	microbial	
translocation60.	It	could	be	raised	directly	by	HIV,	or	by	other	unquantified	
environmental	factors101,102.			
Furthermore,	all	three	molecular	assays	gave	similar	results	of	very	low	levels	of	
bacterial	DNA	across	all	groups.	This	strengthens	the	interpretation	that	if	microbial	
translocation	is	occurring,	it	is	happening	at	such	low	levels	in	all	groups	that	the	
microbial	translocation	itself	may	be	of	little	biological	importance.	Although	each	
assay	had	its	own	limitation	in	terms	of	sensitivity	and	specificity,	using	all	three	
together	increased	the	likelihood	of	identifying	translocating	bacteria.	For	example,	
although	it	was	not	possible	to	design	a	qPCR	assays	that	specifically	identified	
Clostridiales,	bacteria	from	this	family	were	identified	by	NGS,	namely	Veilonellaceae	
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and	Clostridiaceae.		Similarly,	Lactobacillaceae	were	identified	using	NGS	and	these	
were	taxa	that	were	potentially	from	a	different	family	to	that	targeted	by	the	qPCR	
assay.	Perhaps,	as	concluded	by	other	studies,	it	may	be	an	aberrant	host	response	to	
ubiquitous	low	levels	of	microbial	translocation	that	is	problematic,	rather	than	the	
microbial	translocation	itself60.	It	might	be	similar	to	stunting,	in	that	although	
enteropathy	is	widespread,	only	one	third	of	infants	experience	stunting	as	a	result;	
and	that	stunting	is	significantly	associated	with	raised	inflammatory	makers103,104.	
Potentially,	for	some	individuals	microbial	translocation	is	consequential	and	for	
others	it	has	no	impact.			
17.2.2 Limitations	in	Availability	of	Samples	
	
Across	all	three	molecular	assays,	the	pellet	samples	appeared	to	have	high	bacterial	
loads,	likely	for	the	reasons	discussed	in	section	14.5	about	the	potential	advantage	
of	greater	quantities	of	host	DNA	acting	as	carrier	DNA	and	enhancing	the	extraction	
efficiency	of	the	target	DNA.	However,	pellet	samples	were	only	available	at	baseline	
for	the	HIV-infected	urban	groups,	so	comparisons	could	not	be	made	either	with	
HIV-negative	children,	or	over	time,	or	between	urban	and	rural	areas.	In	particular	
this	may	have	affected	NGS	results,	as	while	75%	of	pellet	samples	sequenced	
successfully,	only	11%	of	plasma	samples	did.	Therefore	baseline	samples	from	the	
HIV-infected	group	in	the	urban	setting	were	likely	to	be	over-represented	in	the	NGS	
data.		
Additionally,	the	sample	size	for	the	ART-experienced	group	and	their	age-matched	
controls	was	small.	Therefore	fewer	data	were	available	for	comparison	either	
between	these	two	groups	or	with	the	ART-naïve	groups.			
17.2.3 Cotrimoxazole	
All	participants	enrolled	in	the	CHAPAS-3	trial	received	co-trimoxazole	prophylaxis	
from	baseline	onwards.	This	might	have	impacted	on	results.	However,	there	were	
minimal	differences	seen	between	ART-naïve	and	ART-experienced	at	baseline,	when	
the	ART-experienced	children	would	have	been	receiving	cotrimoxazole.	Elsewhere,	
in	one	small	adult	study	in	a	developed	setting,	initiating	ART	with	cotrimoxazole	
prophylaxis	appeared	to	decrease	sCD14	and	LPS	binding	protein	more	than	ART	
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alone105.	However,	in	adults	in	Uganda,	it	appeared	that	cotrimoxazole	had	little	
impact	on	the	diversity	of	the	microbiome,	although	the	control	population	were	HIV	
negative	as	nearly	all	the	HIV	infected	participants	were	receiving	prophylaxis97.	
In	summary,	in	view	of	little	difference	seen	between	ART-naïve	and	ART-experienced	
groups	at	baseline,	it	appears	unlikely	that	cotrimoxazole	had	a	significant	impact	in	
this	study.		
	
17.3 Future	Research	
	
This	thesis	demonstrates	the	challenges	faced	when	applying	molecular	
methodologies	to	the	investigation	of	microbial	translocation	in	HIV.	An	NGS	method	
optimal	for	sequencing	bacterial	16S	rDNA	in	low-biomass	samples	was	developed.	It	
is	unlikely	that	any	further	gains	in	sensitivity	could	be	achieved	using	this	
methodology.	Pellet	samples	contained	the	most	bacterial	DNA	and	appear	to	be	a	
superior	sample	type	with	assay	than	plasma	for	detection	of	very	low	levels	of	
bacterial	DNA.	This	method	could	be	used	to	investigate	microbial	translocation	in	
other	populations,	not	only	in	HIV-infected	children	in	other	resource-limited	
settings,	but	also	in	HIV-infected	individuals	in	developed	settings	to	explore	a	
relationship	with	other	surrogate	markers	of	microbial	translocation	and	immune	
activation.	It	could	also	be	used	in	other	populations	where	microbial	translocation	is	
thought	to	be	of	significance	such	as	preterm	neonates,	surgical	patients,	patients	
with	inflammatory	bowel	disease	and	immunocompromised	patients	in	general106-109.		
	
Furthermore,	with	additional	quality	control,	it	might	be	feasible	to	adapt	the	method	
for	use	clinically,	enabling	batching	of	large	numbers	of	clinical	samples	as	opposed	to	
16S	rDNA	PCR	with	Sanger	sequencing	as	is	used	in	clinical	settings	currently110,111.		
	
In	terms	of	microbial	translocation	as	an	important	cause	of	poor	clinical	outcome	in	
HIV-infected	children	in	Uganda,	on	the	basis	of	the	lack	of	definitive	evidence	
provided	by	this	large	study,	with	HIV-negative	controls,	in	conjunction	with	the	lack	
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of	efficacy	of	plot	studies	and	clinical	trials	targeted	to	modify	microbial	translocation	
and	improve	outcome	in	HIV-infected	patients	(section	8.4.4),	it	is	difficult	to	justify	
further	clinical	trials	at	this	point	in	time.	Further	studies	using	these	techniques	may	
yield	different	results	in	different	populations,	such	as	very	young	infants	for	example	
who	may	have	a	more	vulnerable	gut	barrier.		
	
In	terms	of	immune	activation,	exploring	link	between	microbial	translocation	and	
immune	activation	in	this	setting	is	beyond	the	scope	of	this	thesis,	but	future	work	
including	cluster	analysis	of	the	link	between	markers	of	immune	activation	and	
microbial	translocation	results	in	this	study	would	be	useful.	Markers	of	immune	
activation,	inflammation	and	disordered	thrombogenesis	decreased	over	time	on	ART	
in	the	wider	CHAPAS-3	cohort112.	Given	the	absence	of	any	change	over	time	or	
between	groups	in	microbial	translocation	markers	in	this	cohort,	a	direct	relationship	
between	immune	activation	and	microbial	translocation	appears	unlikely.	However,	
this	question	should	be	addressed	directly	in	future	analysis.	
Considering	immune	activation	more	broadly,	trials	targeted	to	reduce	immune	
activation	and	improve	outcomes	for	those	with	HIV	have	not	yet	yielded	convincing	
results	(section	8.4.4).	However,	there	is	merit	in	exploring	other	mechanisms	of	
immune	activation	such	as	chronic	infection	with	CMV	for	example.	REALITY,	a	large	
randomised	control	of	severely	immunocompromised	HIV-infected	adults	and	older	
children	aiming	to	reduce	early	mortality	on	ART	demonstrated	a	25%	reduction	in	
mortality	with	a	package	of	enhanced	OI	prophylaxis,	indicating	there	is	considerable	
benefit	to	be	achieved	in	reducing	the	pathogen	load	for	the	severely	
immunocompromised	initiating	ART.113		
	
The	results	from	the	I-FABP	assay	are	intriguing	and	merit	further	investigation.	It	
may	be	that	in	this	setting	there	is	a	different	underlying	mechanism	of	gut	turnover.	
For	these	children,	in	the	context	of	high	background	prevalence	of	intestinal	
parasites,	it	may	be	that	high	turnover	and	high	I-FABP	is	the	marker	of	a	healthy	gut,	
and	that	gains	are	made	over	time	on	ART87.	There	also	appeared	to	be	a	higher	level	
of	I-FABP	in	the	rural	group	with	no	significant	change	over	time.	We	did	not	have	
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access	to	data	on	the	prevalence	of	parasitic	infections	in	these	groups,	although	all	
would	have	received	deworming	as	part	of	the	CHAPAS-3	protocol.	An	avenue	for	
future	research	could	interrogate	further	how	environment	and	parasitic	infection	
impacts	on	gut	turnover	in	this	setting.		
	
To	conclude,	it	appears	that	microbial	translocation	as	detected	by	these	3	molecular	
assays	is	unlikely	to	be	a	significant	driver	of	poor	outcome	in	HIV-infected	children	in	
this	setting.	There	are	technical	issues	with	the	sensitivity	of	the	assays	used,	so	
future	studies	may	yield	more	information.	However,	pragmatically,	it	appears	that	
there	may	be	more	cost-effective	ways	to	intervene	to	improve	outcome	for	HIV-
infected	individuals	over	and	above	commencing	ART,	particularly	for	the	severely	
immunosuppressed	such	as	the	enhanced	OI	prophylaxis	package	used	in	the	REALITY	
trial113.	On	a	larger	scale,	with	the	new	WHO	guidelines	advocating	ART	for	all	at	the	
point	of	diagnosis,	the	resources	of	both	ministries	of	health	and	research	institutes	
are	going	to	be	stretched	to	define	innovative	and	affordable	ways	of	making	this	
ambitious	goal	a	reality.		Faced	with	the	dramatic	clinical	benefits	of	early	ART	in	
improving	mortality,	it	is	difficult	to	see	that	the	gains	achieved	by	targeting	microbial	
translocation	will	be	anything	other	than	marginal.	
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19.1 Appendix	A	Species	in	Microbial	Mock	Communities	
Organism	 NCBI	Reference	Sequence	
Acinetobacter	baumannii,	strain	5377	 NC_009085	
Actinomyces	odontolyticus,	
strain	1A.21	
NZ_AAYI02000000	
	
Bacillus	cereus,	strain	NRS	248	 NC_003909	
Bacteroides	vulgatus,	strain	ATCC®	8482ä	 NC_009614	
Clostridium	beijerinckii,	strain	NCIMB	8052	 NC_009617	
Deinococcus	radiodurans,	strain	R1	(smooth)	 NC_001263,	NC_001264	
Enterococcus	faecalis,	strain	OG1RF	 NC_17316	
Escherichia	coli,	strain	K12,	substrain	MG1655	 NC_000913	
Helicobacter	pylori,	strain	
26695	
NC_000915	
Lactobacillus	gasseri,	strain	63	AM	 NC_008530	
Listeria	monocytogenes,	strain	EGDe	 NC_003210	
Neisseria	meningitidis,	strain	MC58	 NC_003112	
Propionibacterium	acnes,	
strain	KPA171202	
NC_006085	
	
Pseudomonas	aeruginosa,	
strain	PAO1-LAC	
NC_002516	
	
Rhodobacter	sphaeroides,	
strain	ATH	2.4.1	
NC_007493,	NC_007494	
	
Staphylococcus	aureus,	strain	TCH1516	 NC_010079	
Staphylococcus	epidermidis,	
FDA	strain	PCI	1200	
NC_004461	
	
Streptococcus	agalactiae,	strain	2603	V/R	 NC_004116	
Streptococcus	mutans,	strain	
UA159	
NC_004350	
	
Streptococcus	pneumoniae,	
strain	TIGR4	
NC_003028	
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19.2 Appendix	B	Tables	of	barcoded	primer	sequences	for	NGS		
Table	39	Initial	Set	of	Barcoded	Primers	
785F	read	1	primer	sequence	(Forward	primer)	
	 	
	 	 	 	 	
Illumina	P5	adapter	 Index	 Padding	 785F	primer	
Primer	
ID	
AATGATACGGCGACCACCGAGATCTACAC	 TCCCTTGTCTCC	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc0	
AATGATACGGCGACCACCGAGATCTACAC	 ACGAGACTGATT	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc1	
AATGATACGGCGACCACCGAGATCTACAC	 GCTGTACGGATT	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc2	
AATGATACGGCGACCACCGAGATCTACAC	 ATCACCAGGTGT	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc3	
AATGATACGGCGACCACCGAGATCTACAC	 TGGTCAACGATA	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc4	
AATGATACGGCGACCACCGAGATCTACAC	 ATCGCACAGTAA	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc5	
AATGATACGGCGACCACCGAGATCTACAC	 GTCGTGTAGCCT	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc6	
AATGATACGGCGACCACCGAGATCTACAC	 AGCGGAGGTTAG	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc7	
	 	 	 	 	AATGATACGGCGACCACCGAGATCTACAC	 ATCCTTTGGTTC	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc8	
AATGATACGGCGACCACCGAGATCTACAC	 TACAGCGCATAC	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc9	
AATGATACGGCGACCACCGAGATCTACAC	 ACCGGTATGTAC	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc10	
AATGATACGGCGACCACCGAGATCTACAC	 AATTGTGTCGGA	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc11	
AATGATACGGCGACCACCGAGATCTACAC	 TGCATACACTGG	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc12	
AATGATACGGCGACCACCGAGATCTACAC	 AGTCGAACGAGG	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc13	
AATGATACGGCGACCACCGAGATCTACAC	 ACCAGTGACTCA	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc14	
AATGATACGGCGACCACCGAGATCTACAC	 GAATACCAAGTC	 TACCGGGACTTA	 GGATTAGATACCCBRGTAGTC	 Fbc15	
	 	 	 	 	1175R	read	2	primer	sequence	(Reverse	primer)	
	 	
	 	 	 	 	
Illumina	P7	adapter	 Index	 Padding	 1175R	primer	
Primer	
ID	
CAAGCAGAAGACGGCATACGAGAT	 GCATATGCACTG	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc32	
CAAGCAGAAGACGGCATACGAGAT	 CAACTCCCGTGA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc33	
CAAGCAGAAGACGGCATACGAGAT	 TTGCGTTAGCAG	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc34	
CAAGCAGAAGACGGCATACGAGAT	 TACGAGCCCTAA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc35	
CAAGCAGAAGACGGCATACGAGAT	 CACTACGCTAGA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc36	
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CAAGCAGAAGACGGCATACGAGAT	 TGCAGTCCTCGA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc37	
CAAGCAGAAGACGGCATACGAGAT	 ACCATAGCTCCG	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc38	
CAAGCAGAAGACGGCATACGAGAT	 TCGACATCTCTT	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc39	
CAAGCAGAAGACGGCATACGAGAT	 GAACACTTTGGA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc40	
CAAGCAGAAGACGGCATACGAGAT	 GAGCCATCTGTA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc41	
CAAGCAGAAGACGGCATACGAGAT	 TTGGGTACACGT	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc42	
CAAGCAGAAGACGGCATACGAGAT	 AAGGCGCTCCTT	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc43	
	 	 	 	 	CAAGCAGAAGACGGCATACGAGAT	 TAATACGGATCG	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc44	
CAAGCAGAAGACGGCATACGAGAT	 TCGGAATTAGAC	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc45	
CAAGCAGAAGACGGCATACGAGAT	 TGTGAATTCGGA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc46	
CAAGCAGAAGACGGCATACGAGAT	 CATTCGTGGCGT	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc47	
CAAGCAGAAGACGGCATACGAGAT	 TACTACGTGGCC	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc48	
CAAGCAGAAGACGGCATACGAGAT	 GGCCAGTTCCTA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc49	
CAAGCAGAAGACGGCATACGAGAT	 GATGTTCGCTAG	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc50	
CAAGCAGAAGACGGCATACGAGAT	 CTATCTCCTGTC	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc51	
CAAGCAGAAGACGGCATACGAGAT	 ACTCACAGGAAT	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc52	
CAAGCAGAAGACGGCATACGAGAT	 ATGATGAGCCTC	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc53	
CAAGCAGAAGACGGCATACGAGAT	 GTCGACAGAGGA	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc54	
CAAGCAGAAGACGGCATACGAGAT	 TGTCGCAAATAG	 AACACGTTTTA	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc55	
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Table	40	Second	Set	of	Barcoded	Primers	
	
785F	read	1	primer	sequence	
	 	
	 	 	 	 	
Illumina	P5	adapter	 Index	 Padding	 785F	primer	
Primer	
ID	
AATGATACGGCGACCACCGAGATCTACAC	 CTCTCTAT	 ACGTGCGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc0	
AATGATACGGCGACCACCGAGATCTACAC	 TATCCTCT	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc1	
AATGATACGGCGACCACCGAGATCTACAC	 GTAAGGAG	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc2	
AATGATACGGCGACCACCGAGATCTACAC	 ACTGCATA	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc3	
AATGATACGGCGACCACCGAGATCTACAC	 AAGGAGTA	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc4	
AATGATACGGCGACCACCGAGATCTACAC	 CTAAGCCT	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc5	
AATGATACGGCGACCACCGAGATCTACAC	 CGTCTAAT	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc6	
AATGATACGGCGACCACCGAGATCTACAC	 TCTCTCCG	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc7	
	 	 	 	 	AATGATACGGCGACCACCGAGATCTACAC	 TCGACTAG	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc8	
AATGATACGGCGACCACCGAGATCTACAC	 TTCTAGCT	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc9	
AATGATACGGCGACCACCGAGATCTACAC	 CCTAGAGT	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc10	
AATGATACGGCGACCACCGAGATCTACAC	 GCGTAAGA	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc11	
AATGATACGGCGACCACCGAGATCTACAC	 CTATTAAG	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc12	
AATGATACGGCGACCACCGAGATCTACAC	 AAGGCTAT	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc13	
AATGATACGGCGACCACCGAGATCTACAC	 GAGCCTTA	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc14	
AATGATACGGCGACCACCGAGATCTACAC	 TTATGCGA	 ACGTACGTACGT	 GGATTAGATACCCBRGTAGTC	 Fbc15	
	 	 	 	 	1175R	read	2	primer	sequence	
	 	
	 	 	 	 	
Illumina	P7	adapter	 Index	 Padding	 1175R	primer	
Primer	
ID	
CAAGCAGAAGACGGCATACGAGAT	 TAAGGCGA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc32	
CAAGCAGAAGACGGCATACGAGAT	 CGTACTAG	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc33	
CAAGCAGAAGACGGCATACGAGAT	 AGGCAGAA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc34	
CAAGCAGAAGACGGCATACGAGAT	 TCCTGAGC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc35	
CAAGCAGAAGACGGCATACGAGAT	 GGACTCCT	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc36	
CAAGCAGAAGACGGCATACGAGAT	 TAGGCATG	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc37	
CAAGCAGAAGACGGCATACGAGAT	 CTCTCTAC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc38	
CAAGCAGAAGACGGCATACGAGAT	 CGAGGCTG	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc39	
CAAGCAGAAGACGGCATACGAGAT	 AAGAGGCA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc40	
CAAGCAGAAGACGGCATACGAGAT	 GTAGAGGA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc41	
CAAGCAGAAGACGGCATACGAGAT	 GCTCATGA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc42	
CAAGCAGAAGACGGCATACGAGAT	 ATCTCAGG	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc43	
	 	 	 	 	CAAGCAGAAGACGGCATACGAGAT	 ACTCGCTA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc44	
CAAGCAGAAGACGGCATACGAGAT	 GGAGCTAC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc45	
CAAGCAGAAGACGGCATACGAGAT	 GCGTAGTA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc46	
CAAGCAGAAGACGGCATACGAGAT	 CGGAGCCT	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc47	
CAAGCAGAAGACGGCATACGAGAT	 TACGCTGC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc48	
CAAGCAGAAGACGGCATACGAGAT	 ATGCGCAG	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc49	
CAAGCAGAAGACGGCATACGAGAT	 TAGCGCTC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc50	
CAAGCAGAAGACGGCATACGAGAT	 ACTGAGCG	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc51	
CAAGCAGAAGACGGCATACGAGAT	 CCTAAGAC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc52	
CAAGCAGAAGACGGCATACGAGAT	 CGATCAGT	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc53	
CAAGCAGAAGACGGCATACGAGAT	 TGCAGCTA	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc54	
CAAGCAGAAGACGGCATACGAGAT	 TCGACGTC	 AGTCAGTCAGCC	 ACGTCRTCCCCDCCTTCCTC	 Rrcbc55	
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19.3 Appendix	C	QIIME	script	settings	
	
#	Assemble	paired	end	reads	using	FLASH		
#This	script	assembles	paired	end	reads	
	
./flash	-m	110	-M	150	-d	/home/qiime/felicity/	
/home/qiime/felicity/Undetermined_S0_L001_R1_001.fastq	
/home/qiime/felicity/Undetermined_S0_L001_R2_001.fastq	
	
cd	/home/qiime/	
	
#This	script	is	to	reverse	the	complementarity	of	the	index	read.	Run	twice	to	extract	
both	indexes	before	combining	to	one	barcode	matching	mapping	file.	
	
python	extract_bcs_from_fastq.py	felicity/1_S1_L001_I1_001.fastq	
felicity/extracted_barcodes1.fastq	felicity/extracted_reads1.fastq	12	True	
	
python	extract_bcs_from_fastq.py	felicity/1_S1_L001_I2_001.fastq	
felicity/extracted_barcodes2.fastq	felicity/extracted_reads2.fastq	12	False	
	
python	combine_fastq_barcodes.py	felicity/extracted_barcodes1.fastq	
felicity/extracted_barcodes2.fastq	felicity/combined_barcodes.fastq		
	
#Extra	script	in	FLASH	directory	that	writes	barcodes	in	same	order	as	assembler.	
Assembler	works	in	random	parallel	order	leading	to	random	list	of	reads	in	output	
fastq	file.	Need	this	script	to	make	sure	both	read	file	and	barcode	file	headers	match.	
	
python	remove_unused_barcodes.py	/home/qiime/felicity/combined_barcodes.fastq	
/home/qiime/felicity/out.extendedFrags.fastq	
/home/qiime/felicity/updated.barcodes.outfile.fastq	
	
#Split	libraries	and	demultiplex	illumina	fastq	file	(matching	barcoded	amplicons	to	
samples	in	mapping	file).	Use	--barcode_type	as	argument	for	how	long	barcode	is-	in	
this	case	24.		
	
split_libraries_fastq.py	-i	/home/qiime/felicity/out.extendedFrags.fastq	-o	
/home/qiime/felicity/split_lib/	-b	
/home/qiime/felicity/updated.barcodes.outfile.fastq	-m	
/home/qiime/felicity/Miseq_2_mapping.txt	--barcode_type	24	
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#pick	OTUS	reference	
parallel_pick_otus_uclust_ref.py	-i	felicity/split_lib/seqs.fna	-o	felicity/pick_otus/	-r	
qiime_software/gg_otus-13_8-release/rep_set/97_otus.fasta	-O	8	-T	
	
pick_rep_set.py	-i	pick_otus/seqs_otus.txt	-f	pick_otus/seqs.fna	-m	most_abundant	-
o	rep_set.fna	
	
#Parallel	align	sequences	using	PyNAST	
parallel_align_seqs_pynast.py	-i	rep_set.fna	-o	pynast_aligned_seqs/	-T	
	
#Filter	alignment	against	lanemask	file	
filter_alignment.py	-o	pynast_aligned_seqs/	-i	
pynast_aligned_seqs/rep_set_aligned.fasta	
	
#Build	phylogenetic	tree	
make_phylogeny.py	-i	pynast_aligned_seqs/rep_set_aligned_pfiltered.fasta	-o	
rep_set.tre	
	
#Assign	Taxonomy	via	uclust	
	
parallel_assign_taxonomy_uclust.py	-i	rep_set.fna	-o	
pick_otus/uclust_assigned_taxonomy/	-O	2	
	
#Build	OTU	table	
	
make_otu_table.py	-i	pick_otus/seqs_otus.txt	-t	
pick_otus/uclust_assigned_taxonomy/rep_set_tax_assignments.txt	-o	
otu_table.biom	
	
#Print	OTU	table	summary	to	text	file	
	
biom	summarize-table	-i	otu_table.biom	-o	pick_otus/otu_table_summary.txt	
	
	
#Print	OTU	table	to	text	file	
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biom	convert	-i	otu_table.biom	-o	pick_otus/otu_table.txt	-b	--header-key	taxonomy	
	
#Filter	out	OTUs	that	appear	less	than	0.001		
	
filter_otus_from_otu_table.py	-i	otu_table.biom	-o	otu_table_mcf0001.biom	--
min_count_fraction	0.001	
	
	
#Print	filtered	OTU	table	to	text	file	
	
biom	convert	-i	otu_table_mcf0001.biom	-o	otu_table_mcf0001.txt	-b	--header-key	
taxonomy	
	
#Print	OTU	table	summary	to	text	file	
	
biom	summarize-table	-i	/home/qiime/felicity/pick_otus/otu_table_mcf0001.biom	-o	
/home/qiime/felicity/pick_otus/otu_table_mcf0001_summary.txt	
	
#Perform	a	single	random	rarefaction	on	otu	table	to	produce	even	sampling	depth	
across	all	samples	(In	this	case	1000	sequences	per	sample)	
	
single_rarefaction.py	-i	/home/qiime/felicity/pick_otus/otu_table_mcf0001.biom	-o	
/home/qiime/felicity/pick_otus/otu_table_mcf0001_1000.biom	-d	1
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19.4 Appendix	D	Missing	samples	across	groups	and	time	points	
Baseline	 qPCR	 	 	 	 	 SYBR	 	 	 	 	 I-FABP	 	 	 	 	
	 Naïve	 Experienced	 Gulu	 Naïve	
Controls	
Experienced	
Controls	
Naïve	 Experienced	 Gulu	 Naïve	
Controls	
Experienced	
Controls	
Naïve	 Experienced	 Gulu	 Naive	
Controls	
Experienced	
Controls	
total	 119	 22	 55	 89	 20	 119	 22	 55	 89	 20	 119	 22	 55	 89	 20	
total	missing	 9	 0	 4	 0	 0	 9	 0	 4	 0	 0	 10	 2	 9	 0	 0	
Sample	not	
available	
9	 	 4	 	 	 9	 	 4	 	 	 9	 	 8	 	 	
Assay	Failure	 	 	 	 	 	 	 	 	 	 	 1	 2	 1	 	 	
Unknown	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Week	12	 qPCR	 	 	 SYBR	 	 	 I-FABP	 	 	 	 	 	 	 	 	
	 Naïve	 Experienced	 Gulu	 Naïve	 Experienced	 Gulu	 Naïve	 Experienced	 Gulu	 	 	 	 	 	 	
Died	 0	 0	 2	 0	 0	 2	 0	 0	 2	 	 	 	 	 	 	
Loss	to	Follow	up	 0	 0	 0	 0	 0	 0	 0	 0	 0	 	 	 	 	 	 	
total	excluding	
deaths	and	loss	to	
follow	up	by	W12	
119	 22	 53	 119	 22	 53	 119	 22	 53	 	 	 	 	 	 	
total	missing	 11	 3	 5	 11	 3	 6	 12	 3	 16	 	 	 	 	 	 	
Sample	not	
available	
11	 3	 5	 11	 3	 5	 11	 3	 15	 	 	 	 	 	 	
Assay	Failure	 	 	 	 0	 0	 1	 1	 	 1	 	 	 	 	 	 	
Unknown	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Week	72	 qPCR	 	 	 SYBR	 	 	 I-FABP	 	 	 	 	 	 	 	 	
	 Naïve	 Experienced	 Gulu	 Naïve	 Experienced	 Gulu	 Naïve	 Experienced	 Gulu	 	 	 	 	 	 	
Died	 3	 0	 2	 3	 0	 2	 3	 0	 2	 	 	 	 	 	 	
Loss	to	Follow	up	 4	 0	 2	 4	 0	 2	 4	 0	 2	 	 	 	 	 	 	
Unknown	 4	 1	 	 	 	 	 	 	 	 	 	 	 	 	 	
total	excluding	
deaths	and	loss	to	
follow	up	by	W72	
112	 22	 51	 112	 22	 51	 112	 22	 51	 	 	 	 	 	 	
total	missing	 2	 0	 7	 3	 0	 7	 3	 1	 12	 	 	 	 	 	 	
Sample	not	
available	
2	 	 7	 3	 	 7	 3	 	 10	 	 	 	 	 	 	
Assay	Failure	 	 	 	 	 	 	 	 1	 2	 	 	 	 	 	 	
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19.5 Appendix	E	Paper:	“Evidence	Microbial	Translocation	Occurs	in	HIV-
Infected	Children	in	the	United	Kingdom”;	AIDS	Research	and	Human	
Retroviruses;	October	2013	
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19.6 Appendix	F	Conference	Abstract	“Microbial	translocation	does	not	drive	
immune	activation	in	Ugandan	children	with	HIV”;	Conference	for	
Retroviruses	and	Opportunistic	Infections	February	2017,	Seattle,	
Washington;	Abstract	number	188	
Microbial	translocation	does	not	drive	immune	activation	in	Ugandan	children	with	
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Background	
Immune	activation,	potentially	driven	by	microbial	translocation	(MT),	is	linked	to	
increased	morbidity	and	mortality	despite	ART	in	HIV	infection.	This	study	aimed	to	
investigate	MT	as	a	driver	of	poor	outcome	in	HIV-infected	African	children		
Methods	
The	study	population	comprised	ART-naïve	and	ART-experienced	children	recruited	to	
Ugandan	sites	of	the	CHAPAS-3	Trial	(ISRCTN69078957),	a	toxicity	trial	of	fixed-dose	
combination	ART	regimens,	and	HIV-uninfected	age-matched	controls	from	the	same	
communities.	HIV-infected	children	were	followed	up	for	96	weeks	including	viral	
suppression,	immune	recovery	and	anthropometric	measures.	MT	was	assessed	using	
a	panel	of	specific	bacterial	polymerase	chain	reactions	(PCRs),	broad-range	16S	rDNA	
PCR	and	next	generation	sequencing	(NGS)(Illumina®	method).	19	markers	of	
immune	activation	were	measured	including	cellular	and	humoral	markers.	Intestinal	
fatty	acid	binding	protein	(I-FABP)	was	used	to	quantify	gut	damage.	Analysis	
including	cluster	analysis	was	performed	in	R	Studio	(v.0.99.896).		
Results	
250	children	were	included:	119	ART	naïve	(median	age	2.8	years,	interquartile	range	
(IQR)	1.7-4,	median	baseline	CD4%	20,	IQR	14-24)	and	22	ART	experienced	children	
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(median	age	6.5	years	IQR	5.9-9.2,	median	baseline	CD4%	34,	IQR	31-39)	and	109	age-
matched	HIV-uninfected	controls.	Immune	recovery	was	good	in	both	HIV-infected	
groups,	and	viral	load	suppression	<100	copies/ml	was	achieved	in	76%	(ART-naïve)	
and	91%	(ART-experienced)	at	96	weeks.	Four	children	died	(all	ART-naïve).	Specific	
PCRs	for	Bifidobacterium,	Lactobacillus,	Fusobacterium,	and	Streptoccocus	pyogenes	
were	negative	in	all	groups	at	most	time	points.	Enterobacteriaceae	PCR	was	positive	
in	23-55%	of	samples	at	different	time	points	and	was	higher	in	controls	than	ART-
naive	at	baseline	(p=0.03).	There	was	no	significant	change	in	proportions	positive	
over	time.	Baseline	Staphylococcus	aureus	proportions	positive	were	23%	(95%	CI	8-
45%)	in	ART-experienced	and	10%	(95%	CI	5-16%)	in	ART-naïve	(no	difference	vs	
controls,	p=0.22	&	0.81	for	age	matched	naïve/experienced)	and	decreased	non-
significantly	to	4.8%	(95%	CI	1-23%)	vs	6.7%	(95%	CI	2.5-12.4%)	at	week	72.	At	
baseline	using	NGS,	very	low	levels	of	microbial	DNA	were	found	in	both	HIV-infected	
groups,	including	S.aureus,	Enterobacteriaceae,	Veillonellae	&	Clostridiales.	Cluster	
analysis	showed…		The	improvement	in	immune	activation	markers	over	time	had	no	
relationship	to	markers	of	MT.	
	
Conclusion	
Levels	of	bacterial	DNA	were	low	in	all	children	regardless	of	HIV	or	ART	status.	
Immune	activation	decreased	over	time	on	ART.	MT	may	not	be	a	significant	driver	of	
immune	activation	in	this	setting.			
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Table	 1.	 Characteristics	 of	 the	 clustering	 and	 distribution	 of	microbial	 translocation	
markers	among	children	from	a	Ugandan	site	of	CHAPAS	3	trial.	
Characteristics	 Cluster	1	 Cluster	2	 Cluster	3	 Cluster	4	 P-value	
	 	 	 	 	 	 	N	(%)	 105	(42)	 120	(48)	 11	(4)	 13	(5)	
	
	 	 	 	 	 	 	ART	at	baseline	
	 	 	 	
0.0036	
	
ART	naive	 57	(54)	 50	(42)	 6	(55)	 7	(54)	
	
	
ART	experienced	 14	(13)	 5	(4)	 0	(0)	 3	(23)	
	
	
HIV	negative	 34	(32)	 65	(54)	 5	(45)	 3	(23)	
	
	 	 	 	 	 	 	Virally	suppressed	at	W96	
(<100	copies/ml)	
	 	 	 	
<0.0001	
	
Yes	 65	(62)	 32	(27)	 3	(27)	 3	(23)	
	
	
No	 6	(6)	 14	(12)	 3	(27)	 6	(46)	
	
	
HIV	negative	 34	(32)	 65	(54)	 5	(45)	 3	(23)	
	
	
Viral	load	missing	 0	(0)	 9	(8)	 0	(0)	 1	(8)	
		 	 	 	 	
I-FABP	pg/ml*	 176	(139)	 187	(191)	 158	(72)	 192	(115)	 0.93	
16S	rDNA	**	 48	(46)	 61	(51)	 6	(55)	 6	(46)	 0.86	
Bifidobacterium	spp.	**	 0	(0)	 0	(0)	 0	(0)	 0	(0)	 -	
Staphylococcus	aureus**	 3	(4)	 5	(10)	 0	(0)	 0	(0)	 0.58	
Streptococcus	pyogenes**	 0	(0)	 0	(0)	 1	(9)	 0	(0)	 0.05	
Fusobacterium	spp.**	 1	(1)	 1	(1)	 1	(9)	 0	(0)	 0.21	
Enterobacteriaceae**	 47	(45)	 30	(26)	 5	(45)	 1	(8)	 0.006	
Staphylococcus	spp.	**	 0	(0)	 0	(0)	 0	(0)	 0	(0)	 -	
Lactobacillus	spp.**	 1	(1)	 1	(1)	 0	(0)	 0	(0)	 0.54	
*I-FABP:	Intestinal	fatty	acid	binding	protein,	mean	(standard	deviation)	
**Number	of	samples	testing	positive	using	PCR.	Sensitivities	from	0.5-500	colony	forming	unit	(CFU)	
equivalents	when	compared	with	standard	of	known	CFUs	depending	on	assay.	
	
